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Green Tea Polyphenol Increases Ap1 Factor-Dependent Human Involucrin (HINV)
Gene Expression in Normal Human Keratinocytes
S. Balasubramanian, H. Mukhtar, and R. Eckert
Physiology and Biophysics, and Dermatologys, and Dermatology, Case Western Reserve Univeristy School of
Medicine, Cleveland, Ohio
(±)-Epigallocatechin-3-gallate (EGCG) is an important bioactive constituent of green tea that
ef®ciently reduces epidermal cancer cell proliferation. This inhibition is associated with a reduction
in activator protein 1 (AP 1) transcription factor level and activity. However, the effect of this
candidate therapeutic agent on normal keratinocyte function has not been extensively explored.
Our present studies suggest that EGCG is a potent regulator of normal keratinocyte function. To
understand the mechanism of action, we studied the effects of EGCG on AP1 factor activity, and
expression of the AP1-factor regulated human involucrin (hINV) gene. hINV is an established,
well-studied marker of human epidermal keratinocyte terminal differentiation (Welter et al, JBC
270:12614, 1995; Crish et al, JBC 273:30460, 1998; E®mova et al, JBC 275:1601, 2000). hINV
promoter activity is induced in a concentration-dependent manner at 5, 10, 15 and 20 mg per ml of
EGCG. An 8-fold increase in activity is observed at 20 mg per ml. This response appears to be
physiologic, as a parallel increase in endogenous hINV gene expression is observed. The activation
is comparable to that observed for phorbol ester, a known keratinocyte differentiating agent.
Mutation of a functionally important AP1 site, AP1-1, located within the hINV gene promoter
proximal regulatory region (PRR), eliminates this regulation, suggesting that the response is
mediated via an AP1 transcription factor-dependent mechanism. Fra-1, Fra-2, fosB, junB, junD, c-
jun and c-fos levels are increased by EGCG treatment. Moreover, AP1 factor binding to the AP1-1
site is increased by EGCG and this complex contains Fra-1 and junD. Thus, our results indicate
that EGCG markedly increases AP1 signaling, and differentiation-associated gene expression in
normal keratinocytes. This is in sharp contrast to previous reports in transformed keratinocytes, and
indicate that the mechanism of EGCG action is markedly different in normal vs. immortalized/
transformed keratinocytes.
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The Human Involucrin Gene Contains Spatially Distinct Regulatory Elements that
Regulate Expression During Early Versus Late Epidermal Differentiation
J. Crish, F. Bone, E. Banks, and R. Eckert
Physiology and Biophysics, and Dermatology, Case Western Reserve Univeristy School of Medicine,
Cleveland, Ohio
Human involucrin (hINV) is a keratinocyte protein that is expressed in the suprabasal compartment
of the epidermis and other stratifying surface epithelia. Involucrin gene expression is initiated early
in the differentiation process and is maintained until just prior to terminal cell death. The distal
regulatory region (DRR) is a segment of the hINV promoter (nucleotides ±2473/±1953) that
accurately recapitulates the normal pattern of suprabasal (spinous and granular layer) expression in
transgenic mouse epithelia. To identify sequences that mediate expression at speci®c stages of
differentiation, we divided the DRR into two segments, a 376 nucleotide upstream region (DRR-
2473/±2100) and a 147 nucleotide downstream region (DRR-2100/±1953), and evaluated the
ability of these sequences to drive expression in transgenic mice. The DRR-2473/±2100 segment
drives expression at a level comparable to that observed for the DRR, but expression is restricted to
the upper granular layers (i.e. no spinous layer expression). In contrast, the DRR-2100/±1953
segment does not drive expression. However, reassembling the DRR restores the complete range
of expression. These results suggest that two distinct, spatially separate elements are required to
specify the complete differentiation-dependent program of involucrin gene expression. To identify
speci®c transcription factor binding sites involved in this region, we mutated an activator protein-1
binding site, AP1-5, located within DRR-2473/±2100 segment. This site binds AP1 transcription
factors present in mouse epidermal extracts, and its mutation eliminates appropriate hINV
expression. This result suggests that a multiprotein complex that forms over multiple, spatially
separate, regulatory elements is required for appropriate expression of the hINV gene, and that AP1
factors participate as components of this complex.
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Regulation of Human Involucrin Gene Expression by Serine/Threonine Protein
Phosphatase Inhibitor Okadaic Acid
T. E®mova and R. Eckert
Physiology and Biophysics, and Dermatology and Dermatology, Case Western Reserve Univeristy School of
Medicine, Cleveland, Ohio
Involucrin is a component of the keratinocyte corni®ed envelope that is an important marker of
keratinocyte terminal differentiation. Okadaic acid (OA) is a potent and speci®c inhibitor of
serine/threonine protein phosphatases PP2A and PP1. The role of okadaic acid-sensitive
phosphatases in epidermal differentiation has not been elucidated. In the present study, we examine
the effect of this agent on involucrin gene expression. We show that OA enhances human
involucrin (hINV) promoter activity in cultured human epidermal keratinocytes, and potentiates
phorbol ester-dependent activation of the promoter. The endogenous hINV protein level is also
increased by OA treatment, suggesting that inhibition of OA-sensitive phosphatases induces
keratinocyte differentiation. Regulation of hINV promoter activity by OA requires the AP1-1 and
C/EBP binding sites within the hINV promoter proximal regulatory region (PRR), and activation
of hINV gene expression is associated with an OA-dependent increase in both AP1 and C/EBP
DNA binding activity, respectively, at the hINV promoter AP1-1 and C/EBP sites. In addition,
OA increases the expression of the AP1 transcription family members c-Jun, JunB, JunD, Fra-1
and Fra-2, and alters their phosphorylation state. This increase does not require protein kinase c, as
pretreatment with PKC-speci®c inhibitor, bis-indolylmaleimide, does not block the OA-associated
increase in AP1 protein level. C/EBPa and C/EBPb level are also increased, and their
phosphorylation state is altered by OA in a time- and a concentration-dependent manner. These
changes are associated with an OA-dependent increase in p38 and JNK activity. Thus, OA appears
to increase hINV gene expression via a mechanism whereby the p38 and JNK MAPKs increase
AP1 and C/EBP factor levels and DNA binding.
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AP-1 and Sp1 Cooperatively Regulate Differentiation-Speci®c Expression of the Mouse
Loricrin Gene Via Direct Association
Y. Kawachi and D. Roop
Molecular and Cellular Biology and Dermatology, Baylor College of Medicine, Houston, Texas
We have previously shown that an AP-1 element in the proximal promoter of the mouse loricrin
gene is necessary but not suf®cient for expression in vivo in transgenic mice. To identify additional
regulatory elements required for expression of the loricrin gene, we performed deletion and
mutation analysis of the promoter region. Deletion or mutation of a 8-bp sequence
(GGGAGGAG), which is located 14 bp upstream of the AP-1 element, resulted in a signi®cant
decrease in promoter activity to a level similar to that observed by disruption of the AP-1 element.
Electrophoretic mobility shift assays and supershift assays with speci®c antibodies showed that Sp1
and Sp3 speci®cally bound to this sequence. Overexpression of Sp1 in cultured keratinocytes
resulted in a 12-fold enhancement of the promoter activity, however, Sp3 did not increase
promoter activity. Immunoblotting studies using nuclear and whole cell extracts from
undifferentiated or differentiated keratinocytes indicated that Sp1 translocated to nucleus in
differentiated keratinocytes, potentially inducing differentiation-speci®c expression of the loricrin
gene. Further support for this hypothesis was obtained by cotransfection experiments which
demonstrated that c-fos and Sp1 synergistically activated loricrin promoter activity. Interestingly,
jun family members (c-jun, JunB, JunD) suppressed the positive effect of c-fos on the loricrin
promoter. Site-speci®c mutagenesis of either the AP-1 and/or the Sp1 element indicated that both
elements were essential and acted synergistically for differenciation-speci®c expression of the
loricrin gene. These data suggested functional cooperation between AP-1 and Sp1, therefore we
examined the physical interaction between thees two factors. In vitro binding by means of a
glutathione S-transferase pull down assay showed that both c-jun and c-fos could directly associate
with both Sp1 and Sp3. Taken together, these data provide evidence for both physical and
functional interactions between AP-1 and Sp1 during differentiation-speci®c expression of the
loricrin gene.
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Different Properties of Three Isoforms of Transcription Factor AP-2 in Human
Keratinocytes
N. Oyama, K. Iwatsuki, Y. Homma,* and F. Kaneko
Dermatology, Fukushima Medical University School of Medicine, Fukushima, Japan; *Biomolecular Sciences,
Fukushima Medical University School of Medicine, Fukushima, Japan
Transcription factor AP-2/promoter system is essential for the complex keratinocyte biology
mediated by in¯ammatory cytokines, as we demonstrated previously (JID 113 : 600±6, 1999).
Three isoforms, AP-2a, b, and g, share a high homologous structure, but their functions are
considered to be different. We therefore studied the implication of each AP-2 isoform in the
keratinocyte proliferation, differentiation, and carcinogenesis. Serial skin sections from different
sources, normal, psoriasis, and squamous cell carcinoma (SCC), were examined for AP-2
immunoreactivty. AP-2a was present only in the nuclei of normal basal keratinocytes, but
signi®cantly increased in the lesional keratinocytes of both diseases. AP-2b was completely absent
in all samples, whereas AP-2g was homogeneously observed throughout the epidermis in normal
and psoriatic skin as well as the SCC lesion. There was a strong correlation in the expression
pattern between AP-2 isoforms and major keratinocyte markers such as keratin K1, K14,
transglutaminase (TGase) I, and epidermal growth factor receptor (EGFR). Furthermore, in vitro
DNA binding assay revealed the isoform-speci®c gene activation. AP-2a was highly accessible
with the promoter fragments of K14 and EGFR rather than those of K1 and TGase I, all of which
are critical regions for the AP-2-dependent gene activation. In contrast, AP-2g bound to these four
promoter fragments with similar af®nities, but AP-2b did not despite the binding with AP2
consensus oligonucleotide. These results suggest that three AP-2 isoforms perform unique
properties in the spatial and temporal expression of keratinocyte-related genes, thereby maintaining
the epidermal homeostasis. Disruption of the epidermal AP-2 balance may lead to the
establishment of hyperproliferative and neoplastic phenotypes, such as psoriasis and SCC.
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Transcriptional Regulation of Human Papillomaviruses by Interferon Regulatory
Factor-1
S. Tyring,* I. Arany, W. Whitehead, K. Grattendick, and L. Hoskins
Microbiology and Immunology, UTMB, Galveston, Texas; *Dermatology, UTMB, Galveston, Texas
Human papillomaviruses (HPVs) are frequently associated with various lesions of the squamous
epithelium. Cell-mediated immune responses against HPV infection result in release of various
cytokines that in turn could regulate HPV transcription. Interferon regulatory factor-1 (IRF-1) is
induced by several cytokines, and it activates transcription of target genes by binding to a speci®c
sequence in their promoter region. Here we describe the properties of an Interferon Responsive
Element (HIRE) in close proximity to the TATA box of HPV type 16. This site resembles the
consensus IRF-binding element (IRF-E) or interferon-stimulated response element (ISRE) and
overlaps viral E2 binding sites. HPV16 HIRE-1 binds IRF-1 protein in an inducible manner.
Mutational analyses revealed the importance of crucial nucleotides in this binding. In a reporter
system we demonstrated that HIRE-1 stimulates transcription in response to IRF-1 from both
homologous and heterologous promoters in a dose-dependent manner. We also analyzed HIREs
of some known mucosal HPV types by gel-shift assay and showed that some high-risk, but not
low-risk, mucosal types also bind IRF-1. We can assume that transcription of those HPV types is
regulated via HIRE in a fashion similar to that of HPV16. These results might provide important
insights regarding the immune responses against HPVs.
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SMaRT Repair of Collagen 17A1 mRNA: Semi-Quantitytive PCR Analysis of cis- vs.
trans-splicing
G. Dallinger, M. Puttaraju,² L. Mitchell,² K. Yancey,* A. Klausegger, H. Hintner, and J. Bauer
Dermatology, General Hospital Salzburg, Salzburg, Austria; *Dermatology Branch, National Institute of
Health, Bethesda, Maryland; ²Intronn, LLC, Durham, North Carolina
Spliceosome mediated RNA trans-splicing (SMaRT(tm)) can be used to correct mutant
premessenger RNA (premRNA). Recently we demonstrated the repair of a COL17A1 mini-
gene premRNA harbouring the recessive mutation 4003delTC located on exon 52 causing
generalized atrophic benign epidermolysis bullosa (GABEB). RNA and protein repair by
pretherapeutic molecules (PTM's) was shown using a LacZ model-system. To further de®ne the
requirements for a gene therapy approach we cotransfected 293T cells and a GABEB cell line with
plasmids expressing target (a COL 17A1 mini-gene with the mutation) and PTM6 consisting of a
trans-splicing domain followed by the correct cDNA sequence spanning exons 52±56 of
COL17A1. Trans-spliced mRNA was detected by RT-PCR reactions using gene-speci®c
primers. To determine the percentage of cis- vs. trans-splicing, PTMs with high trans-splicing
ef®ciency were selected using the LacZ repair model. To measure trans-splicing ef®ciency a
semiquantitative PCR was performed, using Roche LightCycler and SYBR green. The results
showed trans-splicing ef®ciencies up to 6.5% of cis-spliced mRNA. This ef®ciency is low but can
be increased by modi®ying PTMs and transfection procedures. As shown in the context of the
cystic ®brosis gene even 6% of corrected protein might be suf®cient for phenotypic correction.
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ICAM-1 Expression in Skin Cells is Dependent on Chromatin Remodeling
S. Naik, P. Kowalczyk, G. Burbach, and S. Caughman
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
ICAM-1 plays a critical role in cutaneous in¯ammation. Multiple cytokine-induced, ICAM-1-
speci®c regulatory element and transcription factor interactions have been described in cutaneous
cells. However, little is known about modi®cations of higher order chromatin structure in regions
of regulatory elements of the ICAM-1 gene that may be critical to its regulated expression. Histone
acetylation causes relaxation of chromatin structure around regulatory elements, making them
accessible to activated transcription factors in a promoter-speci®c fashion. Speci®c histone
acetylases, such as CBP/p300, can act as transcriptional coactivators for STAT1 and NF-kB,
transcription factors that are critical to IFNg- and TNFa-induction of ICAM-1. We asked if IFNg-
and TNFa- induction of ICAM-1 was dependent upon histone acetylation-mediated chromatin
remodeling and recruitment of CBP/p300. Acetylated chromatin immunoprecipitation assays,
using antiacetyl-histone antibodies to precipitate crosslinked histone-DNA complexes, demon-
strated that the IFNg-response region of the ICAM-1 gene could be PCR-ampli®ed from genomic
DNA of IFNg-treated but not untreated keratinocytes, indicating that acetylation of histones
surrounding the IFNg-response region occurred temporally with IFNg treatment. Additionally,
basal uninduced histone acetylation is normally countered by nuclear deacetylases, keeping DNA
regulatory element accessibility to a minimum. We observed that the deacetylase inhibitor, sodium
butyrate, induced de novo ICAM-1 mRNA and protein in keratinocytes, further supporting the
role of histone acetylation in the regulated expression of ICAM-1. Finally, expression of adenoviral
E1A protein, which inhibits the activity of CBP/p300, inhibited the induction of ICAM-1 by
TNFa, while mutated E1A had no such effect. These data indicate that induction of ICAM-1
expression in skin cells is dependent upon histone-acetylation-mediated chromatin remodeling and
the recruitment of active CBP/p300 acetylases.
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From Enhancesome to Repressosome: Molecular Antagonism Between Corticosteroids
and Proin¯ammatory Cytokines/Growth Factors
M. Tomic-Canic, B. Lee, H. Bender, and E. Robinson
Dermatology, NYU School of Medicine, New York, New York
We have shown that glucocorticoids (GCs) suppress, while cytokines/growth factors (TNFa, IL-1
and EGF) induce the expression of keratins K6 and K16. To understand the molecular basis of this
antagonism we tested K6/K16 expression during simultaneous presence of GCs and EGF in
cotransfection experiments. We found that GCs inhibit the induction of K6/K16 by EGF. We
believe GCs antagonize EGF/TNFa on K6/K16 promoters by breaking their enhancesome, a
complex structure consisting of an assembly of transcription factors, and converting it to
repressosome. To determine the in vivo relevance of this switch, we used an organ culture model in
which all of the above K6, K16, GCs, TNFa, IL-1 and EGF play important biological roles. We
induced K6 expression by making 3 mm wounds and stained sections with a K6 speci®c antibody.
K6 induction, strong at the wound edge, decreased with the distance and was strongly inhibited by
topical GCs. This is similar to the ®ndings from cotransfection experiments. In addition, K6
expression induced by application of the EGF, rather than wounding, was completely inhibited by
topical GCs in organ cultures. Furthermore, EGF and TNFa treated wounds heal faster than
untreated skin, whereas topical GCs inhibit the healing process. When simultaneously present,
GCs inhibited healing of the wounds treated with EGF. Since K6/K16, as cytoskeletal proteins,
play a role in keratinocyte migration GCs inhibition of their expression and antagonism of EGF/
TNFa effects may affect keratinocyte migration. Using a monolayer scratch assay method, we
found that EGF and TNFa stimulated, whereas GCs strongly inhibited keratinocyte migration.
Importantly, when simultaneously present, GCs inhibited EGF/TNFa effects and keratinocytes
did not migrate. We conclude that the switch from enhencasome to repressosome by GCs converts
the induction of K6/K16 to repression, which leads to blocking of keratinocyte migration and
inhibition of wound healing.
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Human Homeobox HOXA7 Regulates Keratinocyte Transglutaminase Type 1 and
Inhibits Differentiation
P. LaCelle and R. Polakowska
Dermatology, University of Rochester School of Medicine, Rochester, New York, New York
Keratinocyte proliferation and differentiation result from expression of speci®c groups of genes
regulated by unique combinations of transcription factors. In order to better understand these
regulatory processes, we studied homeobox transcription factor HOXA7 expression, and its
regulation of differentiation-speci®c keratinocyte genes. We isolated HOXA7 from keratinocytes
through binding to a differentiation-dependent viral enhancer, and analyzed its effect on
coregulated endogenous keratinocyte genes, primarily transglutaminase 1. Induction of
keratinocyte differentiation with phorbol ester markedly decreased HOXA7 message, and
increased transglutaminase 1 message, in a protein kinase C-dependent manner. Raising the
extracellular calcium concentration also repressed HOXA7 and activated TGM1 expression,
whereas EGF receptor activation stimulated HOXA7 expression. HOXA7 overexpression
repressed transglutaminase 1-reporter activity, and attenuated the transglutaminase 1 induction
by phorbol ester, indicating that HOXA7 expression is inversely related to keratinocyte
differentiation and transglutaminase 1 expression. Antisense HOXA7 expression activated
transglutaminase 1, involucrin, and keratin 10 message and protein levels, demonstrating that
endogenous HOXA7 down-regulates multiple differentiation-speci®c keratinocyte genes. HOX
genes function in groups, and we found that HOXA5 too was down-regulated by phorbol ester.
These results provide the ®rst example of protein kinase C-mediated homeobox gene regulation in
keratinocytes, and new evidence that HOXA7, potentially in conjunction with HOXA5,
transrepresses differentiation-speci®c genes during keratinocyte proliferation, that are then released
from inhibition in response to differentiation signals.
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Vitamin D Regulations of Keratinocyte Proliferation and Differentiation Involves the
Transcription Coactivator DRIP complex
Y. Oda and D. Bikle
Departments of Medicine and Endocrinology, University of California, San Francisco and VA Medical
Center, San Francisco, California
The proliferation and differentiation of epidermal keratinocytes involve the sequential transcription
regulation of genes critical for this process. Vitamin D (1,25(OH)2D3) and calcium modulate this
transcription machinery. The transformation of keratinocytes to squamous cell carcinoma is
characterized by impairment of this regulatory system. In order to investigate the molecular
mechanism of transcription regulation through vitamin D receptor (VDR), we sought coactivators
that have been implicated in transcription regulations by VDR in other cells. We identi®ed
coactivators that interact with VDR using an af®nity matrix linked to GST-VDR. This enabled
the puri®cation of protein complex from nuclear extract of keratinocytes. The complex from
proliferating keratinocytes was similar to DRIP complex (vitamin D receptor interacting proteins)
previously puri®ed from Namalwa B and Hela cells. This complex contained p205 found in
previous studies to directly bind to VDR. In contrast, keratinocyte induced to differentiate by
calcium had a different pro®le with decreased expression of p205, 130, 92, and 77. The squamous
carcinoma cells (SCC12B2, SCC4) showed a pattern similar to proliferating keratinocytes. The
mRNA of p205 was expressed in proliferating keratinocytes and SCC lines, but was decreased by
calcium in normal keratinocytes. These results suggest that the DRIP complex plays a role in
vitamin D regulation in keratinocyte proliferation and differentiation.
810
Estradiol Stimulates Retinoid Receptor Expression and Potentiates Retinoid Response
in Dermal Fibroblasts as Measured by Increased Cellular Retinoic Acid Binding Protein-
2 Expression
S. Pillai, M. Mahajan, S. Granger, and D. Pocalyko
Skin BioScience, Unilever Research, Edgewater, New Jersey
Retinoic acid and other retinoids induce the expression of cellular retinoic acid binding protein 2
(CRABP-2) in human dermal ®broblasts. CRABP-2 response in ®broblasts has been suggested to
be a reproducible predictor of retinoid bioactivity in human skin. In mouse cervical epithelial cells
and estrogen receptor-positive breast cancer cells, estradiol induces retinoid receptor expression.
Since human skin cells respond to retinoids and contain estrogen receptors, we evaluated the effects
of estradiol on retinoid receptor and CRABP-2 expression in human skin ®broblasts. 1±10 nM
estradiol stimulated the expression of RXR-a and RAR-g by 3±4 fold in ®broblasts as measured
by Western Blots. The effect was maximal at 4 h of treatment with estradiol. Retinoic acid, retinol
or retinyl esters (nM to uM levels) stimulated the CRABP-2 expression of ®broblasts by 3±5 fold in
48 h. Pretreatment with estradiol potentiated the retinoid effects on ®broblasts CRABP-2
expression. 4 h of pretreatment with 1±10 nM estradiol increased the ®broblast CRABP-2 response
to retinoids to 10±30 fold, suggesting a synergy between estradiol and retinoids in ®broblasts. From
these studies we conclude that estradiol stimulates retinoid action in skin ®broblasts by increasing
retinoid receptor expression.
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Bexarotene (Targretin(r)) Regulates Retinoid Receptor and TIG-3 Expression in
Cutaneous T-Cell Lymphoma Lines But Does Not Induce Apoptosis
C. Zhang, P. Hazarika, X. Ni, and M. Duvic
Department of Dermatology, Maryland Anderson Cancer Center, University of Texas, Houston, Texas
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of extra-nodal, non-Hodgkin's
lymphomas in which malignant T-lymphocytes present as skin lesions. Retinoids have long been
used alone and in combination with other therapy for CTCL. Bexarotene (Targretin(r)) is a novel
synthetic retinoid X receptor (RXR) selective retinoid effective systemically for treating skin
manifestations in all stages of CTCL and topically in early stages. Bexarotene inhibits cell growth
and causes apoptosis in some leukemic and epithelial cell lines. However, its mechanism of action
in CTCL is unclear. To determine whether bexarotene has direct effects on cell proliferation,
apoptosis, and modulation of gene expression, CellTiter 96(r) AQ Cell Proliferation Assay, Flow
cytometry, Western blotting and QT-RT-PCR were employed to study in well-established
CTCL cell lines (MJ, Hut 78 and HH). Over 24±72 h, bexarotene at 0.1±10 mM inhibited cell
growth by less than 10% in dose-independent manner, and did not induce apoptosis as determined
by Annexin V binding, sub-G1 populations and apoptotic proteins (Bcl-2 and Fas ligand). All three
lines expressed a, b, g isoforms of RARs and RXRs. Bexarotene at 1 mM down-regulated
expression of RXR-a protein (p < 0.05, n = 6) and mRNA (p < 0.05, n = 6), and up-regulated
expression of RAR selective retinoid inducible tumor suppressor, Tazarotene Induced Gene-3
(TIG-3) mRNA (p < 0.05, n = 6) in Hut 78 and HH lines at 24±72 h compared to controls. In
summary, although bexarotene improves the skin manifestations of CTCL in patients, it does not
appear to induce apoptosis directly in vitro in CTCL cell lines. Bexarotene down-regulates its
cognate receptor RXR-a, and may work through inducing expression of TIG-3. In vivo,
therapeutic effects of bexarotene may also involve indirect mechanisms affecting the survival of T-
cells in skin.
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Mutations of Tazarotene-Inducible Gene-3 (TIG-3) Occur in Human Squamous Cell
Carcinoma Lines
C. Schulz, P. Hazarika, R. Lotan,* and M. Duvic
Dermatology, M.D. Anderson Cancer Center, Houston, Texas; *Thoracic/Head & Neck Medical
Oncology, M.D. Anderson Cancer Center, Houston, Texas
Tazarotene-inducible gene-3 (TIG-3) cloned from treated keratinocytes is homologous to a class II
tumor suppressor, H-rev 107, and maps to chromosome 11q23, a site of loss of heterozygosity in
several malignancies. We previously reported that TIG-3 mRNA and protein are signi®cantly
decreased relative to normal skin in psoriasis lesions and in basal and squamous carcinomas [Clin
Cancer Res 6:3249±3259, 2000]. TIG-3 inhibits growth and is upregulated in cell lines that are
inhibited by retinoid treatment, thus we have postulated that TIG-3 may function as a RAR
inducible tumor suppressor [PNAS 95:14811±14815, 1998]. To study the mechanism(s)
responsible for loss of TIG-3 expression, we ®rst determined the structure of the TIG-3 gene
using a series of overlapping PCR primers derived from coding sequences to sequence all intron-
exon boundaries. The gene was found to consist of four exons of 38 to 317 base pairs, separated by
three introns. We next established four exon-speci®c PCR essays to analyze all coding regions in
six human squamous cell carcinoma lines. PCR products from each line were then screened for
mutations using SSCP and denaturing high-performance liquid chromatography (DHPLC). Two
SCC lines showed shifts of exon-1 on DHLPC that were not detected by SSCP. One lung SCC
line (H 460) that lacks both constitutive and inducible TIG-3 expression and is not growth
inhibited by retinoid treatment, was found to have a deletion involving both exon-1 and 2. These
data suggest that loss of TIG-3 expression in some skin and lung squamous carcinoma lines may
result from underlying mutations in the coding regions. Further studies involving the nature of
speci®c mutations and screening of human skin cancer specimens will be necessary to understand
the function of the TIG-3 protein and the role of TIG-3 in squamous carcinogenesis and epidermal
differentiation.
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Notch1 Functions as an Essential Determinant of Keratinocyte Exit from the Cell Cycle
and Entry into Differentiation
C. Talora, A. Rangarajan, F. Radtke,* R. Okuyama, and P. Dotto
Dermatology Department, CBRC, Harvard Medical School and Mass. General Hosp., Charlestown,
Massachusetts; *Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland
The molecular mechanisms that control the balance between epithelial cell growth and
differentiation are likely to involve a complex interplay between classical cell regulatory pathways
and development-related signals. Our ®ndings indicate that when primary keratinocytes are
induced to differentiate endogenous Notch activity increases, while inhibition of Notch activation
suppresses differentiation. Ectopic expression of activated Notch1 causes keratinocyte growth arrest
by a p21WAF1/Cip1- dependent mechanism, inducing p21WAF1/Cip1 expression at the
transcription level in a RBP-Jk-dependent fashion. Activated Notch1 induces also the early
differentiation markers associated with the transition from the basal to intermediate epidermal
layers, while suppressing the late markers characteristic of the outermost epidermal layers. In
parallel with these effects, enhanced Notch1 activity causes loss of adhesion of keratinocytes to the
substratum and down-modulation of integrin b1 and b4 expression. Thus, Notch1 appears to
function as a key determinant of the ordered transition between keratinocyte growth and early vs.
late stages of differentiation.
814
Modulation of mRNA Level of Darier Disease Gene in Cultured Human Keratinocytes
by UV and Calcium Concentration and the Effects of Antisense Oligonucleotide on
ATP2A2 in Cultured Skin Explant
N. Mayuzumi, S. Ikeda, and H. Ogawa
Dermatology, Juntendo University, Tokyo, Japan
Darier Disease (DD) is an autosomal dominantly inherited skin disorder characterized histologically
by acantholysis and dyskeratosis of keratinocytes. Although DD was found to be caused by
mutations in the ATP2A2 encoding sacro/endoplasmic reticulum calcium ATPase type 2 isoform
(SERCA2), the pathomechanism links between gene mutations and the formation of unique
histology is still uncertain. In this study, we initially examined the mRNA expression levels of
ATP2A2 in cultured normal human keratinocytes using the on-line ¯uorescence quantitative RT-
PCR system (Light Cycler) after UV-B irradiation and by increasing extracellular calcium
concentration. We then determined the effects of SERCA inhibitor (Thapsigargin) and sense and
antisense oligonucleotides on SERCA2 and SERCA 3 in cultured skin explants. The expression of
ATP2A2 mRNA in cultured keratinocytes was suppressed temporarily after UV irradiation. A
temporary increase was achieved after switching from a low to high extracellular calcium
concentration. The SERCA inhibitor, the antisense oligonucleotide to SERCA2 (but not the
sense oligonucleotide to SERCA2) and the antisense oligonucleotide to SERCA3 can induce
morphological changes similar to DD in organ cultured normal human skin explant. These results
suggest that modulation of ATP2A2 mRNA expression by environmental factors might contribute
to the formation of the lesions seen in DD and points to haploinsuf®ciency as being the
pathological mechanism underlying the disease. Because ATP2A2 hemi-knock out mouse did not
show any skin manifestations, this organ culture system will most likely have application only as a
skin model for DD.
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Wnt-4 is Down-Regulated Early in Wound Healing in the Rat: Elucidating the Role of
Morphogens in Tissue Repair Processes
R. Galiano, T. Elias, M. Armour, and G. Gurtner
Plastic Surgery, NYU Medical Center, New York, New York
The Wnt family of morphogens is important in developmental processes such as body axis
development, CNS formation and limb/digit growth. Wnt-4 in particular has been detected in
wounds and is thought to be important in epithelial±mesenchymal interactions in the skin. Prior
studies of Wnt expression in wounds were limited due to the use of degenerate PCR primers. We
therefore sought to de®nitively determine the expression of Wnt family members in wounds, and
to determine if the expression of Wnt-4 is altered during the course of skin wound repair. A 6-mm
punch was used to create full-thickness wounds on the dorsal skin of 30 rats. Using gene-speci®c
primers, we detected by RT-PCR the expression of 10 different Wnt genes, including Wnt-4, in
unwounded skin and wounds. In addition, we utilized nonradioactive RNAse protection assays to
measure the relative changes in Wnt-4 and GAPDH expression as a function of healing. GAPDH
levels did not vary at any of the time points tested. However, Wnt-4 RNA expression was down-
regulated by 60% as early as 12 h postwounding; by day 7 levels had risen to 75% that of
unwounded skin and had normalized to levels found in unwounded skin by day 21. This is the ®rst
report to show a change in a Wnt family member during wound healing processes. In addition, we
have demonstrated a more widespread expression of Wnt family members in skin and wounds than
has been previously been reported. These results suggest that the Wnt family of morphogens may
be important in the baseline maintenance of skin morphology as well as the restoration of proper
form and architecture following skin injury.
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Generation of Inducible NF-kB Subunits: Con®rmation of a Primary Growth Inhibitory
Role for NF-kB in Epidermal Cells
Y. Zhang and P. Khavari
VA Palo Alto and Department of Dermatology, Stanford University, Stanford, California
The IKK/NF-kB axis has recently been appreciated as a dominant epidermal regulator, with IKK
dysfunction established as central in incontinentia pigmenti and constitutive NF-kB activation
leading to epidermal growth inhibition. These data suggest that NF-kB may be the primary
mediator of the effects of this axis on epidermal growth. The relative importance and physiologic
role of NF-kB subunits, however, has recently been questioned as an artifact of constitutive
overexpression and a model advanced in which growth inhibition of this axis is mediated by IKK
targets other than NF-kB. To resolve this, we have generated inducible mutant estrogen receptor-
(ER) fusions of all ®ve NF-kB subunits [p65, p50, p52, c-rel, relB] to de®ne the effects of direct,
temporally regulated NF-kB induction. Expression of the NF-kB subunit ER-fusions in primary
keratinocytes via retroviral transduction produced expected NF-kB-driven transcription in the
following order of potency p65 RelB c-rel p50 p52. NF-kB-ER fusions translocated from
cytoplasm to nucleus upon tamoxifen treatment in primary keratinocytes. This induction was
speci®c in that it did not alter transcription directed by other promoter elements, including those
driven by AP1. Upon induction, all 5 NF-kB subunits caused rapid keratinocyte growth inhibition
with the level of inhibition correlated with the level of transcriptional potency of each subunit.
These growth inhibitory effects were blocked by a dominant-negative form of IkB that can
physically bind and sequester all 5 NF-kB subunits, indicating a primary role for NF-kB in
triggering epidermal cell growth arrest. To study the effects of temporally controlled NF-kB
induction in vivo, transgenic mice targeting all 5 inducible subunits to epidermis are being
generated. These data indicate that direct induction of NF-kB is suf®cient to trigger epidermal
growth arrest, characterize a full panel of NF-kB subunits subject to exogenous control and
indicate that NF-kB subunits exert differential activity in growth inhibition associated with their
transcriptional potency in epidermal cells.
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Regulated Induction of Ras and its Effectors in Epithelial Cells
M. Tarutani, M. Dajee, and P. Khavari
VA Palo Alto and Department of Dermatology, Stanford University, Stanford, California
Ras GTPases, acting via 3 main effector pathways, Raf, PI3K and RalGDS, alter growth and
differentiation in many tissues. Ras effects, however, can vary depending on tissue setting and
signal strength, with strong constitutive Ras signal inductive of growth arrest in normal cells. In
epidermis, Ras is best characterized in neoplasia models, however, these studies rely on a
constitutive Ras activation that may not re¯ect the impact of the spatially controlled, physiologic
strengths of Ras activation we have recently identi®ed in normal epidermis. To regulate Ras signal
strength and study the range of Ras function in a temporally controlled manner, we generated a
panel of tamoxifen (4OHT)-responsive mutant estrogen receptor (ER)-H-Ras fusions, including
N-terminal ER additions and myristylated C-terminal fusions; to study relative contributions of
Ras downstream effectors, we have also generated ER-fusions to Raf, RalGDS as well as the PI3K
target Akt. N-terminal ER-Ras fusions displayed no detectable leakiness and strongly induced Ras
activity in response to 4OHT when expressed in primary keratinocytes via retroviral transduction.
Addition of high concentrations of 4OHT, while displaying no effect on growth or differentiation
of lacZ controls, inducibly suppresses growth in cells expressing ER-Ras as does overexpression of
constitutively active Ras; ER-Ras expressing cells without 4OHT proliferate normally. In
addition, inducible Ras actively suppresses induction of keratinocyte differentiation markers by
calcium. Interestingly, inducible activation of Akt leads to increased differentiation marker
expression and growth inhibition suggesting that the impacts of downstream Ras effectors may
exert distinct ± and sometimes opposing ± effects and that non-PI3K pathway Ras effectors may be
dominant mediators of Ras effects on cellular differentiation in this setting. Consistent with this,
Raf-ER fusions inducibly suppress differentiation. The effects of regulated induction of Ras and its
effectors are being characterized in epidermal tissue via generation of mice transgenic. Taken
together, these data provide a new approach to regulate the function of Ras and its effectors in
order to study Ras pathway impacts on epidermal growth and differentiation.
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Iron Chelators Inhibit VCAM-1 Expression in Human Dermal Microvascular
Endothelial Cells
S. Koo, K. Casper, and R. Swerlick
Dermatology, Emory University, Atlanta, Georgia
Vascular cell adhesion molecule (VCAM) 1 gene expression may be coupled to oxidative signals
through speci®c redox-sensitive regulatory pathways. Iron may play a role in generation of reactive
oxygen and lipid species that participate in signaling pathways. To investigate the role of iron in
VCAM-1 gene expression, human dermal microvascular endothelial cells (HDMEC) were
stimulated with TNF in the presence or absence of iron chelators and examined for induced
expression of VCAM-1 protein and mRNA by ELISA and real-time PCR, respectively. Both
dipyridyl (DP) and desferrioxamine (DFO) inhibited VCAM-1 protein and mRNA induction in a
dose- and time-dependent manner. DP also inhibited the induction of ICAM-1 and E-selectin, but
inhibition required higher doses than those effective in blocking VCAM-1 induction. In order to
rule out a metal chelation-independent antioxidant effect, we examined the effect of DMPO, a
nonmetal binding ROS scavenger. The induction of VCAM-1, ICAM-1 and E-selectin was not
inhibited by DMPO, implying a direct effect of iron in the expression of these adhesion molecules.
Since oxidative signaling has been implicated in NF-kB activation, we utilized electrophoretic
mobility shift assays to examine whether DP pretreatment of HDMEC would inhibit TNF-
mediated NF-kB activation and translocation. TNF treatment resulted in increased binding of
nuclear-derived p50/p65 complexes to an oligonucleotide corresponding to the VCAM-1 kB
elements. Pretreatment of HDMEC prior to TNF treatment had no effect on the nuclear
localization of these complexes. These data demonstrate that iron chelation inhibits cytokine
mediated VCAM-1 protein and mRNA up-regulation but does not affect NF-kB activation or
DNA binding.
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MEK7-Dependent Activation of p38a Map Kinase Increases Differntiation-Associated
Gene Expression in Keratinocytes
S. Dashti, T. E®mova, and R. Eckert
Physiology and Biophysics, and Dermatology, Case Western Reserve Univeristy School of Medicine,
Cleveland, Ohio
However, the kinase that functions immediately downstream of MEK7 has not been identi®ed.
Our present studies show that constitutively active MEK7 markedly increases p38a activity, but
not the activity of the other p38 isoforms (b, d and g). This p38a-dependent activation is not
accompanied by any change in p38a levels. Pharmacologic inhibitors of p38a activity also inhibit
the MEK7-dependent increase. Additional evidence shows that the other major MAPK signaling
families, the JNK and ERK kinases, do not participate as MEK7-dependent gene activators. We
also demonstrate that this regulation is physiologically important, as the MEK7-associated p38a
activity increases hINV promoter activity and expression of the endogenous hINV gene via an AP1
transcription factor-dependent mechanism. The observation that MEK7 regulates gene expression
via activation of p38 MAPK signaling is a completely novel ®nding, as previous reports, in a variety
of systems, have assigned JNK as the sole downstream target of MEK7. We conclude that MEK7
regulates hINV gene expression via a novel MAPK regulatory cascade that includes PKC, Ras,
MEKK1, MEK7, and p38a.
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MEK6 Regulates Human Involucrin Gene Expression Via a p38a and d-Dependent
Mechanism
S. Dashti, T. E®mova, and R. Eckert
Physiology and Biophysics, and Dermatology, Case Western Reserve Univeristy School of Medicine,
Cleveland, Ohio
Involucrin (hINV) is an important marker of epidermal keratinocyte differentiation, and hINV
gene expression is regulated by signals transmitted via the mitogen-activated protein kinase
(MAPK) cascades. A MAPK cascade that includes PKC, Ras, and MEKK1 regulates involucrin
(hINV) gene expression in epidermal keratinocytes (E®mova et al, J Biol Chem 273:24387, 1998;
E®mova et al, J Biol Chem 275:1601, 2000). However, since signal transfer downstream of MEKK1
may involve more than one of the seven MAPK kinases (MEKs), it is important to evaluate the
regulatory role of each MEK isoform. In the present study we con®rm that MEK6 is expressed in
keratinocytes and we evaluate the role of MEK6 in transmitting the MEKK1-dependent signal.
We show that constitutively active MEK6 (caMEK6) increases hINV promoter activity and
increases endogenous hINV levels, while dominant-negative MEK6 (dnMEK6) decreases
expression. The caMEK6-dependent increase in gene expression is inhibited by the p38 MAPK
inhibitor, SB203580, and is associated with a marked increase in p38a MAPK activity; JNK and
ERK kinases are not activated. In addition, hINV gene expression is inhibited by dominant-
negative p38a. caMEK6 also activates p38d and overexpression of p38d inhibits the caMEK6-
dependent increase in hINV gene expression. These results suggest that MEK6 increases hINV
gene expression via a unique mechanism that involves modulating the balance between activation
of p38a, which increases gene expression, and p38d, which decreases gene expression.
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Oligonucleotide-Induced MAP Kinase Signaling Events in Human Keratinocytes
J. Maschke, A. Mirmohammadsadegh, K. Bohner, F. Tschakarjan, and U. Hengge
Department of Dermatology, Venerology and Allergy, University of Essen, D-45122 Essen, Germany
Oligonucleotides (ODNs) are currently under investigation for therapeutic purposes due to their
immune stimulatory effects mediated through CpG sequences. Furthermore, antisense ODNs are
used as agents against cancer and viral infections. Because skin gene therapy is a new approach to
treat diseases, we started to examine the in vitro modulation of the mitogen-activated protein
(MAP) kinase signaling pathways and of activator protein (AP) 1 and AP2 transcription factors in
normal human keratinocytes (NHKs) exposed to ODNs. Using immunoblot techniques, we found
AP2 almost exclusively in the nuclear compartment upon exposure of NHKs to ODNs (100 pM,
12 h). In addition, AP2 protein was decreased when compared to unstimulated or phorbol ester
(TPA) treated cells. MAP kinase p38 was induced as soon as after 2 min by ODN exposure and
returned to basal levels within 15 min Control stimulation with TPA induced maximum p38 MAP
kinase phosphorylation at 15 min Therefore, early and short-termed p38 MAP kinase activation
may be responsible for the induction of in¯ammatory cytokine production in NHKs upon
exposure to ODNs.
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Differential Target Gene Induction Mediates Opposing Growth Effects of NF-kB in
Keratinocytes and Fibroblasts
K. Hinata and P. Khavari
VA Palo Alto and Department of Dermatology, Stanford University, Stanford, California
NF-kB in¯uences cellular processes that include in¯ammation, apoptosis and cell division. In
epidermis, NF-kB inhibits both growth and death, in contrast to its effects in other cell types
which can include promotion of both processes. In skin, for example, the NF-kB inducer TNF-a
is associated with growth inhibition in keratinocytes and growth promotion in dermal ®broblasts.
To explore the basis for these differences, we expressed NF-kB in primary keratinocytes and
®broblasts at 95% ef®ciency via retrovectors. In order to identify NF-kB targets we used high
density cDNA microarrays and 2D gel analysis to characterize NF-kB genomic and proteomic
targets. Striking differences between keratinocytes and ®broblasts were found in NF-kB induction
of growth regulatory genes. In keratinocytes, growth inhibitory genes including p21 and GIF
(Growth Inhibitory Factor) were up-regulated by NF-kB, whereas in ®broblasts these genes were
not induced. Instead, growth promoting genes including cyclin B1, FGF-2 and FGF-5 were up-
regulated. Consistent with this, NF-kB caused growth arrest in keratinocytes while it supported
rapid ®broblast proliferation. Overexpression of p21 alone in keratinocytes is suf®cient for growth
inhibition similar to that caused by NF-kB and, not surprisingly, p21 has the same effect in
®broblasts, indicating that the difference in NF-kB growth effects in the two cell types is
determined by differential target gene induction. p53 is known to be involved in p21 up-regulation
in response to UV irradiation. To test whether the induction of p21 by NF-kB in keratinocytes is
p53-dependent, we transiently transfected NF-kB or its super repressor IkBaM, along with a
reporter construct expressing luciferase driven by the p53-binding site of the p21 promoter. No
signi®cant difference was observed in p53-directed transcription compared with control, indicating
that NF-kB induction of p21 may be p53-independent in keratinocytes. These data suggest that
cell type speci®c responses to NF-kB are mediated by differential target gene induction, that cell
speci®c effects can be mimicked by expressing target genes and that NF-kB growth inhibition in
keratinocytes may mediated through p53-independent induction of growth inhibitory targets that
include p21Cip1 and GIF.
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Phospholipase C-g1 is Required for 1,25-Dihydroxyvitamin D-Induced Keratinocyte
Diffrentiation
Z. Xie and D. Bikle
Endocrine Unit, VA Medical Center, University of California, San Francisco, San Francisco, California
Keratinocytes produce vitamin D3 and convert it to the most active form, 1,25-dihydroxyvivtamin
D3 [1,25(OH)2D3] which in turn regulates keratinocyte proliferation and differentiation.
Phospholipase C-g1 is the most abundant member of the phospholipase C family in keratinocytes
and is induced by 1,25(OH)2D3. Therefore, we examined the hypothesis that phospholipase C-g1
played an essential role in the signaling pathway mediating 1,25(OH)2D3-induced keratinocyte
differentiation. Phospholipase C-g1 expression in human keratinocytes was reduced by transfecting
the cells with an antisense PLC-g1 construct then evaluating the response of the keratinocyte
differentiation markers involucrin and transglutaminase to 1,25(OH)2D3. The results showed that
1,25(OH)2D3 induced involucrin and transglutaminase protein and mRNA levels were markedly
reduced in keratinocytes transfected by the antisense phospholipase-g1 construct. Similarly,
cotransfection of keratinocytes with an involucrin or transglutaminase promoter construct and the
antisense phospholipase C-g1 construct showed decreased involucrin and transglutaminase
promoter activity, respectively, in response to 1,25(OH)2D3. To further investigate the mechanism
by which phospholipase-g1 regulates keratinocyte differentiation, the calcium level in keratinocytes
transfected by the antisense phospholipase C-g1 construct was measured following 1,25(OH)2D3
administration. The increase in keratinocyte intracellular free calcium level following
1,25(OH)2D3 administration was markedly reduced by the transfection of the antisense
phospholipase C-g1 construct. These studies indicate that phospholipase C-g1 plays a critical
role in the signal transduction pathway mediating 1,25(OH)2D3-induced keratinocyte differentia-
tion at least in part by mediating the increase in intracellular calcium mobilization following
1,25(OH)2D3 administration.
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Delayed Dermal Fibroblast Aging and Promotion of a Matrix Synthetic Phenotype with
Novel Nitrone-Based Free Radical Trap Molecules
M. McKay, B. Fuller,* and B. Pilcher
Cell Biology and Dermatology, UT South-western Medical Center, Dallas, Texas; *Biochemistry and
Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Innate cutaneous aging progresses as a consequence of organismal aging and results in skin
de®ciencies such as ®ne wrinkling, epidermal and dermal atrophy, loss of subcutaneous fat,
decreased rates and quality of wound repair, and an increased susceptibility to wounds that fail to
heal. The free radical theory of aging proposes that reactive oxygen species cause oxidative damage
over the lifetime of the organism and that the accumulated oxidative insults contribute to many of
the dysfunctions and pathologies associated with aged skin. Previous studies have implicated
oxidative damage in promoting replicative senescence in dermal ®broblasts. Senescent ®broblasts
accumulate in the dermis with increased age, remain metabolically active, and switch their gene
expression patterns from that which supports the extracellular matrix milieu to one that results in
progressive destruction of the tissue (e.g. up-regulation of collagenase-1 and down-regulation of
type I collagen). Nitrone-based free radical trap molecules have been shown to increase lifespan
and reverse age-associated de®ciencies in cognitive function in an experimental mouse model.
Furthermore, treatment of human diploid ®broblasts with a molecule from this class (a-phenyl-N-
tert-butyl-nitrone, PBN) delays senescence and rejuvenates those close to senescence. The present
study was undertaken to determine if CX-412, a novel nitrone-based free radical trap, could
prevent dermal ®broblast senescence or reverse the gene expression patterns associated with
senescent cells. Human dermal ®broblasts were isolated from neonatal foreskins and aged in vitro in
the presence of vehicle control or CX-412 (25±500 mM). We found that extended treatment of
dermal ®broblasts (4 days to 3 months) with CX-412 resulted in a dose-dependent stimulation of
clonal cell growth and 3H-thymidine uptake, signi®cantly improved cell morphology, and a
marked reduction in the expression of senescence-associated b-galactosidase activity when
compared to vehicle control. Interestingly, cells treated with CX-412 had an extended lifespan of
approximately 10 population doublings when compared to cells treated with vehicle alone. CX-
412-treated ®broblasts were not immortalized or transformed, however, as no telomerase activity
or growth in soft agar was noted. CX-412 also reversibly inhibited the expression of genes
associated with senescent ®broblasts. Cells treated with CX-412 chronically (4 days to 3 months) or
acutely (0±72 h) demonstrated a signi®cant dose-dependent inhibition of collagenase-1 and
enhanced expression of type I collagen mRNA. Thus, treatment of dermal ®broblasts with CX-
412 prolongs proliferative lifespan and prevents the expression of senescence-associated proteolytic,
destructive genes and induces a matrix synthesis phenotype.
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Up-Regulation of Galanin Gene Expression by Heat Treatment in Human Keratinocytes
J. Bauer,* D. Almer, B. Ko¯er, A. Klausegger,* and W. Sperl
Department of Pedriatrics, *Department of Dermatology, General Hospital, Salzburg, Austria
Neuropeptides, that innervate the skin mediate actions important in skin in¯ammation and wound
healing by induction of vasodilatation, plasma extravasation, cytokine production or adhesion
molecule expression. Based on our previous observation that the neuropeptide galanin (GAL) is
expressed in epithelial cells of the skin (1), we analysed the thermal regulation of GAL gene
expression in the human keratinocytes (KC). mRNA expression of GAL and Heat Shock Protein
70 (HSP70) in primary cultured human KC was detected by Northern Blot analysis. GAL-like
immunoreactivity was determined by immunohistochemistry and GAL peptide concentration by
ELISA. Northern Blot analysis revealed a 100-fold induction of GAL and HSP70 mRNA in KC
by heat treatment at 42°C. In vivo the GAL-like immunoreactivity in KC of human epidermis is
decreased 2 h after heat treatment (75 J per cm2). After 24 h GAL staining was similar to untreated
skin. Furthermore, we detected high amounts of GAL peptide in the supernatant of heat treated
human cultured KC and blister ¯uid of burned human skin. Therefore, we speculate that GAL
released by KC might be involved in the pathophysiology of the burn reaction probably via its
known effect on vasodilatation and plasma extravasation.
1. Ko¯er et al, Arch Derm Res 210:56, 1998
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Identi®cation of Novel TGF-b/Smad Gene Targets in Dermal Fibroblasts Using a
Combined cDNA Microarray/Promoter Transactivation Approach
A. Mauviel, F. Verrecchia, and M. Chu*
Skin Research Institute, INSERM U532, Paris, France; *Dermatology and Cutaneous Biology, Thomas
Jefferson University, Philadelphia, Pennsylvania
Despite major advances in the understanding of the intimate mechanisms of transforming growth
factor-b (TGF-b) signaling through the Smad pathway, little progress has been made in the
identi®cation of direct target genes. In this report, using cDNA microarrays, we have focussed our
attention on the characterization of extracellular matrix-related genes rapidly induced by TGF-b in
human dermal ®broblasts, and attempted to identify the ones whose up-regulation by TGF-b is
Smad-mediated. For a gene to qualify as a direct Smad target, we postulated that it had to meet the
following criteria: (1) rapid (30¢) and signi®cant (at least 2-fold) elevation of steady-state mRNA
levels upon TGF-b stimulation (2) activation of the promoter by both exogenous TGF-b and
cotransfected Smad3 expression vector, and (3), up-regulation of promoter activity by TGF-b
blocked by both dominant-negative Smad3 and inhibitory Smad7 expression vectors. Using this
stringent approach, we have identi®ed COL1A2, COL3A1, COL6A1, COL6A3 and TIMP-1 as
de®nite TGF-b/Smad3 targets. Extrapolation of this approach to other extracellular matrix-
related-gene promoters also identi®ed COL1A1 and COL5A2, but not COL6A2, as novel Smad
targets. Together, these results represent a major step toward the identi®cation of novel, early
induced, Smad-dependent TGF-b target genes in ®broblasts.
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cDNA Microarray Analysis of Gene Expression in Non-Melanoma Skin Cancer
N. Montiel, H. King, D. Becker, and A. Sinha
Dermatology, Weill Medical College of Cornell University, New York, New York
We have sought to determine gene expression differences between basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC) lesions and normal skin at a genome-wide scale. Total RNA was
prepared from lesional and site-matched nonlesional skin biopsy samples from patients with biopsy
proven BCC or SCC and enriched for mRNA. cDNA was then synthesized, radiolabeled, and
hybridized to Atlas Human Cell Interaction Arrays. These arrays allow the simultaneous analysis of
expression of 265 genes. Expression was quantitated using a Storm 840 PhosphorImager, and
analysis was performed using ImageQuant 1.2 software (Molecular Dynamics). Preliminary results
for BCC show that 13 genes exhibited differential expression, which was de®ned as a two-fold or
greater difference in expression between lesional and nonlesional tissue, in at least two patients.
Genes of interest include the malignant melanoma metastasis-suppressor gene and the L1 neural
cell adhesion molecule precursor, which have been previously implicated in melanoma. Also of
note were ezrin, which is in the same gene family as moesin (previously shown to have altered
expression in BCC and SCC); and PuF, which has been shown to transactivate the c-myc gene
(overexpressed in many tumors of the skin). Preliminary results for SCC show that approximately
20 genes exhibited differential expression. Genes of interest include sonic hedgehog, patched
homolog, and smoothened, all of which have previously been implicated in BCC but not SCC.
These results are being con®rmed with a larger data set and with Affymetrix Human Genome
U95A Arrays, which permit the simultaneous analysis of expression of approximately 12 500
sequences. These data on the global patterns of gene expression in BCC and SCC should allow
further insights into disease pathogenesis and basic mechanisms of skin oncogenesis.
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Gene Expression Pro®ling in In¯ammatory Skin Disease by cDNA Microarray Analysis
H. King, R. Pothiraj, and A. Sinha
Dermatology, Weill Medical College of Cornell University, New York, New York
In¯ammatory skin diseases, including psoriasis vulgaris and atopic dermatitis, are chronic,
polygenetically determined skin disorders. The expression levels of many genes have been shown
to be increased in lesional psoriatic and atopic skin, but in spite of these advances, broad
perspectives on the gene expression abnormalities characterizing these disorders have been
unavailable. Thus far, functional genomic studies have been of limited scope, only able to elucidate
the role of one or a few genes at a time in one system. To this end, we are utilizing the technology
of high density oligonucleotide arrays, or so-called ``gene chips'', to systematically and
comprehensively document differential gene expression between psoriatic and atopic skin and
normal skin at a genome-wide scale. Total RNA was prepared from lesional and site matched
nonlesional skin biopsy samples from ®ve patients with stable chronic plaque psoriasis, and from
two patients with atopic dermatitis. The RNA was then reverse transcribed and labeled using
¯uorescent nucleotides, followed by hybridization to Affymetrix Human Genome U95A Arrays.
These arrays permit the simultaneous analysis of expression of approximately 12 500 sequences that
have been previously characterized in terms of function or disease association. Up- and down-
regulated sequences are currently being con®rmed and catalogued. Study of global patterns of gene
expression in psoriasis and atopic dermatitis form a basis for further insights into the pathogenesis of
in¯ammatory skin disease.
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Analysis of the UVB Response in Primary Human Keratinocytes Using Oligonucleotide
Microarrays
A. Sesto, M. Navarro, F. Burslem,* and J. Jorcano
Cell and Molecular Biology and Gene Therapy, CIEMassachusettsT, Madrid, Spain; *P®zer Global R &
D, Sandwich, Kent, United Kingdom
UV light is the most important physical carcinogen in the environment, and the skin is its natural
target. UVB irradiation of skin keratinocytes produces characteristic mutations, but also causes the
induction or repression of a number of genes. Our aim is to identify the subset of genes whose
transcription is altered during the UVB response in human keratinocytes using microarray
technology. We have used commercial high density oligonucleotide arrays (HuGeneFL,
Affymetrix), capable of detecting transcript levels of over 6000 human genes, to analyze RNAs
from primary human keratinocytes irradiated with three different UVB doses (10, 20 and 40 mJ per
cm2) at two time points post irradiation (4 and 24 h). The data analysis shows that approximately
10% of the represented transcripts are affected by UVB irradiation. Approximately 200 genes
changed their expression 4 h after irradiation, 30% of which were induced. At 24 h, the number of
affected genes was increased to around 550, and the percentage of induced genes also rose to 50%.
Using GeneCluster software these genes were further organized into nine discrete groups,
according to their pattern of induction or repression at the different times and doses. In addition to
®nding genes already known to respond to UVB, such as GADD45, cyclooxygenase 2, and
members of the matrix metalloprotease and interleukin gene families, we have also identi®ed
several genes whose response to UV has not been described. These include transcripts involved in
adhesion, angiogenic and proliferative events. Our data demonstrate the complexity of the
transcriptional response to UVB light in keratinocytes and supports the use of this kinetic model to
undertake a global characterization of UV regulated genes and pathways.
830
Characterization of a Complex Interacting Gene Regulation Pro®le by Microarray
Analysis in Human Skin Triggered by Simulated Solar Radiation
M. Takahara, C. Bosko,* K. Cooper, H. Ramirez, B. Jones,* L. Jiang, J. Nadeau, J. Teal, S.
Stevens, and T. McCormick
Departments of Derm. and Genetics, University Hosp. Research Institute and Case Western Reserve
University, Cleveland, Ohio; *Avon Products, Inc, Suffern, New York, New York
DNA microarray analysis allows establishment of a pattern of gene expression from multiple genes
and facilitates an understanding of the complex interactions elicited by selective interventions such
as exposure to ultraviolet radiation. In this study, keratome biopsies were taken from exposed and
normal skin of ®ve human subjects 32 h following exposure to 4 MED solar simulated radiation
(SSR). To minimize interindividual variation, fractions of tissue from the ®ve subjects were pooled
prior to RNA extraction. Following microarray hybridization, gene expression was quanti®ed via
phosphoimage analysis, normalized to the average density of all the genes on the membrane and
corrected for background hybridization using ImageQuaNTTM software. The entire extraction,
array procedure, and calculation of the gene changes was repeated ®ve times on the pooled tissues,
and the change in each gene's expression from ®ve hybridizations was averaged (n = 5). Gene
changes two standard deviations either above or below baseline were considered signi®cant and
provided an expression pro®le associated with SSR. Up-regulation of gene expression following
SSR was con®rmed by RT-PCR analysis for selected genes. Thus, these ®ndings constitute a
unique gene expression/regulation pro®le of human skin under in vivo SSR challenge. Study of
selective pro®le modi®cations as well as speci®c novel gene changes following in vivo interventions
may lead to new understandings of complex regulatory pathways and the relative ef®cacy of
interventions.
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Identi®cation of Mutated as well as Differentially Expressed Sequences in a Cutaneous
Lymphoma Line by the Novel Ligation Mediated Subtraction (Limes)
T. Hansen-Hagge, U. Trefzer, A. zu Reventlow, K. Kaltoft,* and W. Sterry
Department of Dermatology and Allergy, Medical Faculty ± ChariteÂ, Humboldt-University, Berlin,
Germany; *Institute of Human Genetics, University of Aarhus, Aarhus, Denmark
Primary cutaneous T- and B-cell lymphoma have a largely unknown etiology and exhibit
considerable variation in clinical presentation, histology, immunophenotype or prognosis. In order
to contribute to a better understanding of their biology and etiology, the representational
difference analysis (RDA) was used to isolate tumor-associated mutations from a cutaneous
lymphoma cell line (My-La). RDA and other subtraction techniques allow to enrich sample-
speci®c sequences by elimination of ubiquitous sequences existing in both, the sample of interest
(tester) and the subtraction partner (driver). After application of RDA to genomic DNA, however,
repetitive sequences and arti®cial fusion products of otherwise independent PCR fragments (PCR
hybrids) were predominately isolated. Since these products severely interfered with the isolation of
tumor-relevant fragments, we developed a considerably more robust and ef®cient approach, which
is termed ligation mediated subtraction (Limes), because the resistance of this novel method to
artifact production is mediated by a highly speci®c and exclusive ligation of oligonucleotides to the
ends of perfectly matched tester/tester hybrids. In ®rst applications of Limes, genomic sequences
and/or transcripts of genes involved in the regulation of transcription such as the transforming
growth factor b stimulated clone 22 related gene (TSC-22R), cell death and cytokine production
(caspase-1), or antigen presentation (HLA class II) were found to be absent in My-La. Moreover,
mutations in¯uencing the transcription pattern of the affected genes, were identi®ed by a modi®ed
Limes protocol. Due to these results, Limes may substitute/supplement other techniques such as
RDA or DNA microarray techniques in a variety of different research ®elds.
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Microarray Analysis of Gene Expression Following Exposure to Skin Irritants
S. Fletcher, V. Baker, J. Fentem, D. Basketter, and D. Kelsell*
SEAC Toxicology, Unilever Research, Sharnbrook, United Kingdom; *Centre for Cutaneous Research,
Queen Mary and West®eld College, London, United Kingdom
Understanding of the mechanistic basis of the human skin irritation response is key to the
development of relevant in vitro test systems for the predictive identi®cation of skin irritation
hazards. Recent progress in genomic technologies means that tools for the identi®cation and
investigation of important biochemical events in the processes of skin irritation are now available.
This work was designed to identify genes for further mechanistic investigation which are regulated
in response to skin irritation, following exposure of the EpiDerm(tm) skin model to the known
irritant sodium lauryl sulphate (SLS). EpiDerm(tm) cultures were treated in triplicate with a
noncytotoxic dose of SLS (0.1 mg per ml, as determined by the MTT assay and histological
examination) for 15 min, 30 min, 1 h, 2 h, 3 h, 4 h and 24 h. Total RNA was extracted from
pooled EpiDerm(tm) cultures and used to probe Atlas(tm) human arrays (Clontech) covering
approximately 3600 genes. Data indicated an up-regulation at early time points (15±30 min) of a
number of genes involved in transportation (e.g. the sodium and chloride dependent taurine
transporter) and receptors (e.g. ZAP70). The gene encoding the UV excision repair protein and
other DNA repair genes (e.g. DNA-directed RNA polymerase II) were up-regulated at 1±3 h
along with TGFb3 and other tumour suppressors (which play a role in cellular development and
wound healing). At the later time points of 4±24 h, genes involved in protein translation (e.g.
Cathepsin D receptor) and metabolism (e.g. CYP27A) were up-regulated. In addition, a number
of genes were down-regulated in response to treatment with SLS, although these followed less of a
time dependent pattern. These results indicate the differential regulation of a number of genes in
response to treatment with SLS which may provide insights into the molecular events in the
response to this irritant.
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Microarray Analysis of Cutaneous Basal Cell Carcinomas
M. Libkind, T. Belbin,* G. Childs,* J. Prystowsky², and M. Prystowsky
Pathology, Albert Einstein College of Medicine, Bronx, New York; *Molecular Genetics, Albert Einstein
College of Medicine, Bronx, New York; ² Surgery, Columbia University Medical Center, New York, New
York
Background: Basal cell carcinomas (BCC) are the most common cutaneous malignancy. Although
linked to UV exposure, the carcinogenic pathway of BCC has not been elucidated. Microarray
analysis is a high through-put method of screening thousands of genes simultaneously. We used
microarray analysis to identify gene expression differences between BCC and normal keratinocytes.
Design: Fresh tissue from 7 cases of cutaneous BCC, including surrounding normal skin, was
obtained. Labeled cDNA probes were synthesized (Cy5 for tumor, Cy3 for normal), and applied to
microarrays containing approximately 9000 human genes. The microarrays were scanned and
analyzed to determine gene expression. BCC genes were considered overexpressed compared to
normal epidermal genes when the red to green ratio was greater than 1.8. Results: We identi®ed 9
genes overexpressed in at least 5 of the 7 BCC (compared to corresponding normal tissue). A third
of these are known cancer associated genes, including squamous cell carcinoma antigen 1, and S100
calcium binding protein. One EST (expressed sequence tag) was increased in 6 of the 7 BCC. In
addition, a subgroup of four closely related tumors was isolated by gene cluster analysis. These
tumors over-expressed a group of genes not increased over normal skin in the other BCC samples.
Conclusion: Microarray analysis is useful in identifying potential genes involved in BCC
carcinogenesis. In addition, different subgroups of BCC may be revealed, which may differ
clinically as well as genetically.
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Constitutive Expression and Distribution of Cytochrome P450 Isozymes in Normal
Human Skin
A. Lee, W. Choi, D. Ko,* and Y. Kang*
Dermatology, Eulji Hospital University of Medicine, Seoul, South Korea; *Medical Science Institute, Eulji
Hospital University, Seoul, South Korea
Cytochrome P450 (CYP) isozymes play a major role in drug metabolism. The expression and
distribution of CYPs in the skin would be helpful in understanding the cutaneous drug
metabolism. The aim of this study is to examine the constitutive mRNA expression and
distribution of CYP isozymes in the normal human skin. To determine the location better,
epidermis was separated from dermis and immunohistochemistry was carried out. 32 skin
specimens were prepared for semiquantitative RT-PCR to examine mRNA expression. 10 of
them were separated epidermis from dermis by heat (65 C, 2minutes) for the RT-PCR at each
portion. 10 skin specimens were stained with anti-CYP isozyme, 1A1, 2C9, 2E1 and 3A4,
antibodies. The results obtained from the RT-PCR were analyzed and compared with those from
immunohisto-chemical staining. The condition of heat separation was considered reasonable from
the histologic ®ndings and the RT-PCR results. The levels of mRNA expression showed
individual variation, but sex and/or age variation was not signi®cant, except for 2C8/19. mRNA
was expressed higher in epidermis than in dermis, except CYP2E1. Immuno-histochemistry
showed the main location of CYP isozymes was lower portion in epidermis. In dermis,
appendages, such as sebaceous glands, hair follicles, sweat ducts and glands were stained more, it
may explain the regional difference of therapeutic or adverse effects from topical agents. The results
con®rmed the skin to be an important organ for drug metabolism and provided a basic data for the
study of cutaneous drug metabolism.
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Genetics of Keratinocyte Colony Formation in Mice
N. Popova, K. Teti, K. Wu, and R. Morris
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
We tested 7 strains of female mice in a quantitative assay for clonogenic keratinocytes having
characteristics of stem cells from the cutaneous epithelium. We found three signi®cantly different
subsets of colony counts: C57Bl/6>>SENCAR=DBA/2=C3H=BALB/c>CD-1=FVB. Average
counts per 1000 viable cells harvested from dorsal skin ranged from 81.5 6 9.44 for C57Bl/6±
29 6 4.24 for BALB/c to 13.8 6 2.19 for CD±1 (n = 12 6 SEM). C57Bl/6 and BALB/c, two
inbred parental strains were chosen for further analysis. The F1 generation of these two parental
strains had an intermediate number of colonies (53.0 6 6.98; n = 10 6 SEM). Analysis of the
parental strains, the two backcrosses and the intercross demonstrates that keratinocyte colony
number is quantitative multigenic trait. A genome scan maps the number of keratinocyte colonies
to the central region of mouse chromosome 9. The allele on chromosome 9 locus is inherited from
the C57Bl/6 parent and appears to in¯uence the high number of keratinocyte colonies. The
analysis of keratinocyte colony size in two parental strains, the F1 and the segregating crosses
suggests that size of keratinocyte colonies is also a quantitative genetically de®ned trait. We showed
that there are at least two populations of keratinocytes that gave small (less then 2 square mm) and
large (more then 2 square mm) colonies, that are associated with different loci. The C57Bl/6 allele
of the central region chromosome 9 appears to regulate small colonies (genome wide p-
value = 0.01). A locus on the proximal region of chromosome 4 is associated with the large
colonies. We suggest that there are at least two subpopulations of cutaneous progenitor cells
regulated by two different loci. Investigation of genes regulating stem cell number may play an
important role in the development gene therapy or other therapies where it is desirable to
manipulate keratinocyte stem cell number.
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Topical Selection of Keratinocytes Transduced with the Multidrug Resistance (MDR)
Gene Results in Sustained High-Level Transgene Expression In Vivo
W. Pfutzner, T. Kolodka, R. Foster, E. Snead, L. Taichman,* and J. Vogel
Dermatology, National Cancer Institute, NIH, Bethesda, Maryland; *Johnson & Johnson, New Brunswick,
New Jersey
In gene therapy, a clinically relevant therapeutic effect requires long-term expression of the desired
gene at a level suf®cient to correct the underlying gene defect. One solution would be to select for
keratinocytes (KC) expressing both the desired gene and a linked selectable gene, such as the
multidrug resistance (MDR) gene, in a bicistronic vector. Utilizing an in vivo mouse model to
topically select grafts containing MDR-transduced human KC and ®broblasts with colchicine, we
determined: (1) Are MDR-transduced KC protected during topical selection? (2) Can topical
selection increase the percentage of MDR-transduced cells over time and increase the cellular level
of MDR expression? Titration of topical colchicine (100±500 mg per g) on mouse skin and grafted
control (MDR-negative) human KC resulted in a dose-dependent increase of KC blocked in
mitosis (up to 45%) and eventual ulceration. In constrast, MDR-transduced KC treated with
topical colchicine formed an epidermis with normal differentiation and strati®cation and few
mitotic ®gures (approx. 4%), demonstrating protection from the cytotoxic properties of colchicine.
At different time points, colchicine treatment (200 mg per g) of MDR-transduced grafts
signi®cantly increased the percentage of human KC expressing MDR compared to vehicle-treated
controls; approximately 4-fold by FACS at 9 weeks (49 6 9% vs. 13 6 2%) and 10-fold at 15 weeks
(50 6 8% vs. 5 6 1%). The average level of MDR expression per cell was also increased
approximately 2-fold on quantitative FACS analysis. Even when the initiation of topical selection
on MDR transduced grafts was delayed, signi®cant enrichment of MDR-expressing KC could be
achieved, suggesting selection for MDR-expressing KC stem cells. Interestingly, colchicine
selection of grafts containing MDR-transduced human KC with MDR-negative human ®broblasts
further increased MDR-expressing KC (80 6 12%), but had a signi®cant percentage of ulceration
(57%), suggesting that ®broblasts are needed for graft support. Thus, topical selection presents a
strategy to ef®ciently increase long-term high level expression of transgenes linked to MDR by
utilizing both MDR-transduced KC and ®broblasts and holds promise for future clinical
applications.
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Lentiviral Vectors Mediate Highly Ef®cient and Sustained Gene Transfer in Dystrophic
Epidermolysis Bullosa Skin Cells
M. Chen, N. Kasahara,* F. Costa, M. Constance,* and D. Woodley
Division of Dermatology and the Norris Cancer Center, University of Southern California, Los Angeles,
California; *Department of Pathology and Institute for Genetic Medcine, University of Southern California,
Los Angeles, California
Dystrophic epidermolysis bullosa (DEB) is a family of inherited mechano-bullous disorders caused
by mutations in the type VII collagen (COL VII) gene and subsequent perturbations in anchoring
®brils. The lack of therapy for DEB provides an impetus to develop gene therapy strategies which
can offer highly ef®cient transfer and stable expression of genes delivered to the skin cells in vivo. In
this study, we applied a highly ef®cient lentiviral delivery approach to express both a full-length
COL VII a chain and a type VII minicollagen a chain using a self-inactivated third generation
lentivirus-based vector, pRRLsinCMV. Transduction of lentiviral vectors containing COL VII
transgenes into RDEB keratinocytes and ®broblasts (in which COL VII was absent) resulted in the
synthesis and secretion of either a 290-kDa full-length COL VII or a 240-kDa type VII
``minicollagen'' at levels similar to or higher than normal cells. The expression of the COL VII
transgenes was sustained for at least 6 months. Gene-corrected RDEB keratinocytes and ®broblasts
demonstrated an enhanced cell-substratum adhesion and an increased proliferative potential. The
gene-corrected keratinocytes also showed reversal of the hypermotility phenotype characteristic of
RDEB cells. We also carried out a series of gene delivery experiments with cells in culture and
compared the transduction ef®ciencies of the lentivirus-based vector with a retrovirus-based
vector, LZRS. By immunoblot analysis of proteins from conditioned media of viral-transduced
RDEB cells, the expression of minicollagen using lentiviral vectors was signi®cantly higher than
the expression with retroviral vectors. By immuno¯uorescence staining of the transduced cells with
an anti-COL VII antibody, lentiviral vectors achieved a much higher transduction ef®ciency (80±
90%) than retroviral vectors (40±50%). These data indicate that ef®cient COL VII transgene
delivery to keratinocytes and ®broblasts can produce a population of phenotypically corrected
RDEB cells. Lentivirus-based vectors are more ef®cient at transducing human keratinocytes and
®broblasts than retroviral vectors and may be among the most promising approaches to achieve
high ef®ciency and stable gene expression in skin cells.
838
Retroviral Gene Therapy Reverses Cutaneous Granuloma Formation in a Murine Model
of X-Linked Chronic Granulomatous Disease
J. Petersen, W. Goebel,* F. Azmi, A. Hood, J. Travers, and M. Dinauer
Dermatology, Indiana University School of Medicine, Indinapolis, Indiana; *Pediatrics, Indiana University
School of Medicine, Indinapolis, Indiana
As a result of the inability of their phagocytes to undergo a respiratory burst, patients with the
genetic condition chronic granulomatous disease (CGD) develop recurrent infections with
catalase-positive bacterial and fungal pathogens, and are predisposed to chronic in¯ammatory
granulomatous lesions in many organs including the skin. CGD can result from mutations in any
one of four genes encoding different subunits of the leukocyte NADPH oxidase. Thus, CGD is a
candidate disease for gene therapy. Previously, our laboratory has generated a murine model of X-
linked CGD by homologous recombinant deletion of the gp91phox component of the NADPH
oxidase. Functional studies with these X-CGD mice demonstrated exaggerated in¯ammatory
response which consists of neutrophils which later form granulomas in response to intratracheal,
intraperitoneal, or intradermal administration of sterile Aspergillus fumigatus (AF) hyphae, in
comparison to wild-type mice (J Exp Med 185:207, 1997). In our present study, sterile AF hyphae
or PBS vehicle were injected into the ears of X-CGD, wild-type control mice, and X-CGD mice
who have received therapy with bone marrow cells transduced with a replication-de®cient
retrovirus encoding the gp91phox gene. In¯ammation was assessed by obtaining 5 mm punch
biopsies of the injection sites at various times (1±30 days) following injection for weighing and
measurement of ear thickness, as well as histologic evaluation. Intradermal injection of AF (but not
PBS alone) resulted in a signi®cant (p < 0.05, ANOVA) in¯ammatory response in X-CGD mice by
24 h, with formation of neutrophil-rich granulomas within one week. However, wild-type mice
did not exhibit in¯ammation or granuloma formation over a 30-d period in response to
intradermal AF. Both genotypes reacted similarly in a model of allergic contact dermatitis. X-CGD
mice which underwent replacement gene therapy were protected against the enhanced reactivity
to intradermal AF in comparison to untreated X-CGD mice. AF-induced in¯ammation in X-
CGD mice exhibiting a high level of gene replacement approached that seen in wild-type mice.
These studies describe an experimental model system for cutaneous granuloma formation, as well as
a clinical functional test for CGD gene therapy.
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Expression of a Single Chain Variant of Human Factor VIII Targeted to Epidermis
Corrects Factor VIII De®ciency in Hemophilia A Mice
S. Fakharzadeh, R. Kobayashi,* A. Sarkar,* H. Goldbeck, and S. Kazazian Jnr*
Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; *Genetics, University of
Pennsylvania, Philadelphia, Pennsylvania
Hemophilia A is an X-linked bleeding disorder that results from lack of functional factor VIII
protein, making it a good model disease for gene therapy. Epidermis is an attractive tissue for
targeting gene therapy because it is highly accessible and gene products expressed there can enter
the systemic circulation. Previously, we generated transgenic mice that express human B domain-
deleted factor VIII in the suprabasal epidermis under control of the involucrin promoter and bred
them into a factor VIII knockout background. These mice had functional circulating factor VIII
and displayed phenotypic correction. This demonstrated proof of principle that targeting factor
VIII expression to epidermis can correct hemophilia A. We are now exploring strategies for
optimizing factor VIII expression in the epidermis to maximize both delivery to and activity in the
circulation. One approach is to express factor VIII as a single peptide rather than the normal
precursor that is cleaved into heavy and light chains, which form an unstable heterodimer. We
have generated a transgene construct that uses the involucrin promoter to express a variant of
human B domain-deleted factor VIII that lacks the proteolytic cleavage site at residue 1648. Six
transgenic founder mice have been obtained that express this construct as shown by RT-PCR
analysis of total RNA from tail tissue. To date, three transgenic lines have been bred into a factor
VIII knockout background. Mice from these lines produce functional factor VIII and show average
factor VIII activity of 3±39% of normal. We are comparing factor VIII expression, activity and
antigen levels of these mice to those of transgenic mice that express standard B domain-deleted
factor VIII under control of the involucrin promoter. In this way, we will assess whether epidermal
expression of single peptide factor VIII is superior to two-peptide factor VIII for gene therapy.
840
Speci®c Inhibition of Constitutive and Inducible Keratinocyte Gene Expression in
Human Skin Following Topical Application of Antisense Oligonucleotides
J. Karras, S. Cooper, C. York-DeFalco, S. Henry, B. Monia, and C. Bennett
Antisense Drug Discovery, Isis Pharmaceuticals, Carlsbad, California
Disruption of normal keratinocyte homeostasis commonly occurs in basal cell and squamous cell
skin cancers and in in¯ammatory skin disease. We have previously shown that topical application of
a 20mer deoxyphosphorothioate antisense oligonucleotide in a cream formulation results in dose-
dependent, sequence-speci®c, inhibition of tumor necrosis factor-alpha (TNF-a)-induced
intercellular adhesion molecule-1 (ICAM-1) protein expression in human skin engrafted on
SCID mice. To extend this observation to novel oligonucleotide chemistries, as well as to
determine whether topically applied antisense oligonucleotides could be broadly utilized to inhibit
gene expression in human skin, we targeted a constitutively expressed gene, Bcl-x, and an
inducible cytokine gene, TGFb1, which are highly expressed in human epidermis. In these studies,
we utilized second-generation 2¢-O-methoxyethyl (MOE)-modi®ed oligonucleotides that display
higher hybridization af®nity for target mRNA and greater nuclease resistance, compared to
deoxyphosphorothioates. Immunohistochemical analysis showed that topical application of these
antisense oligonucleotides to engrafted human skin effectively diminished target protein expression
in keratinocytes. Topical application of oligonucleotides in mouse, rat, and pig skin demonstrated
rapid absorption of oligonucleotide in epidermis and dermis followed by slow clearance. These
studies also showed a favorable safety pro®le, with only mild and transient erythema observed at
higher doses in rats during prolonged exposure regimens. Together, the data indicate that both
deoxyphosphorothioate and MOE-modi®ed antisense oligonucleotides potently inhibit gene
expression in human skin xenografted onto SCID mice. Pharmacokinetic and toxicological studies
suggest that topical administration of antisense oligonucleotides represents an intriguing option for
therapy of diseases of the skin. Data addressing the relative potency, duration of action, and
systemic exposure of our various proprietary antisense oligonucleotide chemistries following
topical administration in vivo will also be presented.
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Targeted Gene Correction by Single-Stranded Oligonucleotides in Mammalian Cells
O. Igoucheva, V. Alexeev, and K. Yoon
Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, Pennsylvania
Previously, we have shown that RNA-DNA oligonucleotides (RDOs) can correct or cause a
speci®c point mutation in episomal and genomic DNA. Frequency of gene correction by RDO
was measured using a shuttle vector containing a single point mutation in the LacZ gene. Here, we
demonstrate that relatively short single-stranded oligodeoxynucleotides, 25±61 bases homologous
to the target sequence except a single mismatch to the targeted base, are capable of correcting a
point mutation in the LacZ gene, in nuclear extracts, episome, and chromosome of mammalian
cells, with a correction rates of approximately 0.05%, 1%, and 0.1%, respectively. Surprisingly,
these short single-stranded oligonucleotides (ODNs) showed similar gene correction frequency to
chimeric RNA-DNA oligonucleotide, measured using the same system. The in vitro gene
correction induced by ODN in nuclear extracts was not dependent on the length nor the polarity
of the oligonucleotide. In contrast, the episomal and chromosomal gene corrections were highly
dependent on the ODN length and polarity. ODN with a homology of 45 nucleotides showed the
highest frequency and ODN with antisense orientation showed a 1000-fold higher frequency than
sense orientation, indicating a possible in¯uence of transcription on gene correction.
Deoxyoligonucleotides showed higher frequency of gene correction than ribo-oligonucleotides
of the identical sequence. These results show that a relatively short ODN can make a sequence-
speci®c change in the target sequence in mammalian cells, at a similar frequency as the chimeric
RNA-DNA oligonucleotide.
842
Ezrin and Moesin are Involved in Uptake and Traf®cking of Naked Plasmid DNA and
Oligonucleotides
E. Tschakarjan, A. Mirmohammadsadegh, M. Mryen,* H. Kirch, and U. Hengge
Department of Dermatology, Venerology and Allergy, University of Essen, D-45122 Essen, Germany;
*Department of Immunology, University of Bochum, D-44801 Bochum, Germany
As we have already shown that naked plasmid DNA and oligonucleotides are taken up and
expressed by keratinocytes, we now show evidence that ezrin and moesin, two members of the
cytoskeleton-membrane-linker family are involved in this process. By two dimensional gel
electrophoresis and subsequent mass spectrometry (MALDI), ezrin and moesin were found to bind
DNA. By immunohistology using monoclonal antibodies, ezrin was found to be expressed in
suprabasal layers of the epidermis correlating with the location in epidermis that shows highest
uptake of oligonucleotides in immuno¯uorescence studies. Additionally, monoclonal ezrin and
moesin antibodies inhibited one of two oligonucleotide-binding proteins in gel shift analysis, thus
further indicating their involvement in the binding of oligonucleotides. The known functional
association of ezrin with membrane receptor molecules such as CD44, EGF-receptor and ICAM-2
offers different possibilities of DNA uptake by keratinocytes. Currently, we are investigating the
role of such membrane receptor±ezrin associations to elucidate the trans-membrane transport of
oligonucleotides.
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Transformation-Defective Adenovirus 5 E1A Mutants Exhibit Antioncogenic Properties
in Human BLM Melanoma Cells
U. Hengge, H. Kirch,* B. Opalka,* A. Dickopp,* and A. Mirmohammadsadegh
Department of Dermatology, Venerology and Allergy, University of Essen, D-45122 Essen, Germany;
*Institute for Molecular Biology (Cancer Research), University of Essen, D-45122 Essen, Germany
Adenoviral E1A proteins exhibit a strong tumor-suppressive activity in human tumor cells.
However, E1A is capable of transforming rodent and human cells in cooperation with other
oncoproteins, such as activated RAS. Thus, the therapeutic use of wild-type E1A harbors the
principal risk of enhancing tumor malignancy. This prompted us to construct E1A13S cDNA-
derived mutants that were unable to transform baby mouse kidney cells in cooperation with E1B
and to test their tumor-suppressive activity in BLM human melanoma cells. Anchorage-
independent growth in soft agar was reduced for those cell lines expressing the E1AdelCR2
mutant, which lacks the entire conserved region 2 (CR2) sequences, or for cells expressing the
E1AcR3Ex2 mutant, which contains CR3 plus exon 2 sequences. In contrast, cell lines expressing
the entire E1A wild-type (E1Awt) or only the exon 2 sequences (E1AEx2) grew like the parental
BLM cells. Moreover, inoculation of nude mice with BLM cells or cells expressing E1AEx2
revealed large tumors after 2 weeks. In contrast, tumors derived from E1AdelCR2- or
E1ACR3Ex2-expressing cells exhibited a substantial delay in tumor growth accompanied by
loss of E1A expression in the outgrowing tumors. Cell lines expressing E1Awt showed an
intermediate phenotype. Thus, expression of CR3 plus exon 2 sequences is suf®cient to enhance
both the antioncogenic properties and the therapeutic safety of E1A in the experimental model
tested.
844
The Gene Peel: Gene Gun Delivery of the Diphtheria Toxin Fragment A (DTA) Gene to
Mouse Skin Produces Epidermal Blister
M. Lin and J. Uitto
Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, Pennsylvania
Diphtheria toxin fragment A (DTA) is a well-characterized toxin that inhibits protein synthesis by
ADP-ribosylation of elongation factor-2, resulting in cell death. Selective killing of various cell
types can be accomplished through transcriptionally controlled expression of this gene using
expression vectors with different promoters. We have previously demonstrated that the human
involucrin promoter can produce high levels of transgene expression in vivo, as assayed by b-
galactosidase reporter gene. In this study, an expression vector was constructed containing the
human involucrin promoter to direct the expression of DTA. The plasmid DNA was delivered to
adult BALB-C mouse skin by gene gun. Serial histological examination over 48 h revealed the
evolution of an epidermal blister associated with a dense neutrophilic and lymphocytic
in¯ammatory cell in®ltrate. The in¯ammation and necrosis was primarily in the epidermis, with
minimal involvement of the dermis. Epidermal blisters induced by gene delivery can be thought of
as a ``gene peel''. The unique characteristic of the gene peel is the molecular control of gene
expression conferred by the promoter used in this expression vector. The gene peel may provide an
accurate modality for the ablation of speci®c layers of the epidermis and dermis.
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Transduction of Graftskin with a Modi®ed Herpes Vector
E. Badiavas, P. Liu,* and V. Falanga
Dermatology and Skin Surgery, Roger Williams Medical Center, Boston University School of Medicine,
Providence, Rhode Island; *Plastic Surgery, Lahey Clinic, Tufts University School of Medicine, Burlington,
Maine
Graftskin is a bilayered organotypic skin culture consisting of differentiating neonatal derived
keratinocytes layered over neonatal ®broblasts that are embedded in a bovine collagen matrix. In
previous studies, we have shown that graftskin can be transduced by replication de®cient
retroviruses upon wounding. This work illustrated the potential of utilizing bioengineered skin
grafts for gene therapy purposes and showed that these grafts could be genetically modi®ed after
production. In the present study we used a modi®ed replication de®cient herpes virus, THZ.4, as
another potential vector for gene transfer to bioengineered skin. Infection of Graftskin by THZ.4
could be shown when the virus was placed on wounded and nonwounded grafts. Unlike
retrovirus, expression of the herpes virus transgene did not require wounding. Infection of grafts
could be demonstrated histologically with viral titers as low as low as 1 3 104 p.f.u. per ml. Gross
expression of the transgene however, required higher viral titers. Cytotoxicity was demonstrated in
keratinocytes both at high and low titers of viral infection. At higher titers there was cytotoxicity of
both keratinocytes and ®broblasts in the graft. These ®ndings demonstrate limitations of utilizing
herpes virus as a gene therapy vector. Less toxic vectors will need to be developed if herpes virus is
be utilized in bioengineered skin products. The ®ndings also further illustrate that Graftskin can be
easily transduced by viral vectors and can demonstrate cell toxicity due to viral infection in a
manner similar to normal skin.
846
The Microenvironment Affects Transgene Expression by Human Fibroblasts In Vivo
C. Jorgensen, M. Petersen, J. Morgan, and G. Krueger
Dermatology, University of Utah, Salt Lake City, Utah
Using genetically modi®ed ®broblasts (GMFb) we have demonstrated that at least two factors
in¯uence transgene expression (TGE) in vivo: the inherent life span ± immortalized (3T3) cells do
not lose TGE; and the microenvironment? maturing GMFb in a dermal matrix in vitro enhances
TGE in vivo. To further assess the microenvironment we postulated that a dermal matrix substrate
(an empty nylon matrix? ENM) matured in vivo would enhance TGE by GMFb in vivo. In vivo
generated matrixes were generated by transplanting ENM to athymic mice. Later, 4 week, these
IV/ENM were harvested and the resident murine cells were killed via 3 rapid freeze-thaw cycles.
These IV/ENM were seeded with GMFb and held in tissue culture favorable to human ®broblasts
for 4 week before transplantation to athymic mice. Controls were GMFb seeded into an ENM and
matured in vitro for 4 week. Two sets of experiments have been carried out. IV/ENM and the
ENM were loaded with human ®broblasts that were transduced with either lacZ or human
transferrin (hTf) and then subjected to cloning by limiting dilution (hFb.T.lacZ.c or hFb.T.hTf.c).
These were transplanted to athymic mice and analyzed for TGE. Expression of lacZ by the GMFb
after 4 & 8 week in vivo was >> in the IV/ENM than in the ENM. Blood levels of hTf were
measured in mice implanted with an IV/ENM or an ENM containing 1 million hFb.T.hTf.c; the
respective hTf levels were 283 vs. 41 ng per ml @ 4 week, 56 vs. 7.8 ng per ml @ 8 week and 43
vs. 6.7 ng per ml @ 16 week. By 24 weeks blood levels in mice with either construct were at
baseline,? 12 ng per ml. At the time of implantation the amount of hTf in the media was 2803 ng
per ml for the IV/ENM and 2514 ng per ml for the ENM, not a signi®cant difference. Transgene
expression is more robust in vivo, from 2.3 to 7.7 fold, by GMFb that are in a transport system that
carries an in vivo generated microenvironment. However, despite this positive effect there is, with
time, a seemingly inexorable loss of TGE by normal human GMFb in vivo.
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Exogenous Gene Expression in Skin-Equivalent Keratinocytes using a Cre/loxP
Adenovirus System
N. Toriu, Y. Hanakawa, Y. Shirakata, and K. Hashimoto
Dermatology, Ehime University School of Medicine, Ehime, Japan
The adenovirus vector system is one of the most effective techniques for transducing exogenous
genes in normal human keratinocytes, which are suitable for ex vivo gene therapy. For safe gene
therapy, it is very important to regulate the expression of transduced genes. To regulate transduced
gene expression in normal human keratinocytes, we used the Cre/loxP adenovirus vector system.
A stuffer sequence, consisting of a neomycin-resistant gene and polyA ¯anked with loxP, was
interposed between the CAG promoter and the coding region for enhanced green ¯uorescent
protein (EGFP). Co-infection with Ad-expressing nuclear-localizing-signal-tagged Cre recombi-
nase removed the stuffer sequence and turned on the expression of EGFP. EGFP expression was
detected 6 h after infection and reached a plateau at 24±36 h in monolayer normal human
keratinocytes. Initially, to express EGFP in skin-equivalent keratinocytes, we infected
keratinocytes with Ad before seeding them on collagen gels. However, expression was limited
to the corni®ed cell layer when the skin equivalent was completely formed. Therefore, we changed
the method. Keratinocytes were infected with Ad after the skin equivalent was completely formed.
Using this new approach, strong EGFP expression was detected in the basal and suprabasal layers.
The Cre/loxP Ad system is a powerful way to express exogenous genes in monolayer and skin-
equivalent keratinocytes. This excellent method will enable us to investigate the function of the
object genes, to develop disease models using human keratinocytes, and to evaluate gene therapy
methods using skin equivalent.
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Tetracycline Inducible Gene Expression for Studies of Progession in Melanoma Cell
Lines
I. Maxwell, J. Urquhart, D. Norris, and Y. Shellman
Dermatology, University of Colorado Health Sciences Center, Denver, Colorado
The availability of human melanoma cell lines representing different stages of progression provides
the opportunity for transfection studies to assess how various transgenes may contribute to
increased or decreased malignancy. For example, we previously showed that expression of
activated ras in the RGP melanoma cell line, WM35, confers a VGP-like phenotype (Fujita et al,
Melanoma Res 9:279, 1999). Similarly, others have shown that expression of RhoC in the more
advanced melanoma line, A375, markedly increased the metastatic capability of these cells in nude
mice (Clark et al, Nature 406:532, 2000). In these studies, the transgenes of interest were
overexpressed from strong, constitutive viral promoters. The use of inducible transcription systems
allows detection of more subtle phenotypic effects. For this purpose, we have introduced the
positive TET transactivator, rtTA, into both WM35 and A375 cells (Pacheco et al, Gene 229:125,
1999). We encountered considerable dif®culty in isolating stable transfectants of the RGP, WM35
cells by various methods attempted. However, using a retroviral vector, we have now successfully
obtained a population of WM35rtTA that shows 50 fold induction of a TET controlled reporter in
response to doxycycline. Similarly, our clones of A375rtTA display 30±200 fold reporter
induction. We are in the process of transducing various TET controlled transgenes into both of
these cell types. The speci®c goals are to determine effects of regulated expression of Ras and its
downstream effectors on the RGP to VGP transition in WM35, and of RhoC and other candidates
for promoting metastasis in A375 cells. To facilitate detection of metastasis we have further
modi®ed the A375rtTA cells to express uniformly the green ¯uorescent protein, EGFP, using
retroviral transduction and FACS.
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Stability of Transgene Expression by Genetically Modi®ed Immortalized Fibroblasts in
an Encapsulated Eevice in the Subcutaneous Space of Athymic Mice
P. Tresco, D. Messina, C. Jorgensen, and G. Krueger
The Keck Center for Tissue Engineering and the Departments of Bioengineering and Dermatology, University
of Utah, Salt Lake City, Utah
Previously we have reported on the development of an easily retrievable encapsulated cell delivery
device for studying mechanisms of loss of transgene expression (TGE) following the transplantation
of genetically modi®ed ®broblasts (GMFb) to an in vivo setting. We have demonstrated that TGE
by normal human GMFb (lacZ) in this device is robust for 4 week. Thereafter, however, there is
loss of TGE without a loss in viability. Previously we reported that GMFb in an open system lose
TGE over time with senescent GMFb losing TGE more rapidly than younger GMFb. Further, we
have shown that 3T3 cells in this open system do not lose TGE in vivo but grow into tumors. For
comparison we analyzed TGE by spontaneously immortalized 3T3 cells in the encapsulated device
in vivo. 3T3 cells were transduced with a retroviral vector encoding human transferrin (hTf) and
cloned for TGE by limiting dilution (3T3.T.hTf.c). One million of the 3T3.T.hTf.c cells were
loaded into a device and 4 were implanted in the subcutaneous space of athymic mice. Blood was
collected at regular intervals and analyzed for hTf. Levels of hTf (ng per ml) increased throughout
the time of implantation, mean levels @ 2, 6 and 10 week were 92, 130 and 610, respectively.
Devices were harvested and analyzed for viability and TGE. There was no loss of TGE, and all cells
were viable on recovery. We conclude that in contrast to nonimmortal GMFb immortalized
GMFb do not lose TGE in vivo. These observations support the concept of a hierarchical control
TGE by ®broblasts carrying stably integrated transgenes in vivo. We have reported that one of these
hierarchical element is the microenvironment; GMFb in an in vivo generated microenvironment
have TGE that is than one generated in vitro. It appears that another of the hierarchical elements is
the inherent life span of GMFb.
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Use of a Novel Keratinocyte Cell Line, NIKS, for Investigation of Skin-Based Gene
Therapies
S. Liliensiek, S. Schlosser, M. Ryan, J. Clotfelter, and B. Allen-Hoffmann
Pathology, University of Wisconsin, Madison, Wisconsin
Human skin is a readily accessible tissue for gene therapy. Others have reported that human
keratinocytes can be engineered to secrete exogenous bioactive molecules. These genetically
engineered keratinocytes have been successfully grafted onto host animals, supporting the
contention that skin is an attractive target tissue for gene therapy. However, long-term, stable
expression of exogenous genes has not been achieved in part because of the keratinocyte terminal
differentiation program. Differentiating keratinocytes transfected with a transgene are eliminated
from the tissue over time. In this report we use a novel human keratinocyte cell line, NIKS cells,
which possesses the growth and differentiation characteristics of normal human keratinocytes. We
have optimized stable transfection of the NIKS cell line using Green Fluorescent Protein (GFP)-
expressing plasmids to identify stably transfected cells. Using Flow-Activated Cell Sorting (FACS),
transfected NIKS keratinocytes were isolated in the absence of toxic selective agents which
promote cell death of this cell type. To investigate the ability of GFP-expressing keratinocytes to
differentiate and stratify, we constructed organotypic cultures that closely resemble the three-
dimensional microenvironment of human skin. Organotypic cultures of GFP-expressing NIKS
cells were transplanted onto immunocompromised animals for further analysis of gene expression.
We hypothesize that the normal growth and differentiation characteristics of the NIKS cells,
coupled with immortality, will allow for stable long-term expression of GFP and other transgenes.
This report demonstrates that the human NIKS cell line represents an important new cellular
reagent for the development of gene therapy strategies in strati®ed squamous epithelia such as skin.
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A Long-Term Prospective Survey of Atopic Dermatitis and Hand Eczema in a
University Clinic
E. Simpson, D. Nguyen, S. Chan, and J. Hani®n
Dermatology, Oregon Health Sciences University, Portland
To provide a systematic approach to the diagnosis and evaluation of patients with in¯ammatory
skin disease, we designed a standardized evaluation form to prospectively record historical and
physical characteristics of patients with possible atopic dermatitis (AD). During a 20-year period,
we obtained a compilation of features during the initial visit of 950 patients to the Oregon Health
Sciences University Dermatology Clinic. Strati®ed by age, 67.7% were 12-year-old, 17.3% were
3±12-year-old, and 15.0% were 0±2-year-old at the time of evaluation. By history, 57.8% of the
patients had presenting signs and symptoms before age one. The mean age of onset was
approximately 4.3 years. Associated allergic respiratory disease was present in the majority of
patients regardless of age. Seventy-three percent of patients had a history of asthma and/or allergic
rhinitis with the latter found more commonly in all age groups. Among the 626 patients diagnosed
with AD who were two years old, 498 (79.6%) had a history of ¯exural eczema, compared to
62.2% in children 0±2-year-old. Regarding nonspeci®c physical features, signs of ichthyosis were
present in more than 50% and scalp involvement in 37.8%. Active hand eczema was documented
at the time of examination in 61% of patients. Hand eczema tended to begin within one year of the
initial onset of AD. Hand eczema tended to involve primarily dorsal surfaces in all age groups.
However, web space and palmar involvement were more frequent in older age groups compared
to younger age groups. Vesicular lesions of the palms and sides of ®ngers were not uncommon.
This study establishes the frequency of physical and historical characteristics for diagnosis in a large
cohort of patients with AD and indicates a reservoir of active or potential hand eczema in this very
common disease.
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Third-Party Payer Cost of Atopic Dermatitis and Eczema in the United States
C. Ellis, L. Drake,* M. Prendergast,² W. Abramovits,³ M. Boguniewicz,§ C. Daniel,¶ M.
Lebwohl,** S. Stevens,²² D. Whitaker-Worth,³³ and K. Tong§§
Dermatology, University of Michigan Medical School, Ann Arbor, Michigan; *Dermatology, Massachusetts
General Hospital, Harvard Medical School, Boston, Massachusetts; ²Outcomes Research & Product
Economics, Fujisawa Healthcare, Inc., Deer®eld, Illinois; ³Dermatology, University of Texas South-western
School of Medicine, Dallas, Texas; §Allergy, National Jewish Medical and Research Center, Denver,
Colorado; ¶Dermatology, University of Mississippi, Jackson, Mississippi; **Dermatology, Mount Sinai
School of Medicine of New York University, New York, New York; ²²Dermatology, Case Western Reserve
University, Cleveland, Ohio; ³³Dermatology, University of Connecticut Health Center, Farmington,
Conneticut; §§Epidemiology, Quorum Consulting, Inc., San Francisco, California
Atopic dermatitis/eczema (AD/E) is a common disease. Few studies have attempted to quantify the
cost of disease to third-party payers. Our objective was to identify the annual cost to third-party
payers of medical services and prescription medications for the treatment of AD/E. A retrospective
study was conducted using claims data from 1997 and 1998 from: (1) a private insurer, and (2) a
state Medicaid program. Bene®ciaries were considered to have AD/E if they had at least one claim
in 1997 with a primary or secondary listing of one of three diagnosis codes: (1) 691.8, other atopic
dermatitis and related conditions; (2) 692.9, contact dermatitis and other eczema unspeci®ed cause;
or (3) 373.3, noninfectious dermatoses of eyelid. Patients who did not meet these criteria were
evaluated as part of a ``control'' group in each payer for comparisons of expenditures with the AD/
E group. Outcome measures were disease prevalence and total health care costs incurred by each
third-party payer. Disease prevalence was 2.4% (private insurer) to 2.6% (Medicaid) of all eligible
bene®ciaries and 3.5% to 4.1% of patients submitting at least one health care claim during the study
period. The third-party payer cost of illness for AD/E ranged from $0.9 to $3.8 billion when
projected across the total number of people under age 65 insured by private insurance and
Medicaid in the US. Nearly one-third of all health care costs for patients with AD/E may be
attributed to AD/E and comorbid conditions. In conclusion, the annual costs of AD/E are similar
to those of diseases such as emphysema, psoriasis, and epilepsy. AD/E patients incur signi®cant
costs associated with comorbid conditions.
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SDZ ASM 981 Cream 1% is Ef®cacious and Safe in Infants Aged 3±23Months with
Atopic Dermatitis
V. Ho, S. Hedgecock,² C. Bush,* K. Marshall,* M. Thurston,² and M. Graeber
University of British Columbia, Vancouver, BC, Canada; *Novartis Pharmaceuticals Corp, East Hanover,
New York; ²Novatis Pharma AG, Basel, Switzerland
Introduction: SDZ ASM 981, a selective inhibitor of in¯ammatory cytokine release has been
shown to be effective in the treatment of adult subjects and children 2 years or older with atopic
dermatitis (systemic exposure in adults and children is consistently low, even when applied over
large body surface areas). A multicenter vehicle-controlled study in infants from 3-23 months with
atopic dermatitis was conducted to evaluate the ef®cacy and safety of SDZ ASM 981 Cream 1%.
Methods: Subjects with mild-to-moderate atopic dermatitis were randomized to BID treatment for
up to 6 weeks with SDZ ASM 981 Cream 1% (ASM) or the corresponding vehicle (VEH) (2:1
randomization). Ef®cacy was assessed by an Investigators' Global Assessment (IGA), the Eczema
Area and Severity Index (EASI), and assessment of pruritus. Safety was assessed throughout
treatment via reporting of adverse events and monitoring of laboratory tests and vital signs. 186
subjects were enrolled into the study, an interim analysis of the ®rst 83 patients is herein reported.
For this interim analysis the two-sided signi®cance level for testing treatment differences was set at
0.005 (O'Brien Fleming). Results: No demographic differences were noted between treatment
groups. Fifty-six (95%) of the ASM subjects completed the study while only 12 (50%) of the VEH
subjects completed the study. 62.7% of ASM subjects achieved treatment successes (IGA = 0 or 1,
i.e. clear or almost clear) compared to 16.7% VEH subjects (p<0.001). Treatment effect was rapid,
with statistical signi®cance being reached as early as Day 15 (47.5% ASM; 16.7% VEH; p=0.004).
Mean reduction in EASI at the end of study was signi®cantly greater for ASM-treated subjects than
for VEH-treated subjects. Signi®cantly more subjects on ASM had little or no pruritus (score of 0
or 1) than on VEH, a difference noted early in treatment. Treatment effects were consistent across
all measures and were maintained or improved over treatment course. ASM was well tolerated: no
patients discontinued for any adverse event. Only 2 subjects in each treatment group had any
application site adverse events. No systemic or serious adverse events were noted. Conclusions:
This study provides evidence of SDZ ASM 981 cream 1% being safe and signi®cantly more
effective than its corresponding vehicle in the treatment of atopic dermatitis in infants.
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Improvement in Recalcitrant, Childhood Atopic Dermatitis with a Ceramide±
Dominant Barrier Repair Moisturizer
S. Chamlin, I. Frieden, A. Fowler, J. Kao, J. Fluhr, M. Sheu, M. Williams, and P. Elias
Dermatology Service, VAMC, San Francisco, California; *Dermatology & Pediatrics, UCSF, San
Francisco, California
Currently, it is fashionable to consider atopic dermatitis (AD), like many other in¯ammatory
dermatoses, as immunologic in etiopathogenesis (``inside-outside'' hypothesis). Indeed, drugs such
as topical glucocorticoids and immunosuppressives are mainstays of therapy. Yet, the risk of side-
effects and toxicity from these agents is not insigni®cant, particularly in children. Alternatively, the
pathogenesis of AD has been linked to the permeability barrier abnormality, which could drive
disease activity (``outside-inside'' hypothesis). Although moisturizers are mainstays of therapy,
current products do not correct the underlying ceramide (Cer) de®ciency in AD. Hence, we
assessed here the ef®cacy of a new over-the-counter, Cer-dominant, physiologic lipid-based
moisturizer (TriCeram, Osmotics Corp.) in 21 children, aged 2±16, with stubborn-to-recalcitrant
AD. All were receiving optimal therapy (tacrolimus or topical steroids, antihistamines, standard
moisturizers). To avoid seasonal bias, all were enrolled during Oct±Nov, and all continued their
ongoing therapy, only substituting TriCeram for their prior moisturizer. SCORAD scores
improved signi®cantly in 19 of 21 patients by 3 weeks, with further improvement by 6 weeks in
the group as a whole (50%). Transepidermal water loss levels, which were elevated over involved
and uninvolved areas at entry, decreased signi®cantly in parallel with SCORAD scores, while SC
integrity (cohesion) improved signi®cantly. Finally, ultrastructure of TriCeram-treated SC revealed
extracellular lamellar membranes, which were largely absent at baseline. These studies suggest that a
Cer±dominant, barrier repair moisturizer is a useful adjunct in the therapy of stubborn AD. Finally,
these studies support the ``outside-inside'' hypothesis of disease pathogenesis in AD, suggesting that
barrier repair moisturizers, based upon optimal ratios of the three key SC lipids, represent an
alternate, safe approach to the therapy and prevention of in¯ammatory dermatoses.
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The Role of Corneotherapy in the treatment of Skin Barrier Damage Due Allergic
Contact Dematitis
J. Hachem, K. De Paepe,* E. VanpeÂe, V. Rogiers,* and D. Roseeuw
Dermatology, Academisch ziekenhuis- Vrije Universiteit Brussel, Brussels, Belgium; *Toxicology,
Academisch ziekenhuis- Vrije Universiteit Brussel, Brussels, Belgium
Background: Nickel-induced allergic contact dermatitis (ACD) using a contact allergy patch (CAP)
test has been shown to be associated with skin barrier alterations. In human volunteers, CAP tests
combined with skin bioengineering methods including transepidermal water loss (TEWL) and
stratum corneum (SC) hydration measurements, and visual scoring have been used to quantify the
effect of topical agents on ACD. Objective: The aim of this study now is to compare in ACD the
ef®cacy of combination therapy, using a potent topical corticosteroid (¯uticasone proprionate
0.05%) and a corneotherapy agent (barrier cream), with that of a single therapy of the
corticosteroid emollient alone. Methods: 14 Nickel patch-test-positive female volunteers with a
mean age of 31.5 (range 24-36) were included in the trial. On Day 1, six Extra Large Finn
Chambers were symmetrically applied on forearm skin for 48 h. Four of these Chambers contained
5 % nickel sulfate in petrolatum in order to create a standardised dermatitis. The two remaining
chambers contained physiologic saline and served as a control. Either the topical corticosteroid
cream or the barrier cream was applied twice daily and matched with the combination of topical
corticosteroid (once daily at 0 hour) and barrier cream (once daily at 12 hours). This application
method was undertaken on three of the four nickel-ACD skin areas. The fourth nickel-ACD test
spot served as a non-treated control. Clinical scoring, TEWL, and skin hydration measurements
were done at day 1, before applying the patch tests, and after the induction of ACD, namely on
days 4 to 8. Results: Combination therapy proved to provide superior results than those obtained
using the corticosteroid alone twice daily, the barrier cream alone twice daily or no treatment at all
(the later being the physiological recovery of the skin barrier function after induction of ACD). SC
hydration showed better results under both combination therapy and barrier cream (twice daily)
application, than those found when the topical corticosteroid was applied twice or the
physiological recovery of the non-treated control was considered. Conclusion: This study
demonstrates that combining classical corticosteroid anti-in¯ammatory therapeutics with
corneotherapy agents can optimise the healing capacity of the human skin barrier function in
ACD. Therefore, combination therapy can lead to new methodologies in the topical therapy of
in¯ammatory dermatosis (contact allergy, atopy, psoriasis) characterised by an abnormal barrier
function.
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Interleukin-1b Converting Enzyme (Caspase-1) Inhibition with VX-765 Reduces
In¯ammation and Cytokine Levels in Murine Oxazolone-Induced Dermatitis
J. Randle, G. Ku, and A. Qadri
Vertex Pharmaceuticals, Cambridge, Massachusetts
There is evidence for key roles of the cytokines interleukin-1b (IL-1b) and IL-18 as immune
surveillance activators and etiological factors in dermatoses involved in the recruitment of
macrophages, lymphocytes, neutrophils and eosinophils. Thus, a potential target for therapy in
dermatoses is IL-1b converting enzyme (ICE, Caspase-1), the proteolytic enzyme that processes
and activates IL-1b and IL-18 from inactive precursors. We tested this hypothesis using an orally
bioavailable ICE inhibitor, VX-765. Delayed-type and immediate-type skin hypersensitivity to
oxazolone was induced in mice by sensitization on the abdomen on day 0 and challenge on one ear
at day 3, as a model of allergic dermatitis. VX-765 (10±100 mg per kg po bid) administered before
or after oxazolone challenge dose-dependently reduced oxazolone-challenged ear edema by up to
75% (24±94 h postchallenge). Signi®cant reduction of thickening and cellular in®ltration was
observed in both the dermis and epidermis. As expected, the levels of mature IL-1b and mature IL-
18 in ear homogenates were reduced by up to 90% and 75%, respectively. Furthermore, tissue
levels of major downstream in¯ammatory and allergic cytokines and chemokines were reduced (%
inhibition in a representative experiment): IFNg (81%), IL-4 (75%), MCP-1 (74%), MIP-1a
(94%), MIP-2 (99%), as well as myeloperoxidase (80%) and nitric oxide (72%). These data suggest
that both the Th1 (delayed-type) and the Th2 (immediate-type) skin hypersensitivity can be
blocked by targeting ICE, thereby preventing the initiation and propagation of the neutrophil-
mediated in¯ammatory cascade. The effects of ICE inhibition on the eosinophil-mediated allergic
cascade remains to be investigated. ICE inhibition appears to be a promising strategy for the
treatment of in¯ammatory and autoimmune skin diseases.
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Are Corticosteroids of Clinical Value in Lipid-Soluble Induced Irritation in Man?
C. Levin, H. Zhai, and H. Maibach
Department of Dermatology, University of California ± San Francisco, San Francisco, United States
Introduction: Topical corticoids are used to treat irritant contact dermatitis (ICD) in man.
However, their clinical ef®cacy remains sub judice. Objective: We studied the effects of low and
medium potency corticosteroids on lipid soluble-induced ICD in man. Methods: ICD was
induced by 24-h patch application of nonanoic acid (NAA) onto volunteers' forearms.
Betamethasone-17-valerate, hydrocortisone, and petrolatum control were applied twice daily.
Visual grading, transepidermal water loss (TEWL), laser doppler ¯owmetry (LDF) and
chromametry quanti®ed responses on days 1-5 and 8. Results: On day 8, with 90% NAA, a
slight, yet statistically signi®cant improvement in TEWL was observed with betamethasone when
compared to untreated control. Betamethasone also signi®cantly decreased chromametric values on
day 8 with 90% NAA when compared to hydrocortisone. Petrolatum reduced LDF when
compared to untreated control at 60% NAA on day 3. Conclusion: The results suggest a slight
improvement with betamethasone and petrolatum though their bene®t in typical clinical use
remains unclear.
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SDZ ASM 981 is Highly Effective in Animal Models of Skin In¯ammation, but has Only
Low Activity in Models Indicating Immunosuppressive Potential, in Contrast to
Cyclosporin A and FK 506
J. Meingassner, P. Hiestand,* M. Bigout,* M. Grassberger, H. Schuurman,* M. Tanner, and A.
Stuetz
Novartis Research Institute, Vienna, Austria; *Novartis Pharma, Basel, Switzerland
SDZ ASM 981 is a selective inhibitor of in¯ammatory cytokine release, speci®cally designed for
the treatment of in¯ammatory skin diseases. The purpose of this study was to compare SDZ ASM
981 with the immunosuppressants cyclosporin A (CyA) and FK 506 after systemic application in
models of T cell mediated skin in¯ammation (allergic contact dermatitis, ACD) and models of
localized graft vs. host (GvH) reaction and allogeneic kidney transplantation in order to assess the
immunosuppressive potential. In murine ACD, SDZ ASM 981 was as effective as FK 506 (ED50:
48 mg per kg, p.o.) and superior to CyA (ED50: 90 mg per kg, p.o.). In rat ACD, the lowest oral
doses with signi®cant effects were 12.5 mg per kg for SDZ ASM 981 and 50 mg per kg for CyA.
FK 506 had no signi®cant effect even at a dose of 25 mg per kg, p.o. The GvH reaction was
inhibited by FK 506, CyA and SDZ ASM 981 in a dose-dependent fashion after sc. application.
The ED50s were 0.3 mg per kg for FK 506, 2.5 mg per kg for CyA and 20 mg per kg for SDZ
ASM 981. In the transplantation model, the lowest oral dose at which animals survived 100 days or
longer was 15 mg per kg for SDZ ASM 981. In comparison, 5 mg per kg CyA and 1 mg per kg FK
506 were required to achieve the same long-term survival after oral dosing. In summary, SDZ
ASM 981 turned out to be equally effective or superior to FK 506 and superior to CyA in murine
and rat ACD. CyA and FK 506 were superior to SDZ ASM 981 in suppressing GvH reactions by a
factor of 8 and 66, respectively, and in kidney transplant rejection by a factor of 3 and 15,
respectively. These data indicate, that SDZ ASM 981, unlike CyA and FK 506, has a skin selective
pharmacological pro®le.
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Comparative Effect of Different Generic Brands of Fluocinolone Acetonide Cream in an
In Vivo Model of Provoked Skin Irritation with Sodium Lauryl Sulphate
J. Castanedo-Cazares, J. Quistian-Galvan, A. Torres-Ruvalcaba, B. Torres-Alvarez, and B.
Moncada
Dermatology/Immunology, University of San Luis Potosi, San Luis Potosi, Mexico
All over the world, the generic drug market is in the process of expansion. Regarading topical
corticosteroids, there are several preparations but their clinical ef®cacy has been poorly assessed in
relation with the original brand name in an experimental model of skin irritation in vivo. Using
¯uocinolone acetonide cream, we evaluated the anti-in¯ammatory effect of four different brand as
follow: the original brand, generic A, generic B, and generic C. A double blind, vehicle-control
essay was conducted after producing irritation on ®ve sites of the volar aspect of forearm in
20healthy volunteers. For the purpose of creating skin irritation, 10 mL of 10% aqueous sodium
lauryl sulfate were applied in a Finn Chamber during a 24-h period. After that, aliquots of the four
brands of ¯uocinolona cream were applied and occluded during a four-day period. Readings were
made according the scale of Frosch and Kligman at the second and fourth day. The results collected
on the second day showed that one of the generic preparations (C) displayed a score not statistical
different than the control (4.4 vs. 5.25 p = 0.05) and this tendency was also kept through the forth
day (4.45 vs. 5.62 p = 0.05). The rest of those preparations were as effective as the original one in
controlling in¯ammation. The analysis showed that although the cost of the generic drug (C) was
80% less than the original medication, the clinical response was not as good as the others
preparations. After these results, the following question may arise: Is it necessary to perform clinical
studies with the generics in a similar way in which it is being done with the original preparations in
order to con®rm their effectivity before marketing? This deserves some consideration, as newer
and more potent generic drugs will be available in the future.
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Increased bcl-2 Gene Expression in Severe Atopic Dermatitis In Vivo
F. Breuckmann, G. von Kobyletzki, A. Kreuter, A. Avermaete, K. Hoffmann, and P. Altmeyer
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
The purpose of our study was to investigate the baseline expression of the apoptosis inhibitor gene
bcl-2 within the dermal in¯ammatory in®ltrate referring to skin biopsies of patients suffering from
severe atopic dermatitis. Punch skin biopsies of involved skin were obtained from 15 patients with
acute exacerbation of severe atopic dermatitis. All samples were tested immunohistochemically for
features of bcl-2 expression. In order to ensure an over-expression, sections were compared with
healthy controls. With this immunohistochemical study, we succeeded in the detection and the
quantitative assessment of the expression of bcl-2 in atopic dermatitis in vivo in contrast to healthy
controls. Atopic dermatitis is a chronic in¯ammatory skin disease characterized by severe pruritus,
typical eczematous morphology and a chronic relapsing course. Histologically, it is recognized by
an increased number of T lymphocytes, predominantly CD4+ T-helper cells of the Th2-subtype,
connected with the expression of a speci®c cytokine pattern. Within the last years, the discovery of
various gene families being responsible for the regulation of pro- and antiapoptotic mechanisms led
to the development of new staining methods for the detection of lymphocytes undergoing the
programmed cell death, as well as for cells, which develop strategies to circumvent the
physiological pathways. Among these ®ndings the bcl-2 gene expression is of pronounced interest
representing a potential antiapoptotic status in sites of cutaneous in¯ammation. The data obtained
by our immunohistological examination demonstrated a high baseline percentage of bcl-2+ cells
within the dermal in¯ammatory in®ltrate in atopic dermatitis. Referring to the special
characteristics of the apoptosis inhibitor gene bcl-2, we conclude that this modulation of the
low baseline expression in healthy skin may be responsible for the persistence of in¯ammation in
atopic dermatitis.
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Tacrolimus 0.1% Ointment in the Treatment of Eyelid Dermatitis
A. Krupnick, J. Clarke,* D. Fadness,* G. Singer, and M. Lebwohl
Dermatology, Mount Sinai School of Medicine, New York, New York; *Fujisawa Healthcare, Inc.,
Deer®eld, Illinois
Tacrolimus 0.1% ointment (protopic) is a nonsteroidal treatment for atopic dermatitis, that has
been used to safely and effectively treat the face. Localization of atopic dermatitis to the eyelids is
common. Until now, the main treatment for eyelid dermatitis has been the topical application of
corticosteroids. Use of corticosteroids around the eyes has been associated with the development of
glaucoma and cataracts as well as local cutaneous side-effects, such as atrophy and formation of
telangiectasia. We therefore conducted an open-label trial of tacrolimus ointment in 20 patients
with eyelid dermatitis. Patients were treated with tacrolimus ointment twice daily for up to eight
weeks. The severity of eyelid dermatitis was assessed at baseline, at regular intervals throughout the
treatment period, and at two weeks post-treatment. Four eye exams, including intraocular pressure
measurements, were performed before, during, and after treatment. The results of our study
demonstrate the safety and ef®cacy of tacrolimus ointment in the treatment of eyelid dermatitis.
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Intermittent Dosing with Topical Fluticasone Propionate Delays the Time to Relapse in
Adults and Children with Chronic Atopic Dermatitis ± Two Randomised Controlled
Studies
E. Glazenburg,§ R. Graham-Brown, J. Hani®n,* J. Berth-Jones,² and J. van der Meer³
Dermatology, Leicester Royal In®rmary, Leicester, United Kingdom; *Dematology, Oregon Health Sciences
University, Portland, Oregon; ²Dermatology, Walsgrave Hospital, Coventry, United Kingdom;
³Dermatology, Academic Hospital, Groningen, Netherlands; §Medical Department, GlaxoWellcome,
Zeist, Netherlands
A recent study (van der Meer et al, BJD, 1999) suggested that intermittent topical ¯uticasone
propionate (FP) reduces frequency of relapse of chronic atopic dermatitis (AD); two large
randomised, controlled studies have been conducted to investigate further the effectiveness of this
strategy. A total of 643 patients (231 children, 412 adults) with a history of recurrent AD were
treated during an exacerbation with daily FP for 2±4 weeks. Stabilised patients entered a double-
blind Maintenance Phase and received regular daily emollients plus intermittent FP or intermittent
placebo for up to 20 weeks. Median time to relapse and relative risk of relapse were calculated. In
the ®rst study FLTB4012 (a European study, adults only) median time to relapse in both
intermittent placebo treated groups was 6.1 weeks. Median time in the intermittent FP treated
groups could not be estimated, but was in excess of 16 weeks (the majority of patients remained
relapse free at this time-point). Patients were 5.76 times (95%CI 3.08,10.77, p < 0.001) and 1.94
times (95%CI 1.17,3.24, p < 0.01) more likely to relapse on placebo cream and ointment,
respectively, than on intermittent FP. In study FPC40002 (a US study, children and adults, cream
only) median time to relapse on intermittent placebo was 5.1 weeks for children and 4.1 weeks for
adults. Median time to relapse on intermittent FP cream could not be estimated, but exceeded
20 weeks. Patients were 8.1 (95%CI 4.3,15.2, p < 0.0001) times and 7.0 (95%CI 3.0,16.7, p
< 0.0001) times more likely to relapse on placebo than intermittent FP (children and adults,
respectively). There was no evidence of increased risk of skin atrophy with FP. These studies
con®rm that once an acute episode has been treated effectively, intermittent dosing with FP in
addition to regular use of emollients signi®cantly prolongs the relapse free period, delaying the time
to relapse in children and adults with moderate to severe chronic AD.
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SDZ ASM 981 Cream 1%: A New Approach to Long-term Management of Atopic
Dermatitis
U. Wahn, S. Molloy,* M. Graeber,* M. Thurston,* R. Cherill,² and Y. de Prost
Department for Paediatric Pneumology & Immunology, Charite, Campus Virchow, Berlin, Germany;
*Clinical R & D, Novartis Pharma AG, Basel, Switzerland; ²Clinical R & D, Novartis Pharmaceuticals
Corp., East Hanover, New Jersey; ³Dermatology Department, Groupe Hospitalier Necker Enfants Malades,
Paris, France
SDZ ASM 981 Cream 1%, a selective inhibitor of in¯ammatory cytokine release, was found to be
safe and effective in the treatment of atopic dermatitis (AD). To assess long-term safety and ef®cacy
in children (2-to- < 18 years of age) a multicenter, parallel group, double-blind, controlled, 1-year
study was performed. 713 AD patients were randomized to either SDZ ASM 981 Cream 1% or
corresponding vehicle (2:1), to be applied bid according to need. Emollients were allowed, as were
medium-high potency topical corticosteroids (CS) for ¯ares not controlled by study medication
(SM). CS were applied according to label. Following treatment with CS, treatment with SM was
resumed. Consequently, the control treatment (i.e. emollient, vehicle cream, and CS) was
equivalent to current standard care. The vehicle treatment was included in order to maintain the
study blind. A ¯are was de®ned as an Investigator's Global Assessment (IGA) of 4 (severe) or 5
(very severe). Primary ef®cacy analysis was conducted on the incidence of ¯ares observed in 6
months, adjusting for discontinuations. SDZ ASM 981 Cream 1% reduced the incidence of ¯ares
compared to the control group (p < 0.001). 61% of patients in the SDZ ASM 981 Cream 1% group
completed 6 months without a ¯are, compared to 35% in the control group. CS use was less, and
time to ®rst use was greater in the SDZ ASM 981 Cream 1% group compared to the control
group. Treatment with SDZ ASM 981 Cream 1% was signi®cantly more effective than the control
in all secondary ef®cacy assessments. The incidence of adverse events (AEs) in the SDZ ASM 981
Cream 1% group was comparable to that observed in the control group, indicating a good safety
pro®le with a low overall incidence of AEs. Hence, SDZ ASM 981 Cream 1% has signi®cant
therapeutic advantages over the current treatment paradigm (i.e. emollients & topical CS) in the
acute and long-term management of pediatric AD.
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Modulation of Cathepsin G Gene Expression in Severe Atopic Dermatitis Following
Medium-Dose UVA1 Phototherapy
F. Breuckmann, G. von Kobyletzki, A. Avermaete, A. Kreuter, K. Hoffmann, and P. Altmeyer
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
During the last decade, medium-dose UVA1 phototherapy (50 J per cm2) has achieved great value
within the treatment of severe atopic dermatitis (AD). The purpose of our study was to investigate
to what extent UVA1 irradiation is able to modulate the status of protease activity by the use of a
monoclonal antibody labeling cathepsin G. In order to further elucidate the mechanismus by
which medium-dose UVA1 irradiation leads to an improvement of the skin status in patients with
AD, biopsy specimens from 15 patients before and after treatment were analysed immunohis-
tochemically for features of proteolytic activation. As compared with lesional skin of patients with
AD before UVA1 irradiation, the number of cells being positive for cathepsin G within the dermal
in®ltrate has signi®cantly decreased after treatment. The decrease of cathepsin G+ cells was closely
linked to a substantial clinical improvement of skin condition. In summary, our ®ndings
demonstrated that medium-dose UVA1 irradiation leads to a remarkable modulation of the
expression of cathepsin G in the dermal in¯ammatory in®ltrate in patients with severe atopic
dermatitis. As the serine protease cathepsin G is known to attack laminin, proteoglycans, insoluble
®bronectin and collagen I, to induce postin¯ammatory events, to degrade the basement membrane,
to increase the permeability of endothelial barriers and to destroy the tissue inhibitor of
metalloproteinases, its down-regulation by UVA1 phototherapy may contribute to the reduction
of skin in¯ammation combined with the remarkable improvement of the skin status.
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Xerotic Dry Skin of the Elderly. A Summer vs. Winter Comparison Based on Non-
Invasive Measurements of Barrier Function
F. Andersen, S. Stoudemayer, and A. Kligman
S.K.I.N. Incorporated, Conshohocken, Pennsylvania
Dry xerotic skin is an inevitable feature of the aging process presenting as rough, dry scaly skin,
often accompanied by intense pruritus, especially on the legs. We sought to explain why the
condition ameliorates in summer time. We used noninvasive bioengineering methods to compare
leg skin parameters in 8 healthy women, ages 63±78, suffering from winter xerosis, with the
following results: (1) Transepidermal water loss (Evaporimetry). Diffusional water loss was
signi®cantly greater in the winter. (2) Estimation of scaling by serial D-Squames. In winter, more
scales were removed by each of 3 adhesive coated discs, re¯ecting a looser horny layer. (3) A 24-h
occlusive application of 0.75% SLS caused a greater in¯ammatory reaction in wintertime,
accompanied by a signi®cant increase in Laser Doppler blood ¯ow, along with increased erythema
by Minolta colorimetry. (4) Exposure to 20 : 80 chloroform:methanol for a few minutes resulted in
a greatly increased burning sensation in winter time. (5) Application of 90, 95 and 100% DMSO
caused greatly increased wheals and ¯ares in wintertime, accompanied by a marked increase in
Laser Doppler velocimetry. Conclusion: Even though the number of corneocyte cell layers
increases in the winter, the above observations show that this is accompanied by impairment of the
horny layer barrier. Histologic study reveals the presence of ®ne ®ssures and cracks in wintertime,
increasing the permeability to water and exogenous substances.the horny layer barrier.
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Few Aspects of Disability of Children with Atopic Dermatitis
T. Anashkina
Department of Dermatology, and Tuymen Medical School, Tuymen, Russia
Purpose: Little is known about the disability of children with AD. We prospective studed 326
children with AD, ages 5±8, middle index SCORAD 38.25 (from 21.25 to 68.52). Their ®st
complain was itching and discomfort, also; sleep desorders, headache, weakness, sel®shness, low
apettite. Recent studies showed a link between presence of AD and adaptation to school. Children
with AD have low motivation to study compering to helthy children. All needed psycotherapeutic
correction. Another aspect of disability low physical activity was diagnosed among 2/3 our
patients. Most of them had problem with function of vegetative nervous system. Presense of deffect
of external kind also lower the life quality and leads to social disability. Famales with children with
AD had lower income and needed for help. Necessary aspect for good education is present for
child in all classes, but our patient absent in schooll for many days. We compared condition
children with AD were studed in rehabilition center, it is new health care system of treatment
which includes treatment as well as social-pedagogical methods. and children with AD in public
schools after two years. Children from ®st group had middle index SCORAD 8.21 but from
second one - 28.51. GPI was lower among children from public school. Therefo, we suggest that
the prevention of disability as early as possible under and in elementary school children with AD
are required.
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Characterization of Acute, Intermittent and Chronic Mouse Allergic Asthma Models
P. Jungsuwadee, G. Dekan, G. Stingl, and M. Epstein
Dermatology, Immunology, allergy and infectious diseases, Vienna, Austria
Patients with allergic asthma present clinically with chronic or intermittent-seasonal disease, caused
by either persistent or intermittent allergen exposure, respectively. To test novel treatment
modalities during ongoing disease, we established two mouse models which more closely resemble
clinical disease. To generate chronic and intermittent mouse models of allergic asthma, we
immunized BALB/c mice with ovalbumin (OVA) (25 mg) in alum ip. on day 0 and 5 and
nebulized with OVA (1%) 7 days later. We then evaluated the mice for methacholine induced
airway hyperreactivity (AHR), lung in¯ammation (bronchoalveolar lavage ¯uid (BAL) and lung
histology), mucus production and serum and BAL OVA-speci®c IgE and IgG1 either; 1.) at
frequent intervals following sensitization or 2.) after once weekly OVA nebulizations. We
observed increased AHR at 24 h and peak BAL eosinophilia 48 h after the last OVA aerosol
challenge in sensitized mice compared to baseline responses in negative controls. By day 36 both
AHR and BAL eosinophilia decreased to basal levels. However, when re-exposed to aerosolized
OVA on day 41, mice developed increased AHR, BAL and lung eosinophilia that peaked 2 days
later than acute disease. When we nebulized sensitized mice with weekly aerosolized OVA, we
detected persistently elevated AHR, BAL and lung eosinophilia. We found increased mucus
production in relapse and chronic compared to acute disease. All OVA-sensitized mice had
elevated serum OVA-speci®c IgE and IgG1. In addition, we observed a remarkable increase in the
BAL Ig during the relapse and then a steady increase in levels during chronic disease. Moreover,
lung histology revealed an increase in plasma cells during disease relapse and a striking increase
during chronic disease. In summary, we established intermittent and chronic mouse models of
allergic asthma that differ from acute disease and are useful for testing novel treatment strategies.
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Confocal Histopathology of Irritant Contact Dermatitis, In Vivo: A Study of Ethnic
Variability
S. Hicks, S. Matra, R. Anderson, E. Gonzalez, and S. Gonzalez
Dermatology, Harvard Medical School, Boston, Massachusetts
The pathogenesis of irritant contact dermatitis (ICD) is not well-understood. The goal of our study
was to utilize in vivo confocal microscopy (CM), a noninvasive imaging technique that can optically
section biological tissue with high resolution and contrast, to determine whether there is a
difference in the susceptibility to ICD associated with ethnicity. Subjects were placed in groups
based on ethnicity and then exposed to 1, 2, and 4% sodium lauryl sulfate (SLS) using the Finn
Chamber method on inner-forearm skin. Each skin reaction was noninvasively assessed at 6, 24,
and 48 h by in vivo CM, transepidermal water loss (TEWL), and laser Doppler velocimetry. Skin
biopsies of the 4% SLS-treated sites were obtained for comparison. Irritancy threshold was found to
be dose-dependent and related to ethnicity. In all subjects, CM revealed microscopic changes like
stratum corneum damage as early as 6 h after SLS application, even without clinical evidence of
irritation. Stratum corneum ablation was observed in caucasians at 24 h whereas only isolated areas
of disruption were appreciated in black subjects. Although irritancy threshold varied between the
groups, after 24 h there was a perivascular and epidermal in¯ammatory in®ltrate, vascular dilation,
blurred dermal appearance, and increased cell-to-cell demarcation. Routine histology supported
the ®ndings of CM. Ethnic variability was further supported with caucasians having greater TEWL
rates than blacks. Our results demonstrate that in vivo CM can track pathophysiologic events
revealing ethnic differences during the development of ICD.
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Imaged Perfusion is a Sensitive, Non-Invasive Method of Quantifying the Magnitude of
Contact Hypersensitivity Responses in Humans
B. Bjarnason, H. Xu, and C. Elmets
Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama
One of the major deterrents to careful delineation of the immunological mechanisms involved in
contact hypersensitivity reactions in humans has been the lack of a quantitative method with which
to measure the magnitude of the response. In previous studies we have shown that Laser Doppler
Perfusion Imaging (LDPI) is an effective noninvasive method of quantifying patch test reactions in
humans that does not require contact with the skin. The objective of this study was to determine
whether the magnitude of the perfusion of the contact hypersensitivity response as measured by the
LDPI was associated with immunological parameters implicated in the pathogenesis of the disease.
For this purpose, urushiol was applied under occlusion to test areas on one of the forearms of
human volunteers for 48 h while the other forearm served as a control. Twenty-four hours later,
measurements of perfusion of the patch test sites were performed with the LDPI technique. To
determine whether there was a correlation with immunological parameters associated with human
contact hypersensitivity, suction blisters were produced at the patch test sites. Blister ¯uid was
removed and examined for the cytokine interleukin-8 (IL-8) by ELISA. There was an extremely
close correlation between the magnitude of the contact hypersensitivity response as measured by
the imaged perfusion and the level of IL-8 in the blister ¯uid (r = 1.00). Compared to subjects with
visually positive urushiol reactions, patients who failed to develop urushiol contact hypersensitivity
despite repeated exposures to that substance had both greatly diminished perfusion and blister ¯uid
IL-8 levels. The results indicate that LDPI is a sensitive method of quantifying contact
hypersensitivity reactions in humans and that the magnitude of the measurements with this
technique correlates extremely well with cutaneous cytokine levels that have been implicated in
the immunopathogenesis of contact hypersensitivity in humans.
870
Clinical Characteristics and Outcome of Patients with Extracutaneous Mycosis
Fungoides
E. de Coninck, Y. Kim, A. Varghese,* and R. Hoppe*
Dermatology, Stanford University School of Medicine, Stanford, California; *Radiation-Oncology, Stanford
University School of Medicine, Stanford, California
Purpose: To identify prognostic factors predictive of outcome in patients with extracutaneous
(stage IV) mycosis fungoides (MF) and to evaluate the risk of progression to extracutaneous disease
by initial extent of skin involvement. Materials & Methods: One hundred and twelve patients with
extracutaneous disease at presentation or with progression and 434 patients with initial cutaneous-
only disease were identi®ed. Actuarial survival curves were plotted according to the Kaplan-Meier
technique. Results: The median survival of all stage IV patients was 13 months from the date of
®rst treatment for stage IV disease. Neither gender, race, age, extent of skin involvement, nor
peripheral blood Sezary cell involvement was signi®cant to survival outcome. Eleven patients
(10%) had a complete response to therapy resulting in a signi®cantly improved median survival
compared to patients with a partial or no response (1.70 vs. 0.91 years, p = 0.047 and 1.70 vs. 0.57
years, p = 0.011, respectively). At 20 years from diagnosis, the risk for progression to
extracutaneous disease by initial extent of skin involvement was 0% for limited patch/plaque,
10% for generalized patch/plaque, 35.5% for tumorous disease, and 41% for erythrodermic
involvement. Conclusions: This was a larger scale study over a longer time period than had been
completed previously on extracutaneous MF. Prognostic factors important in the cutaneous stages
of disease are no longer signi®cant once extracutaneous disease develops. Patients who had a more
favorable response to therapy may have had a biologically less aggressive disease than their less
fortunate counterparts. The risk of developing stage IV MF is highest in patients presenting with
tumorous or erythrodermic skin disease and it is lowest in patients with limited skin involvement.
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Synergistic Enhancement of Cell-Mediated Immunity by IL-12 Plus IL-2: Basis for
Therapy of Cutaneous T-Cell Lymphoma
M. Zaki, M. Wysocka, S. Everetts, and A. Rook
Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
Cutaneous T-cell lymphoma (CTCL) is a clonally derived, skin-invasive malignancy of CD4+ T-
lymphocytes with the phenotype of mature helper T-cells. Our previous work has demonstrated
that the Sezary form, or typically leukemic form of CTCL, is characterized by prominent
immunologic defects including depressed cell-mediated immunity associated with marked defects
in production of IL-12 and other type 1 helper T-cell cytokines. Previous clinical trials with
recombinant human IL-12 (rhIL-12) for CTCL have demonstrated that it is a potent therapeutic
agent which induces cytotoxic T-cell responses. Nevertheless, a high rate of refractoriness to rhIL-
12 occurred in these studies which may be related to the down-modulation of IL-12 receptor
expression by chronic IL-12 use. In an effort to enhance the overall response rate and to overcome
the refractoriness to rhIL-12 therapy, we studied the immunologic effects in vitro of adding IL-2 to
IL-12 as a model to achieve these goals. We examined the stimulation of IFNg production, natural
killer cell activity and IL-12 receptor expression by T-cells of CTCL patients. The addition of IL-
12 to CTCL patient peripheral blood cells resulted in the production of IFNg (Mean = 27 pg
per ml 6 13, n = 6) as did IL-2 alone (Mean = 70 pg per ml 6 30, n = 6). Importantly, the addition
of IL-2 to the IL-12 synergistically enhanced the levels of IFNg produced (Mean = 1373 pg
per ml 6 435, n = 6) (p < 0.01). Similarly, addition of IL-2 to IL-12 synergistically enhanced both
the NK cell activity of 6 CTCL patients as well as T-cell surface IL-12 receptor expression in
comparison to the effects of IL-12 or IL-2 alone. Thus, IL-2 plus IL-12 unequivocally produces the
synergistic enhancement of multiple parameters of cell-mediated immunity as well as up-
modulating IL-12 receptor expression indicating that protocols combining these two potent
immune enhancing cytokines may have added therapeutic bene®t for CTCL.
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Tacrolimus Ointment in the Treatment of Chronic Cutaneous Graft-Versus-Host
Disease: A Case Series of 18 Patients
C. Choi and P. Nghiem
Department of Dermatology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Tacrolimus (formerly FK506) is an immunosuppressive drug that works by inhibiting calcineurin, a
calcium-dependent protein phosphatase required for immune function. Tacrolimus has been
shown to be effective topically in atopic dermatitis, and systemically in psoriasis and graft-vs.-host
disease (GVHD). However, its ef®cacy in treating cutaneous GVHD when applied topically has
not been reported. The purpose of this case series was to assess the possible therapeutic ef®cacy of
0.1% tacrolimus ointment on chronic cutaneous GVHD which has been refractory to systemic
corticosteroids. Effectiveness was measured by patient report, physical exam, side-to-side
comparisons with a vehicle control, and temporal ¯ares of the cutaneous symptoms of the disease
in the context of stopping tacrolimus therapy. Tacrolimus ointment effectively treated pruritus
and/or erythema in over 70% of 18 GVHD patients. Responding patients had a rapid effect within
a range of several hours to days. However, because of progression of the disease and in two cases,
loss of ef®cacy of the drug, all patients eventually went on to receive more aggressive treatment
including an increase in steroid-dosing, psoralen and ultraviolet A (PUVA) therapy, and
extracorporeal photopheresis (ECP). This case series suggests that tacrolimus ointment has ef®cacy
in treating the erythema and pruritus of steroid-refractory cutaneous GVHD in a majority of
patients. The rapid response of tacrolimus may provide a useful therapeutic bridge to systemic
therapies that have a slower onset, such as PUVA therapy or ECP.
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Photopheresis Monocytes Produce Cytokines that Induce Monocyte-to-Dendritic Cell
Maturation During Overnight Incubation
D. Kanada, C. Berger, and R. Edelson
Dermatology, Yale University, New Haven, Conneticut
A principal challenge for the development of an antitumor immune response is the loading of
potent antigen-presenting cells, with tumor antigens for presentation in the context of accessory
molecules necessary to initiate immune responses. Previous studies have shown that monocytes in
the extracorporeal photopheresis (ECP) system become activated and differentiate after overnight
incubation into immature dendritic cells (DC). We now demonstrate that in¯ammatory cytokines,
derived from activated monocytes, are produced during the overnight incubation of the ECP
product and may contribute to the observed rapid entry into the DC pathway. For analysis of the
cytokine pro®le produced during the ECP procedure, specimens were obtained from blood and
the 3 phases of the treatment: leukapheresis; 8-methoxypsoralen and ultraviolet A light exposure in
the plastic plate; and overnight incubation. Cytokine levels were monitored using ELISA assays
for:TNF-a; IL1-b; IL6; IFN-g; IL4; GMCSF; IL10; and IL12. The results demonstrated that the
overnight cultured ECP cells produced increased amounts of: TNF-a (3±10x); IL1-b (9±11x); and
IL6 (6±11x) beyond that found in the pretreatment serum. No increase in the production of the
cytokines: IFN-g; IL4; GMCSF; IL10 and IL12 was found. The increased production of DC
maturing cytokines, by activated monocytes during the overnight culture of ECP cells, suggests
that these cytokines contribute to the rapid entry into the DC pathway. The presence of apoptotic
tumor cells provides a source of tumor antigens for the differentiating DC and further drives their
maturation. Thus, the cocultivation phase of the modi®ed ECP treatment produces maturing DC
loaded with the patient's unique tumor antigen repertoire, that is required for effective tumor
vaccine immunotherapy, without prolonged culture, extensive manipulation or exogenous
cytokine introduction.
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Narrowband Ultraviolet B Phototherapy for Early Stage Mycosis Fungoides
R. Gathers, L. Scherschun, F. Malick, J. Kim, D. Fivenson, and H. Lim
Dermatology, Henry Ford Hospital, Detroit, Michigan
Narrowband ultraviolet B (NB-UVB) phototherapy is an effective treatment for psoriasis and
atopic dermatitis, but few studies have been published reporting the use of NB-UVB for mycosis
fungoides (MF). This study was performed to evaluate the ef®cacy of NB-UVB in the treatment of
MF. The records of 24 patients with IA (12 patients) and IB (12 patients) disease who received
NB-UVB at Henry Ford Hospital between November 1998 and September 2000 were evaluated.
There were 14 males and 10 females, all with patch stage MF; the mean age was 54.9 years (age
range: 23±83 years), the mean disease duration was 5 years (range: 0.25±25 years), and mean
follow-up period was 29 weeks. Twelve patients each had Fitzpatrick's skin phototypes I-III, and
IV-VI, respectively. NB-UVB (TL-01 bulb) phototherapy was initiated three times weekly on
nonconsecutive days. Minimal erythema dose (MED) determination was performed in all cases and
the initial starting ¯uence was 70% of the MED. The ¯uence was increased by 10±15% increments
each treatment. The physician's global clinical response to NB-UVB was: 13/24 patients
showed = 95%clearing (complete response [CR]), 7/24 patients showed = 50% clearing (partial
response [PR]), and 4/24 patients showed = 50% clearing (no response [NR]). Ten patients with
CR had post-treatment biopsy, and all but one showed histologic clearance. Adverse effects were
limited to erythema (42%) and phototherapy-associated pruritus (29%). This study indicates that
NB-UVB is an ef®cacious and well-tolerated treatment option for patients with early stage mycosis
fungoides.
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Identi®cation of Ampli®ed Clonal T Cell Populations in the Blood of Patients with
Chronic Graft vs. Host Disease: Positive Correlation with Response to Photopheresis
A. Rook, L. French, T. Alcindor,³ M. Shapiro,* D. Porter,² D. Leonard,§ and F. Foss
Dermatology, Geneva University Hospital, 1211 Geneva 14, Switzerland; *Dermatology, University of
Pennsylvania, Philadelphia, Pennsylvania; ²Medicine, University of Pennsylvania, Philadelphia,
Pennsylvania; ³Medicine, New England Medical Center, Boston, Massachusetts; §Pathology, University
of Pennsylvania, Philadelphia, Pennsylvania
Chronic graft vs. host disease (cGVHD) is a major complication of bone marrow transplantation
(BMT) and is responsive to photopheresis, a treatment that induces an anticlonotypic immune
response and has proven to be effective in cutaneous T cell lymphomas with circulating clonal T
cells. We have searched for circulating clonal T cell populations in patients with cGVHD, and
determined whether T cell clonality in the blood is predictive of therapeutic response to
photopheresis. Blood samples of 23 patients after HLA-matched allogeneic bone marrow
transplantation (allo-BMT), 10 without cGVHD and 13 with extensive cGVHD, were screened
for clonal T-cell receptor gamma gene rearrangements. Ampli®ed clonal populations of T cells
with unique TCR gamma gene rearrangements were found in 6 of 10 (60%) allo-BMT patients
without cGVHD and 11 of 13 (84.6%) allo-BMT patients with cGVHD, as compared to 0 of 10
(0%) of healthy controls. Eight patients with cGVHD were treated by photopheresis, and the
presence of ampli®ed clonal populations of T cells was found to correlate with response to
photopheresis, as 6 of 6 (100%) clone positive vs. 0 of 2 (0%) clone negative patients experienced a
clinically signi®cant response to treatment. A high proportion of patients with cGVHD have
detectable expanded clonal T cell populations in their peripheral blood, and such patients may be
more likely to respond to treatment by photopheresis.
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Bexarotene Combination Therapy for Cutaneous T-Cell Lymphoma
R. Talpur, S. Ward, N. Apisarnthanarax, and M. Duvic
Dermatology, M.D. Anderson Cancer Center, Houston, Texas
Bexarotene (bex, Targretin(r) capsules) is an RXR selective rexinoid approved for all stages of
CTCL with an overall response rate RR of 45% at 300 mg per m2 per day. It is frequently used
with statins or lipid lowering agents (LLA) for associated hypertriglyceridemia. Statins inhibit
HMG-CoA reductase, modulate class II MHC expression, and reduce T-cell response (Nature
Medical, December 2000). Bexarotene is now being combined with CTCL therapies, thus we
evaluated 70 CTCL patients treated at MDACC. Fifty-four patients received bex with overall
response rate (RR 48%), stage IA-IIA (n = 13, RR = 53%, 1 CR) and stage IIB-IVB (n = 41,
RR = 46%, 2 CR). of these 54 pts, 41 (76%) received = 1 LLA: gem®brozil (n = 3, RR 33%),
atorvastatin (n = 27, RR 70%), or atovastatin/feno®brate (n = 11, RR 81%). Advanced stage
patients (15/16 erythrodermic) received bex at 225±750 mg per day in combination with ongoing
therapy (interferon IFN, PUVA, photopheresis ECP, ONTAK) for an overall RR of 69% (11/16).
Statins were given in 94% of them. Bex was combined with ECP (n = 6, RR = 66%), ECP/IFN
(n = 4, RR = 50%), ECP/IFN/PUVA (n = 1, RR = 100%), ECP/ONTAK (n = 1, PR), PUVA/
IFN (n = 3, RR = 66%) and IFN/PUVA/NM (n = 1, RR = 100%). Adverse events on combined
therapy were limited to one idiosyncratic reversible neurologic event on bex/ONTAK and slightly
low white counts in 2 patient on IFN. This single center CTCL study con®rms the published
response rate for bex used alone and supports safety of bex with other therapies to increase
responses. Statins may augment therapy by allowing higher doses of bexarotene to be used or by
favorably effecting the disease.
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Oral Bexarotene Therapy Combined with Phototherapy in the Management of
Cutaneous T-Cell Lymphoma
P. Heald, J. Christensen, M. Nankin, and M. Girardi
Dermatology, Yale University, New Haven, Conneticut
Oral bexarotene (BXT) has been found to induce responses in Cutaneous T-Cell Lymphoma
(CTCL)patients at rates of 32±57%. We proposed that combinations of phototherapy and BXT
could improve on monotherapy responses with either modality. Interactions of BXT with
phototherapies for CTCL have not been observed. We report on 15 CTCL patients treated with
oral BXT and phototherapy. The safety and ef®cacy of this combination therapy was recorded. A
total of 15 patients used a combination of a phototherapy (8 with extracorporeal photo-
chemotherapy (ECP), 6 with photochemotherapy with UVA light (PUVA), and 1 with
(UVB)with oral BXT for 3 months or greater. Skin scores and serum tests for BXT toxicity were
monitored. Eight patients with Sezary syndrome and partial responses to ongoing ECP had oral
BXT therapy initiated at 300 mg per M2 (normal weight) or 150 mg per M2 (obese). After a
minimum of 12 weeks of combination therapy, 3 had complete clinical responses, 4 had 50%
improvement of body surface area involvement, and 1 had no response. Four of the Sezary
syndrome patients had elevated lymphocyte counts with elevated (6.0)peripheral blood
lymphocyte CD4:CD8 ratios that did not change as the skin cleared. The initial four patients
treated with PUVA and oral BXT had partial responses to PUVA. In these patients, oral BXT was
started at 150 mg per M2 and UVA doses were reduced 10%. Three patients had a complete
clinical response, one had a reduction of body surface area 50%. Three patients with risk factors for
PUVA failure (histologic variants of CTCL) were started with oral BXT (150 mg per M2) at the
time phototherapy was initiated. All three patients had phototherapy doses safely advanced with
minimal phototoxicity (two with PUVA, one with UVB. All three had complete clinical
responses. Adverse events noted were dose responsive with BXT. Of the eight Sezary syndrome
patients, 3 required antilipemic agents and 5 were given thyroid supplementation to counter the
effects of oral bexarotene. In the 7 patients with PUVA or UVB the lower dose regimen of BXT
required antilipemic therapy in one patient and thyroid supplementation in two. We conclude that
oral BXT therapy can safely and effectively be used in combination with phototherapies in the
management of CTCL. No adverse interactions of oral BXT were observed in patients treated
with ECP, PUVA or UVB. These ®ndings suggest that oral BXT therapy may have a role as a
concomitant agent in the phototherapy of patients with CTCL.
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Natural Killer (NK)/NK-Like T-Cell Lymphoma (CD56+) Presenting in the Skin: An
Increasingly Recognized Entity with an Aggressive Course
S. Mraz-Gernhard, Y. Natkunam,* R. Hoppe,² S. Kohler,* and Y. Kim
Dermatology, Stanford, Palo Alto, California; *Pathology, Stanford, Palo Alto, California; ²Radiation
Oncology, Stanford, Palo Alto, California
Objective: To describe and identify the clinical and pathologic features of prognostic signi®cance
for NK/T-cell lymphoma presenting in the skin. Methods: A retrospective analysis of 34 pt with
CD56+ lymphomas initially presenting with cutaneous lesions with analysis of clinical and
histopathologic parameters. Results: The med survival for all pt is 15 months. Pt with no
extracutaneous (EC) dz (n = 20; localized stage IE = 8, disseminated skin IVD+M- = 12) on intial
staging evaluation have better survival rates at 1 yr (88%) and 3 yr (70%) compared to those with
EC dz (n=12) with 16% alive at 1 yr and with no survivors at 3 yr (p<0.0001). Age, gender, extent
of skin involvement, and initial response to therapy have no signi®cant effect on survival. 22/34
(65%) stain with antibodies against CD3e. 7/24 (29%) demonstrate clonal rearrangement of TCR-
g. 8/30 (26%) patients with unequivocal EBV results have detectable EBV within neoplastic cells.
Rates of EBV+ tumors by pt country of birth: U.S 3/25 (12%), Asia/Pac.Island 2/2 (100%),
Central/S.Amer 2/2 (100%), India 1/1 (100%). 22/29 patients (76%) evaluated have multi-drug
resistant (MDR) gene expression. Pt with tumor cells that co-express CD30 (n=8) have better
survival rates at 1 yr (100%) and at 3 yr (86%) compared to those with CD30- tumor cells with
survival rates of 39% at 1 yr and 17% at 3 yr (p=0.002). Routine histologic characteristics have no
prognostic predictive value and no outcome difference is found for those with tumor cells that are
CD3e+ (p=0.8), EBV+ (p=0.3), MDR+ (p=0.19). Conclusions: NK/T-cell lymphoma
presenting in the skin is an aggressive neoplasm. A subset of pt with a more favorable outcome
is identi®ed in this study. The presence of EC dz at presentation is the most important clinical
variable and portends a poor prognosis. The extent of initial skin involvement does not reliably
predict outcome. As opposed to ®ndings from countries where early infection with EBV is more
common, pt from the U.S. with NK/T-cell lymphoma presenting in the skin have a low incidence
of demonstrable EBV in their tumor cells. Pt with co-expression of CD30 in CD56 lymphomas
tend to have a more favorable outcome than those with CD30- NK/T-cell lymphomas. However,
further studies are needed to con®rm the impression.
879
Cutaneous B-Cell Lymphoma (CBCL): Superior Prognosis for Patients Presenting with
Disease Limited to the Skin
S. Mraz-Gernhard, S. Horwitz,* Y. Kim, S. Kohler,² and R. Hoppe³
Derm, Stanford, PA, California; *Medical Onc, Stanford, Pennsylvania, California; ²Path, Stanford,
Pennsylvania, California; ³Rad Onc, Stanford, Pennsylvania, California
Purpose: Identify prognostic clin features for pt with CBCL. Patients and Methods: Retrospective
analysis of 107 pt with B-cell lymphoma presenting in the skin, single institution. Results:
Classi®cation: 47 diffuse large cell (DLCL), 30 follicular (FL), 26 marginal zone (MZL) lymphoma,
3 other. Med follow-up is 56 mos. For DLCL, med age is 60, 31M/16F. Stages are IE = 23, IIE = 5,
IV = 19. The 4-yr OS for DLCL is 72%. Dz speci®c survival (DSS) is 75%. At presentation, 30
(68%) pt had dz limited to skin, 14 had extracutaneous dz (EC). Of pt with dz limited to skin, 23
are local (IE), 10 are dissem (IVD+M-). 4-yr DSS for IE is 94% and vs. 50% for st IIE-IV with EC dz
(n = 14; p < 0.002). 4-yr DSS is similar for st IE and IVD+M- (94% vs 80%; p = 0.3). DSS is not
affected by age or type of tx. 32/33 pt with DLCL limited to skin had CR to initial tx and 17/32
(53%) relapsed (med 12 mos). Relapse risk by tx is chemo 5/12 (42%), XRT 6/12 (50%), chemo/
XRT 4/7 (57%), other 2/2 (100%). Site of 1st relapse: skin only 13/17 (76%), other extranodal site
3/17 (18%), skin & LN 1/17 (6%). 13/15 (86%) had 2nd tx with a 2nd CR. 12/15 (80%) remain
AIR. Characteristics for low grade (LG): FL med age 54, 22M/8F, MZL med age 52, 9M/18F. Pt
with LG lymphoma limited to skin (IE or IVD+M-, n = 37) have a 4-yr DSS of 100% compared to
80% for st IIE-IV with EC (n = 21; p < 0.001). For st IE (n = 31) and IVD+M- (n = 6) tx are XRT
22,chemo 3, other 12. 16/36 (44%) relapse at a med of 11 mos (1-120). In 14/16 relapse is
con®ned to skin. Conclusions: Pt with CBCL limited to the skin at presentation (IE or IVD+M-),
have a superior prognosis compared to those with EC dz. Pt with EC dz at presentation have OS/
DSS comparable to nodal lymphomas. Among those with IE or IVD limited to skin, DSS and risk
of relapse are not affected by tx type. 82% of relapse is con®ned to the skin and responds well to
further tx.
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Skin Cancer: Epidemiological and Clinical Aspects
B. Bardhi, V. GjencËaj, and A. Harxhi*
Dermatology, clinic of dermatology, TIRANA-Albania, Albania; *INFECTION DISEASE, CLINIC
OF INFECTIOUS DISEASE, TIRANA-Albania, Albania
The studies purpose is to present several epidemiological and clinical characteristics of patients with
Skin Cancer diagnosed in a Dermatology Clinic in Albania. We reviewed the clinical records of
the 48 cases admitted in the clinic of dermatology at UHC of Tirana during 5-year period with the
Skin Cancer. The inclusion criteria was considered the results of skin biopsy positive for skin
cancer. The factors included in the study were:histopatological charasteristics, sex, age, risk factor,
localization. There were 48 cases of skin cancer diagnosed at the clinic of Dermatology during a 5-
year period, 38 cases (79.2%) were male and 10 cases (20.8%) were female. According to
histopatological ®ndings there were 25 cases (52%) with BCC and 23 cases (48%) with SCC.
According to localization of the skin cancer there were 17 cases (35%) with the localization at the
lower lip, 7 cases (14.5%) at the dorsum of the nose,6 cases (12.5%) at the ear and 9 cases (18.7%)
localized at the rest of the face. Skin cancer predominates in male patients. Conclusion: There was
not signi®cant difference between cases with BCC and SCC among our patients. The ultraviolet
sun exposure was seen as the main risk factor for cases with skin cancer. The lesion were localized
mostly in lower lip and other areas exposed more at the sun light.
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Cost of Nonmelanoma Skin Cancer in the United States ± Treatment in Physicians'
Of®ces is More Common and More Cost Effective
S. Feldman, E. Smith, A. Fleischer, and P. Williford
Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Background: Despite being the most prevalent form of cancer, the economic impact of non-
melanoma skin cancer (NMSC) in the United States has not been assessed. Objective: The purpose
of this study was to determine the overall cost and cost per episode of care of NMSC in the United
States in physicians' of®ces, outpatient surgical center, and inpatient settings. Methods: Data from
the Medicare Current Bene®ciary Study 1992-1995 were analyzed to obtain the total cost of
NMSC and the cost in different settings. To normalize these data to a per episode basis, the cost in
each setting was divided by the number of procedures performed in each setting obtained from the
National Hospital Discharge Survey (NHDS, 1992-1997), the National Survey of Ambulatory
Surgery (NSAS, 1994-1996), and the National Ambulatory Medical Care Survey (NAMCS,
1995). Results: Physician of®ce based procedures for NMSC accounted for the greatest percentage
of money spent to treat NMSC and the greatest percentage of procedures. The average cost per
episode of NMSC when performed in a physician's of®ce setting was found to be $492. The cost
per episode of care in inpatient and outpatient settings were $5537 and $1043 respectively.
Conclusion: Physician of®ce-based treatment of NMSC is far more common and signi®cantly less
expensive than outpatient or inpatient care. Legislative or regulatory measures that discourage
of®ce treatment of skin cancer will lead to increased cost and poorer outcome.
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Laws Regulating Tanning Booth use by Minors
R. Dellavalle, B. Hemme,² L. Schilling,* and A. Chen²
Department of Dermatology, University of Colorado, Denver, Colorado;*Department of Medicine,
University of Colorado, Denver, Colorado; ²College of Law, University of Denver, Denver, Colorado
Ultraviolet (UV) light is a carcinogen. Epidemiological data demonstrates that UV irradiation,
especially during childhood, is a risk factor for skin cancer and melanoma. Because greater than
80% of lifetime UV irradiation is estimated to occur before age 20, the behavior of minors with
respect to tanning is a prime target for skin cancer prevention, and restriction of tanning facility use
by minors may be a justi®ed public health intervention. For example, requiring all minors to obtain
parental consent prior to patronizing tanning facilities would better assure thoughtful consideration
of short-term gains, i.e. temporary increased physical attractiveness, vs. long-term risks, i.e.
increased skin cancer, and might decrease the number of minors engaging in this carcinogenic
behavior. The vast majority of US states have no age-speci®c restrictions governing access to
tanning salons. Wisconsin is the only state with an age-speci®c requirement for those seeking
tanning services; tanning booth use is restricted to those age 16 and older. Only seven US states
(FL, IN, LA, MA, MI, TN, TX) require parents to accompany children under age 14 to tanning
booth facilities (Indiana's parental companion restriction, being more extensive, applies to minors
under age 16). And only 10 states (CA, GA, FL, IN, LA, MA, MI, MN, TN, TX) require written
parental consent from minors in their late teens seeking tanning services. Regional variation in the
regulation of minors using tanning parlors may provide an opportunity to measure the effect of
legal restriction on the tanning behavior of US minors. This study further compares US age-
speci®c tanning booth regulations to those of other nations, and to age-speci®c regulations on
other carcinogenic behaviors, e.g. cigarette smoking. To further this comparative summary, SID
meeting participants are asked to inform the presenters of relevant laws in their native lands.
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Nonmelanoma Skin Cancer in Persons with Prior Cutaneous Melanoma
G. Kroumpouzos, H. Cabral,* and C. Karakousis²
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston,
Massachusetts; *Department of Epidemiology and Biostatistics, School of Public Health, Boston
University, Boston, Massachusetts; ² Department of Surgical Oncology, Roswell Park Cancer Institute,
Buffalo, New York
Background: Melanoma has been associated with an overall increase in actinic tumors, including
actinic keratoses, as well as with non-cutaneous malignancies. Objective: Determine the risk of
developing basal cell and squamous cell skin cancer in patients with prior cutaneous melanoma
(actinic keratoses not encountered). Methods: This retrospective study included 1396 white
persons with prior cutaneous melanoma followed at the Roswell Park Cancer Institute in the
period 1977-1978. The control group was the white population of the Detroit area in the same
period (1977-1978). Results: Totally, 25 patients (18 males/7 females) developed 35 basal cell and/
or squamous cell carcinomas of whom 18 developed basal cell carcinoma(s), 2 squamous cell
carcinoma(s) and 5 both. The calculated odds ratio was 3.49 (males 3.67, females 2.86, 95%
con®dence interval 1.52-8.00). No correlations were found with age, type, anatomic site, and
length of follow-up of cutaneous melanoma. Conclusion: History of cutaneous melanoma
signi®cantly increases the risk of basal cell and squamous cell skin cancer.
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How do People Apply Sunscreen?
C. Robert, N. Issachar, M. Cambon, C. Carpentier, and A. Pellegrino
Skin Care Research Institute, Johnson & Johnson, Issy-les Moulineaux, France
Broadband sunscreen agents are effective against sunburns, UV-induced immunosuppression as
well as UV-induced DNA damages, suggesting their potential protective effect in skin
carcinogenesis. However, controversial hypotheses were raised concerning a potential link
between use of sunscreens and the risk of melanoma. Controlled prospective studies are hindered
by the dif®culties in quantifying UV exposure and sunscreen product use over a long period of
time. We studied a critical parameter of sunscreen-mediated photoprotection, i.e. the quantity of
product applied and the quality of sunscreen spreading on the skin by 17 female volunteers. The
women were asked to spread a sunscreen (SPF 30) exactly as they would before sunbathing. The
sunscreen was visualized using UVA light and photos of the entire body were taken. The quantity
of sunscreen applied by each volunteer was calculated and the spreading ef®ciency was evaluated
on the photos by three independent investigators using an intensity visual scale. Our results show
that the mean total quantity of sunscreen agent applied is very low and represents on average only
27% of the quantity required to realize the labeled SPF. Furthermore sunscreen spreading was very
heterogeneous. We provide a sunscreen spreading cartography of the human body and show that
certain skin surface areas were reproducibly forgotten and left unprotected. We show here that
spontaneous sunscreen self-application is quantitatively insuf®cient and qualitatively poor which
obviously hinders photoprotection. This might represent a major bias in epidemiological studies
and explain, at least in part, the risk of sun damage in people who think they are protected. To
reduce this risk, we propose here an optimized method of sunscreen body application and
spreading. We think this is an important public health message that should be brought to public
awareness as much as SPF and UVA protection.
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Lifestyle High-Risk Behaviors and Demographics may Predict the Level of Participation
in Sun Protection Behaviors and Skin Cancer Primary Prevention in the United States
A. Fleischer Jr, B. Santmyire, and S. Feldman
Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Background: Sun and UV radiation exposure are major risk factors for skin cancer. Sun protective
behaviors and skin cancer exams are means of primary prevention of skin cancer. Objective: The
purpose of this study was to evaluate the extent to which demographics and other high-risk lifestyle
behaviors may predict the reported level of participation in sun protection behaviors and skin
cancer primary prevention in the United States adult population. Methods: Data on reported sun
protection behaviors and skin cancer examinations was obtained from surveys completed by adults
in the 1998 National Health Interview Survey. Univariate and multivariate data analyses were
performed using Stata software. Results: For the United States adult population surveyed
(n = 32,440), only 21% indicated that they had ever had a skin cancer exam, and of those, only 45%
indicated that the skin cancer exam was within the past year. For sun protective behaviors, only
23%, 27% and 30% of those surveyed reported to be ``very likely'' to ``wear protective clothing'',
``stay in the shade'' and ``use sunscreen'' respectively. Likelihood of participation in sun protective
behaviors and skin cancer prevention was affected by demographic characteristics such as gender,
race, age, education level, income level, region of the country, marital status and metropolitan area
size. In addition, lifestyle high-risk behaviors, including duration since last general physical
examination, currently smoking cigarettes, wearing of a seatbelt when riding in the front seat of an
automobile and possession of ®rearms appeared to impact the reported level of participation in sun
protective behaviors. Conclusions: A number of demographic factors and lifestyle high-risk
behaviors may predict the likelihood of participating in sun protective behaviors in United States
adults.
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Phase III Clinical Study Demonstrating Prevention of Skin Cancer in Xeroderma
Pigmentosum by Topical Application of T4N5 Liposome Lotion Containing DNA
Repair Enzymes
D. Yarosh, J. Hawk, J. Klein,³ A. O'Connor,³ A. Rafal,* and P. Wolf²
St. Johns Institute Derm., King's College London, London, United Kingdom; *DermResearch Ctr New
York, Stony Brook, New York, New York; ²Department Derm., University of Graz, Graz, Austria; ³AGI
Dermatics, Freeport, New York, New York
Patients with xeroderma pigmentosum (XP) have an elevated incidence of skin cancer resulting
from genetic defects in DNA repair. Intracellular delivery of the bacterial DNA repair enzyme, T4
endonuclease V, increases the rate of repair of sunlight induced DNA damage in human cells.
Therefore, we tested the ability of this DNA repair enzyme in a liposomal delivery vehicle applied
topically (T4N5 liposome lotion) to reduce the incidence of skin cancer in XP patients. This was a
prospective, multicenter, placebo-controlled, randomized and double-blinded study on the
incidence of new skin cancer and actinic keratosis (AK) in 30 XP patients applying T4N5 liposome
lotion daily for one year. The annual rate of new basal cell carcinoma (BCC) was 5.4 cancers per
patient per year in the placebo group and 3.8 in the T4N5 Liposome Lotion group. This represents
a 30% reduction (p = 0.006, Poisson regression). Furthermore, the annual incidence rate of AKs
was 25.9 lesions per patient per year in the placebo group and 8.2 in the T4N5 Liposome Lotion
group. This was a 68% reduction (p = 0.004, Poisson regression). No signi®cant adverse effects
were found among any of the patients. DNA damage plays a powerful role in the development of
both skin cancer and precancerous skin lesions. The topical application of liposomal DNA repair
enzymes to sun damaged skin of XP patients reduces the incidence of at least some forms of these
lesions, namely BCC and AK, within one year.
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Tazarotene Reduces BCC Tumor Number and Size in UV Exposed ptc+/± Mice
K. Lee, M. Aszterbaum, P. Walker,* J. Gibson,* and E. Epstein Jr
Dermatology, University of California San Francisco, San Francisco, California; *Allergan Inc., Irvine,
California
Oral retinoid treatment reduces basal cell carcinoma (BCC) incidence in patients with basal cell
nevus syndrome (BCNS) (Peck et al 1988). Because extended tazarotene gel application results in
regression of 53% of sporadic BCCs (Peris et al 1999), we sought to determine whether oral
tazarotene would have a comparable or superior effect in ptc+/± mice that, like BCNS patients,
have an inactivating mutation of one patched allele. Also like BCNS patients, ptc+/± mice develop
few, microscopic BCC-like tumors on UV-protected skin, and when exposed to ionizing radiation
or UV, develop numerous and signi®cantly larger tumors. Ptc+/± mice were exposed to
tumorigenic doses of UVB for 7 months, irradiation was stopped, and mice were randomized to
receive vehicle or oral tazarotene at 1, 2.5, or 5 mg per kg (n = 18 per treatment arm) ®ve times per
week. Skin biopsies from UV-exposed sites were taken 30, 60 and 120 days after therapy was
initiated. After 60 days of treatment, the average tumor size in all tazarotene treated groups was
50% less than in controls (0.01 vs. 0.02 mm2; p < 0.002 using student's t test). However, the
average tumor number was not signi®cantly reduced by tazarotene treatment at this time point.
After 120 days of treatment, animals receiving 1 and 5 mg per kg tazarotene had 60 and 40% fewer
tumors vs. controls (5.73 and 7.56, respectively, vs. 13.8 tumors in controls; p < 0.002, p < 0.023).
Animals treated with 2.5 mg per kg had a modest but not statistically signi®cant reduction in tumor
number (10.6 vs. 13.8 tumors). Moreover, the average tumor size in all treatment groups was not
reduced at 120 days. We conclude that ptc+/± mice treated with oral tazarotene have a comparable
tumor regression rate (approximately 50%) as humans treated with topical tazarotene. This mouse
model may help elucidate the mechanisms underlying tazarotene's chemotherapeutic effect.
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Clinical and Immunologic Response of Extramammary Paget's Disease to Imiquimod
J. Bamford and S. Seidelmann*
Section of Dermatology, St. Mary's/Duluth Clinic Health System, Duluth, Minnesota; *Department of
Pathology, St. Mary's/Duluth Clinic Health System, Duluth, Minnesota
In an unlabeled use of a commercial product 1% imiquimod cream had a good effect in treatment
for extramammary Paget's disease (~ 14 3 23 cm2 area). Nine years previously the 84 years male
had bright erythema of the urethral meatus, crural folds and scrotum with maceration and discharge
was clinically diagnosed as yeast and contact dermatitis and treated with ketoconazole orally
(200 mg per day) for 5 days and topical steroid and 1% econazole cream. The topicals were
continued. Six months ago, when the tumor diagnosis was made, his symptoms had progressed to
include discouragement, pain, and decreased ability to walk and signs ± enlarged red plaques and
papules covered with blood tinged, purulent, and malodorous discharge ± which involved the
urethral meatus, parts of the shaft of the penis, scrotum, pubic area, inner thigh and buttock. Initial
histology showed classical features of extramammary Paget's disease. The epidermis was nearly
effaced by a population of plump round cells with enlarged hyperchromatic nuclei and occasional
intracytoplasmic lumina. There was increased mitotic activity and individual cell necrosis. The
eccrine glands were also extensively in®ltrated. Paget's cells were positive for CAM5.2, EMA,
mucicarmine and pan-cytokeratin. S-100 was negative. No underlying malignancy was found. The
patient was treated with 1% imiquimod cream applied to all tumor for 3 months. Within a month
pain and foul discharge were markedly improved. At three months all pain, discharge was gone.
Clinically there was the appearance of a postin¯ammatory erythema and microscopically a
complete histologic remission of Paget's disease. There was, however, a lichenoid dermatitis with
eosinophiles most consistent with a drug eruption. The response did not include all areas.
Unresolved smaller plaques of Paget's disease (~ 2 3 3 cm2) were treated with CO2 laser ablation.
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Inhibition of DNA Methylation by Continuous Infusion of 5-Aza-2¢-Deoxycytidine
(Decitabine): A Phase I Study with Molecular Goals
S. Leachman, D. Jones,* A. Karpf,* S. Florell, P. Porter-Gill,* R. Wheeler, and W. Samlowsk
Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah; *Huntsman Cancer
Institute, University of Utah Health Sciences Center, Salt Lake City, Utah
One proposed mechanism of action of the deoxycytidine anaolog, 5-Aza-2¢-Deoxycytidine
(Decitabine), is through the marked reduction in cellular DNA methylation and subsequent gene
reactivation. Decitabine has been used to treat patients with leukemia, but has no proven ef®cacy
in solid tumors. This may be due to inadequate incorporation of the drug into slowly dividing solid
tumor cells (because the drug has a short half-life and is usually administered in a bolus fashion).
Therefore, we have designed a phase I study with the following primary objectives: (1) establish the
feasibility of measuring DNA methylation changes, gene induction, and proliferation status in the
blood and epidermis of patients before and after treatment (2) determine the maximum tolerated
dose of continuous i.v. Decitabine infusion over 7 days and (3) identify the dose-limiting toxicities
of a 7-day Decitabine infusion. Our basic science studies are designed to determine the biologic
optimum of the drug. Preliminary ex vivo experiments, have been proceeding in parallel with the
development of the clinical trial. We have utilized a skin explant model to optimize protocols for
DNA methylation and methylation-induced gene activation in clinical samples. Western blot and
immunohistochemical protocols to evaluate several methylation sensitive genes (MHC class I,
STAT1, STAT3, and transglutaminase I) have been developed. Mitotic index is being evaluated
using topoisomerase II in a well-established semiquantitative assay. Preliminary data from these
experiments suggest that it will be feasible to determine basic scienti®c endpoints in clinical
samples. This protocol translates our understanding of the molecular action of Decitabine into a
clinical trial that tests this mechanism in vivo.
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Imiquimod 5% Cream is Safe and Effective in the Treatment of Actinic Keratosis
A. Persaud, E. Shamuelova, D. Sherer, W. Lou, G. Singer, C. Cervera, S. Lamba, and M. Lebwohl
Dermatology, Mount Sinai School of Medicine, New York, New York
Actinic keratosis (AK) is the earliest clinical manifestation of squamous cell carcinoma. To
determine the ef®cacy and safety of imiquimod 5% cream as a treatment for AK. Twenty-two
patients with AK were treated with imiquimod 5% cream, initially at three times a week, for eight
weeks or until clearance of lesions. Patients applied imiquimod to lesions on one side of the body
and vehicle cream to the other side. Seventeen patients were evaluated for total number of lesions
and adverse reactions before treatment and at weeks 2, 4, 6, and 8, then at 4 and 8 weeks post-
treatment. A signi®cant reduction in the average number of lesions per patients was observed for
imiquimod-treated patients. The majority of patients experienced mild to moderate adverse events.
The two most frequent reactions were irritation and reddening of the skin. Imiquimod 5% cream is
a promising effective treatment of actinic keratosis with an acceptable safety pro®le.
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Photodynamic Therapy (PDT) with Methyl 5-Aminolevulinate 160mg per g Cream in
Patients with Basal Cell Carcinoma (BCC) with a Risk of Complications and Poor
Cosmetic Outcome Using Conventional Therapy
M. Horn, O. LarkoÈ,* H. Wulf,² T. Warloe,³ and P. Wolf
Karl-Franzens University, Graz, Austria; *Sahlgrenska University, Gothenburg, Sweden; ²Bispebjerg
Hosp., Copenhagen, Denmark; ³The Radium Hosp., Oslo, Norway
Patients (pts) with ``high-risk'' BCC in need of advanced surgery or radiation therapy with a risk of
complications and poor cosmetic outcome, received a new selective photosensitizer, methyl 5-
aminolevulinate (MAL) to determine response rate, cosmetic outcome and side effects. Pts with
clinical and histological diagnosis of BCC (mid-face, large, recurrent) excluding morpheic and
highly in®ltrating lesions, received one treatment cycle with MAL PDT (two treatments one week
apart). After lesion preparation and 3 hrs of topical occlusion with MAL cream (Metvixq), the
lesion was illuminated with 75 J per cm2 of red light (570±670 nm). If there was non-complete
response after 3 months as assessed clinically and by histology, the lesion was retreated. Ninety-four
pts with 123 lesions were treated and included in safety analysis. Sixty percent of the lesions were
located in face/scalp; 40% of the patients received two treatment cycles. Eighty-®ve pts with 108
lesions were included in primary ef®cacy analysis, nine pts were excluded by external reviewer
because they did not ful®ll the de®nition of having a ``high-risk'' BCC lesion. Clinical lesion
evaluation resulted in complete response rate of 87%, which dropped to 74% when excluding
lesions with a positive histology. Seventy-®ve percent of pts had good or excellent cosmetic
outcome. Sixty-seven percent of pts reported adverse events, mostly expected local phototoxic
reactions like erythema and burning sensation/pain. The symptoms were transient, and mostly of
mild severity. MAL PDT was effective in pts with ``high-risk'' BCC and the cosmetic results were
mostly good or excellent. MAL PDT was well tolerated and may be a good alternative to
conventional modalities which have the risks of dis®guration and inferior cosmetic outcome.
Follow-up is underway to determine long-term recurrence rate. *Other authors: L. Rhodes, C.
Fritsch, R. Kaufmann, M. de Rie, I. Stender, A. SoleÂr, A.M. Wennberg, G. Wong, F. Legat, S.
Pavel; Univ. of Liverpool, UK, Heinrich-Heine Univ. DuÈsseldorf, Germany, Goethe Univ.
Frankfurt, Germany, Academic Medical Center Amsterdam, The Netherlands, Leiden Univ.
Medical Center, The Netherlands.
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Arsenic Trioxide Induces a p53-Dependent Apoptosis in Skin Cancer Cells
T. Tsai, S. Shen,* Y. Chen,³ C. Hu,* and W. Lee²
Department of Dertamology, Taipei Medical University Hospital, Taipei, Taiwan; *Department of
Dermatology, School of Medicine, Taipei Mediacl University, Taipei, Taiwan; ²Graduate Institute of
Medical Sciences, Taipei Mediacl University, Taipei, Taiwan; ³Graduate Institute of Pharmacognosy Science,
Taipei Mediacl University, Taipei, Taiwan
Arsenic trioxide (As2O3) was recently found to induce complete remission in the patients with
refractory acute promyelocytic leukemia (APL) and to inhibit proliferation and induce apoptosis in
the APL cell line NB4. Afterwards, As2O3 was reported to have cytotoxic effects in several human
cancers including solid tumors by induction of apoptosis. We wondered whether As2O3 was able
to induce apoptosis in skin cancer cells. We demonstrate in this report As2O3 induces apoptosis in
skin cancer cell lines such as human basal cell carcinoma (BCC), human epidermoid carcinoma
(A431), human malignant melanoma (Hs695T) and PRMI 7951 in a dose- and time-dependent
manner, as evidenced by internucleosomal DNA fragmentation and morphologic changes. By
Western blot analysis, we found that the induction of apoptosis involved an early increase in p53
protein and caspase 3 activation; however, the expressions of Bcl-2 and Bax were not changed after
the treatment of As2O3. In addition, pretreatment of these skin cancer cells with p53 antisense
oligonucleotide could effectively block As2O3-induced apoptosis, but not by p53 sense
oligonucleotide. Thus our ®ndings suggest that the p53-associated signaling pathway is critically
involved in As2O3-mediated apoptotic cell death.
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Sequence of Events During Photodynamic Therapy-mediated Apoptosis of Human
Epidermoid Carcinoma A431 Cells
H. Mukhtar, N. Ahmad, and S. Gupta
Department of Derm., University Hosp. Research Institute and Case Western Reserve University, Cleveland,
Ohio
Photodynamic therapy (PDT) is a cancer treatment modality, which takes advantage of preferential
accumulation of porphyrin-based photosensitizers in tumor as compared to normal tissue followed
by selective delivery of visible light to the target tissue. This results in the activation of the
photosensitizer that causes oxidative damage leading to tumor ablation. PDT has emerged as a
novel treatment modality in dermatology inasmuch as it is showing promise for skin cancer and
several nonmalignant skin conditions. Recently PDT has received approval for the treatment of
actinic keratoses. PDT has been shown to cause oxidative stress leading to the killing of cells via
apoptosis. An understanding of molecular events in PDT-mediated apoptosis is not completely
understood; unraveling these pathways could lead to improvement in therapeutic ef®cacy of PDT.
We have earlier shown the involvement of (i) Fas-FADD-FLICE and (ii) bcl2, bax and other bcl2
family proteins during silicon phthalocyanine (Pc 4)-PDT-mediated apoptosis of human
epidermoid carcinoma A431 cells. Extending this work, here we show the involvement of
cytochrome c-Apaf-1-caspases as the downstream events in this apoptotic-pathway. Immunoblot
analysis of cells photosensitized with Pc 4-PDT showed a rapid release as early as 1 h post-PDT of
cytochrome c from mitochondria into the cytosol at which time only less than 7% of cells were
apoptotic. This was followed by a signi®cant increase in (i) the protein expression of Apaf-1
(apoptosis inducing factor-1) (ii) caspase activity (as assessed by the release of AFC from DVED-
AFC substrate by ¯uorescence spectroscopy), and (iii) the protein expression of caspase-3, ±7, ±8
and ±9, at 3 h (12% apoptotic cells) and 6 h (21% apoptotic cells) post-PDT. Further, PDT of cells
also resulted in a gradual loss in the protein expression of DNA fragmentation factor (DFF) and an
increase in the cleavage of PARP in a time-dependent fashion. Based on these data, we suggest that
Pc 4-PDT of A431 cells results in Fas-FADD-mediated loss of bcl2 with an increase in bax, which
leads to a mitochondrial dysfunction causing a release of cytochrome c from the mitochondria into
cytosol. Once released into cytosol, cytochrome c binds to its adaptor molecule, Apaf-1, which
oligomerizes and activates caspases that, in turn, results in cleavage and activation of DFF leading to
PARP cleavage. This series of events ultimately leads to an apoptotic death of cancer cells.
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Increase of Mortality Rate by Malignant Melanoma in Chile
P. Figueroa and J. Toro*
Dermatology, World Dermatology Institute, Santiago, Chile; *School of Public Health, University of Chile,
Santiago, Chile
The purpose of the study is to assess the impact of malignant melanoma in Chile and to evaluate a
long-term trend of its frequency. Mortality rates by all skin cancers and by malignant melanoma
were calculated from 1970 to 1998. In Chile in 1998 the mortality rate by all skin cancers was 1.55
per 100,000, with 230 deaths; mortality rate by melanoma was 0.85 per 100,000, with 126 deaths.
This mortality rate represents a 400% increase as compared with the rates from 1970. There were
no major differences in mortality rates according to gender. Mortality rates by all skin cancers
increased dramatically in patients older than 75-year-old. In conclusion, this study revealed a
substantial increase in the last 30 years in mortality rates by malignant melanoma in Chile.
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Do Lipid-Lowering Medications Prevent Melanoma?
L. Schilling and R. Dellavalle
Department of Dermatology, University of Colorado, Denver, Colorado; *Department of Medicine,
University of Colorado, Denver, Colorado
Two randomized, double-blinded, placebo-controlled, ®ve-year trials of lipid-lowering agents
have revealed signi®cantly lower melanoma rates in treated patients than in patients receiving
placebo. One trial (the VA-HIT study) utilized a member of the ®brate drug class, gem®brozil, and
the other trial (the AFCAPS study) utilized a member of the statin drug class, lovastatin.
Interestingly, lovastatin has previously been shown to inhibit melanoma cell growth in tissue
culture, and to decrease melanoma metastasis in mice injected with melanoma cells. The hypothesis
that lipid-lowering medications prevent melanoma was explored via a case-control analysis of the
Denver Veterans Administration Medical Center (VAMC) diagnostic and pharmaceutical
databases. 328 melanoma cases were identi®ed (64 in-patients from 1986 to 2000 and 264 out-
patients from 1996 to 2000) along with a random sample of two thousand controls. To assure that
controls represented active patients, controls were chosen from a pool of patients who had ®lled at
least one prescription for any medication from July±August 1999 and again from July±August
2000. The exposure rate of any statin prescription ®lled at the Denver VAMC pharmacy from 10/
1/92 to 9/30/00 was 18% among cases and 30% among controls. The exposure rate for ®brates was
4.9% among cases and 5.9% among controls. Further characterization of the temporal sequence and
size of exposure is needed before these preliminary results (lower prescription ®ll rates of lipid-
lowering drugs in cases) can be said to support the hypothesis that lipid-lowering medication
prevent melanoma. Still lipid-lowering medications may provide a novel method of modifying
melanoma risk. Further investigation of lipid-lowering medications for the chemoprevention of
melanoma will determine whether randomized trials of these agents should be initiated in persons
at high risk of developing melanoma.
896
A Population-Based Study of Gender Differences in Melanoma Epidemiology: 1988±97
F. Bedding®eld, S. Litwack,² A. Ziogas,² T. Taylor,², and H. Anton-Culver²
Division of Dermatology, University of California, Los Angeles, Los Angeles, California; *The RAND
Corporation, Santa Monica, California; ²Epidemiology Division, University of California, Irvine, Irvine,
California
To date, gender differences in melanoma (MM) epidemiology have not been fully elucidated. We
hypothesized that there are distinct age-speci®c incidence patterns for MM in males and females.
Subjects included 10 489 primarily non-Hispanic whites with MM analyzed from population-
based cancer registries of three Southern California counties, 1988±97. For further analysis of age-
and gender-speci®c incidence, we also evaluated 39 806 subjects from the entire California Cancer
Registry, 1988±97. The incidence of MM increased with increasing age during the study period
for both men and women, except in perimenopausal women aged 45±60, during which time the
incidence remained constant. The incidence of MM in subjects less than 40 in both genders was
roughly equal. After age 40 the incidence of MM increased with age considerably faster for males.
MMs in both genders increased dramatically during the study period, due primarily to localized,
thin tumors. The incidence in males increased at an annual rate of 4.4%, but 5.5% in females
(p < 0.0001). Melanoma in situ increased at a rate of 15% per year. In a multivariate analysis the
following variables, but not gender (p < 0.906), were associated with worse survival: increasing
tumor thickness (p < 0.0001), increasing age (p < 0.0001), truncal vs. limb (p < 0.0001) or head/
neck (p < 0.016) location, and nodular melanoma vs. all other histologic types (p < 0.0001).
Survival did not change over the study period. In this population-based study, we note for the ®rst
time a striking female perimenopausal plateau in the age-speci®c incidence of MM. The cause of
this perimenopausal plateau is unknown, but could include a transient hormonal or other
menopausal in¯uence, the waning of a premenopausal hormone, or a cohort-speci®c effect.
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Pilot Study of the Diagnostic Accuracy of Patients with Dysplastic Nevi in Performing
Skin Self-Examination (SSE)
P. Christos,* S. Oliveria, D. Chau, C. Charles, A. Koenigsberg, and A. Halpern
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; *Department of
Public Health, Weill Medical College of Cornell University, New York, New York
We conducted a pilot study to determine the sensitivity and speci®city of SSE to detect new and
changing moles, with and without the aid of baseline digital photography, in patients at high risk
for skin cancer. Patients with 5 or more dysplastic nevi were recruited from the outpatient clinic at
Memorial Sloan-Kettering Cancer Center. Patients had baseline digital photography and mole
counts of their back and abdomen and were instructed to perform a baseline SSE. This was
followed by the alteration of existing moles and the creation of new moles with the use of body
paint. Each patient had approximately 3 mol altered and/or created. Blind-folding of patients and
sham drawing on multiple sites were used to ensure that the patients were unaware of the location
of cosmetically altered moles. Patients were then asked to perform SSE ®rst without the aid of
baseline photographs and subsequently with access to photographs. Data were recorded for the
number of new and altered moles correctly and incorrectly identi®ed by the patients and the
sensitivity and speci®city of SSE (using the mole as the unit of analysis) were calculated. Mole
counts on 45 patients provided data on 2957 mol. A total of 101 and 197 mol were altered and
created, respectively. The sensitivity and speci®city of SSE for detection of both altered and new
moles without photography (WOP) were 59.7% and 96.5%, respectively. SSE with photography
(WP) yielded a sensitivity and speci®city of 73.2% and 98.6%, respectively (p < 0.0001 for paired
comparison of SSE tests). For the back only, the sensitivity of SSE for detection of altered/new
moles was 57.1% (WOP) and 69.3% (WP) (p < 0.0001). For the abdomen only, the sensitivity of
SSE was 64.2% (WOP) and 79.8% (WP) (p < 0.0001). The sensitivity of SSE for detection of
altered moles was 53.5% (WOP) and 65.3% (WP) (p = 0.001). The sensitivity of SSE for detection
of new moles was 62.9% (WOP) and 77.2% (WP) (p < 0.0001). No important differences were
observed for speci®city in the strati®ed analyses. Access to baseline photography improved the
diagnostic accuracy of SSE on the back and abdomen and improved detection of changing and new
moles. Our results suggest that baseline digital photography in tandem with SSE may be effective in
improving the diagnostic accuracy of SSE.
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Bryostatin Potentiates the Susceptibility of Human Melanoma Cell Lines to Fas-
Mediated and Cisplatin-Induced Apoptosis
J. Urquhart, Y. Shellman, and D. Norris
Dermatology, University of Colorado Health Sciences Center, Denver, Colorado
Melanoma cells maintain a wide-variety of antiapoptotic defenses which limit the effectiveness of
chemo-, immuno-, and radiotherapy designed to induce apoptosis. Bryostatin also shows limited
effectiveness in single agent therapy for melanoma, but signi®cantly enhances the susceptibility of
malignant T cells to apoptosis. To determine if bryostatin might potentiate apoptosis in melanoma,
we studied its effects on apoptotic pathways induced by death receptors or cytotoxic drugs. We
conducted cytotoxicity experiments in WM35, a human radial growth phase melanoma cell line,
and A375, a human metatstatic melanoma cell line. Treatment of these cells with bryostatin
increased susceptibility to Fas-mediated apoptosis signi®cantly. Bryostatin also potentiated the
susceptibility of both melanoma cell lines to cisplatin-induced apoptosis. Interestingly, bryostatin
showed a ``biphasic'' effect, inhibiting apoptosis at low concentrations, but potentiating
susceptibility to apoptosis at higher concentrations, consistent with the biphasic effect of bryostatin
on PKC. Our results suggest that bryostatin might be an effective adjuvant for immunotherapy or
chemotherapy in melanoma, since it potentiated both Fas-mediated and cisplatin-induced
apoptosis. Our initial studies on the mechanism indicate that the effect of bryostatin is complex,
involving expression of death receptors as well as downstream antiapoptotic factors.
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Tumor Regression Induced by Intratumoral Injection of DNA Coding for Human
Interleukin 12 into Melanoma Metastases in Gray Horses
L. Heinzerling, K. Feige,* S. Rieder,² M. Akens,* R. Dummer, G. Stranzinger, and K. Moelling
Dermatology, Virology, University hospital; University, Zuerich, Switzerland;*Large animal medicine,
Veterinary university hospital, Zuerich, Switzerland; ²Animal Sciences, Swiss Federal institute of technology,
Zuerich, Switzerland; ³Institute for medical virology, University of Zuerich, Zuerich, Switzerland
Introduction: Presently, preclinical studies investigating new therapeutic principles against
melanoma are studied in mouse models, which are not optimal. Gray horses tend to spontaneously
develop melanomas that subsequently metastasize in a pattern similar to human disease. Thus, they
provide a highly relevant large animal model for preclinical studies testing new immunotherapy
protocols. Methods: Seven gray horses with metastatic melanoma were included in the study.
Tumor size was assessed before and regularly during the study using calipers, ultrasound
measurements and endoscopic assessment. Established tumor metastases were injected with naked
DNA coding for human interleukin 12 (IL-12) or control vector. Some lesions were left untreated.
Biopsies and blood samples were taken and analyzed at speci®ed time points during the study.
Biological activity of human IL-12 in the horse was assessed by measuring induction of equine
interferon gamma by real time RT-PCR and proliferation after stimulation with recombinant
human IL-12. Results: Injection of human IL-12 encoding plasmid DNA induced signi®cant
regression in all 12 treated lesions in a total of 7 horses. Complete disappearance was observed in
one treated lesion, with no recurrence after 8 months. No adverse events have been observed in
any of the animals during and after treatment. Conclusion: The results demonstrate the
effectiveness and safety of IL-12 encoding plasmid DNA therapy against established metastatic
disease in a large animal model and serve as a basis for a clinical trial.
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Immunotherapy of Metastatic Melanoma with Tumorlysate-/or Peptide-Pulsed
Monocyte Derived Mature Dendritic Cells Leads to Regression of Metastases
S. Kiske, G. Reinhard, F. Feil, H. Kaiser, and T. Bieber
Dermatology, University of Bonn, Bonn, Germany
Malignant melanoma is a highly aggressive tumor with increasing morbidity and mortality
worldwide. To date there is no therapy for metastatic melanoma with predominantly curative
effects. Based on the emerging concept of the central role of antigen presenting cells (APC) in the
initiation of immune responses ± especially the unique potency of dendritic cells (DC) in activating
cytotoxic T-cells (CTL) ± in the last years DC-based vaccines are under investigation. However,
the best vaccination strategy still remains unclear. The elucidation of this question presents the
central object of this study. We use tumorlysate-/or peptide-pulsed monocyte derived DC to
induce a tumorspeci®c immune response by activation of tumorspeci®c CTL. In our phase II-trial
14 patients with progressing metastatic melanoma (state IV of UICC) have been investigated so far.
The ®rst 4 patients ± vaccinated with immature DC ± showed progress of disease within the
induction period (< 5 weeks). Therefore the following 10 patients were treated with mature
dendritic cells. We observed a clinical response in 5 cases: 3 patients showed a stable disease (SD)
over a long period of time, 2 patients a partial remission (PR). 5 patients progressed in disease. One
of these patients with PR responded with regression of extensive abdominal metastases, lymph
node metastases and bone metastases, the other one with necrotic desintegration of abdominal
lymph nodes. 4 of the patients with PR or SD were treated with autologous tumorlysate-pulsed
DC, one with peptide-pulsed DC. To judge the performance of peptides/tumorlysate in
vaccination strategies we investigated the functional stimulation of T-cells by ELISPOT analysis.
First results show that a tumor-/peptide-speci®c CTL-response could be induced.
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Decreases in Serum Levels of S100 May Predict Response to Therapy in Melanoma
Patients Treated with a Polyvalent Melanoma Vaccine
A. Bar, P. Amin, S. Reynolds, R. Shapiro, D. Roses, M. Harris, and J. Bystryn
Dermatology, NYU School of Medicine, New York, New York; *Surgery, NYU School of Medicine, New
York, New York
Serum levels of S100 appear to be predictive of prognosis in patients with melanoma. In this study
we explored whether changes in the level of this antigen could be used to evaluate. response to
therapy. We measured serum levels of S100 at multiple time points during therapy with a
polyvalent, shed antigen melanoma vaccine in 106 melanoma patients (58 with AJCC stage IIB/
IIIA, and 48 with stage IIIB disease). S100 was measured immediately prior to treatment and
following 2, 4, and 10 months of therapy using a double sandwich ELISA. We found that patients
who were S100 positive at baseline and whose S100 levels decreased during vaccine treatment
(n = 30) had a recurrence-free survival that was signi®cantly longer than that of patients whose
levels increased or remained stable during therapy (n = 11). By Kaplan-Meier analysis the mean
recurrence-free survival was 12.5 6 0.7 months in the ®rst group vs. 9.2 6 0.7 months in the
second group. Patients who were S100 negative throughout the study (n = 65) had the longest
recurrence-free survival, i.e. mean of 20.2 6 0.8 months. These results suggest that serial assays of
S100 in the circulation may provide an intermediate marker of the clinical effectiveness of
melanoma vaccine therapy.
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Atypical Cells in Malignant Melanoma Re-excision Scars: An Immunohistochemical
Study
O. Trejo, J. Reed,* and V. Prieto
Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas; *Pathology, Baylor College
of Medicine, Houston, Texas
Background: Re-excision scars for melanoma may be hypercellular and contain atypical cells with
prominent nucleoli mimicking residual disease. Immunohistochemical analyis with anti-S100 may
be used to detect malignant melanoma cells within the scar. The speci®city of anti-S100 is limited
because it also labels dendritic and Schwann cells which appear to be increased in number and size
in scars. No studies exist that address the question of the nature of these cells. Design: Ten skin re-
excision scars for melanoma (MS) and ®ve for non-melanoma cases (NMS) were studied by routine
histology and immunohistochemical labelling for S100, gp100 (HMB45), and MART1. The
presence of atypical cells, their morphology, and location were correlated with their
immunolabelling pattern. Results: Numerous large, hyperchromatic, spindled to polygonal cells,
with occasional prominent nucleoli were present mostly within the papillary dermis (10/10 MS, 5/
5 NMS). They were often near or adjacent to blood vessels and surrounded by lymphocytes and
were strongly labeled with anti-S100 (10/10 MS, 5/5 NMS). All were negative with HMB45 (0/
10 MS, 0/5 NMS). In some cases, rare cells close to the epidermis were labeled with MART1 (4/
10 MS, 4/5 NMS). In one MS case, MART1 was useful in detecting a focus of residual melanoma
that was negative with HMB45. Conclusions: Atypical cells can be seen within re-excision scars
and may be confused with residual malignant melanoma. Analysis of S100 expression alone may
result in a false positive diagnosis of residual melanoma. Additional routine use of HMB45 and
MART1 is, therefore, recommended in all re-excisions scars for melanoma. Further studies are
required to delineate the origin of these cells.
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Evidence for an Association between Cutaneous Melanoma and Non-Hodgkin's
Lymphoma
H. Tsao, W. Goggins,* and D. Finkelstein²
Department of Dermatology and the Melanoma Center, Massachusetts General Hospital, Boston,
Massachusetts; *Department of Mathematics, Hong Kong Baptist University, Kowloon Tong, Hong
Kong; ²Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts
For decades, both cutaneous melanoma (CM) and Non-Hodgkin's lymphoma (NHL) have
increased in incidence dramatically. We looked for a possible relationship between these two
cancers by examining the risk of NHL in CM survivors and the risk of CM in NHL survivors. To
this end, we followed cohorts of CM and NHL patients registered through the National Cancer
Institute's Surveillance, Epidemiology, and End Results (SEER) program between 1973 and 1996
and identi®ed patients who developed CM after NHL and NHL after CM. To evaluate relative
risk, we compared the observed number of cases to the expected number of cases. Between 1973
and 1996, a total of 54 803 CM patients and 62 597 NHL patients who met our inclusion criteria
were identi®ed through SEER. We found statistically signi®cant elevated risks of NHL among CM
survivors (SIR = 1.42, 95% CI = 1.23±1.63) and CM among NHL survivors (SIR = 1.75, 95%
CI = 1.48±2.07). These results support an association between CM and NHL. Although detection
bias and post therapy effects may contribute to this association, shared genetic or etiological factors,
such as sunlight exposure, may also play a role.
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Risk of Death in Inherited Epidermolysis Bullosa (EB): Cumulative and Conditional
Probabilities, Based on the Experience of the National EB Registry (NEBR), 1986±2000
L. Brock, J. Fine, L. Johnson, M. Weiner, A. Stein, and C. Suchindran
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
It is known that inherited EB may prove fatal. One subtype of junctional EB (JEB) was once
named ``EB letalis'', to emphasize this risk. We have analyzed 14 years' data collected through 12/
31/00 on the ®rst 2650 enrollees in the NEBR to quantitate the risk of death in each major EB
subtype. During this time, 7.5% of all NEBR enrollees had died, ranging from 0.9% of EB simplex
(EBS) Weber-Cockayne to 53.5% of JEB-Herlitz (JEB-H) patients. Among EBS patients, the only
signi®cant subtype at risk of premature death (and only during the ®rst year of life) was Dowling-
Meara (EBS-DM), with a cumulative risk of 3.1% on or after age 1. With rare exceptions, death in
JEB patients occurred primarily within the ®rst 3 years of life. Non-Herlitz JEB (JEB-nH) and
JEB-H patients had cumulative risks of 37.3% and 40.0%, 43.2% and 45.6%, and 43.8 and 48.5%,
by ages 1, 2, and 3, respectively. The highest conditional probabilities for death in JEB-nH (36.7%)
and JEB-H (40.0%) both occurred during the ®rst year of life. There was no signi®cant increased
risk of death in dominant dystrophic EB (DDEB) patients. A bimodal distribution of deaths was
seen in patients with Hallopeau-Siemens recessive dystrophic EB (RDEB-HS), with the highest
interval at risk (conditional probability = 47.6%) between ages 35±40. Cumulative risks of 1.6%,
3.2%, 5.0%, and 7.9%, were seen by ages 1, 6, 10, and 15, and then rapidly increased to 20.1%,
35.4%, 44.4%, 63.0%, 80.6%, and 86.1%, by ages 20, 25, 30, 35, 40, and 45, respectively. A similar
pattern occurred in RDEB-nHS, although the cumulative risks were much lower at every age
interval, being 0.8%, 2.4%, 9.4%, 17.7%, and 29.9%, by ages 1, 15, 30, 45, and 55, respectively.
These data suggest several conclusions: (1) Among EBS subtypes, EBS-DM is the only one with
signi®cant risk of premature death, and only during infancy; even then, the cumulative risk is only
3%; (2) Most JEB deaths occur within the ®rst 3 years of life, with nearly identical cumulative risks
in each of the two major JEB subtypes; (3) Death occurs much more often in RDEB-HS than
RDEB-nHS, and in both, most deaths occur during adulthood; (4) Differences in when deaths
occur suggest the likelihood of different etiologies, and further suggest differences, by EB subtype,
in when patients require closest surveillance against possible risk factors.
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Inherited EB and the American Health Care System: Differences in EB Type in the
Utilization of Inpatient and Outpatient Facilities and of Specialists, and Patient-Parental
Satisfaction
J. Zhou, J. Fine, L. Johnson, A. Stein, C. Suchindran, and M. Weiner
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
A cross-sectional study of approximately 400 randomly selected National EB Registry enrollees
was undertaken to assess health care system utilization and patient perceptions of their care within
the past 12 months. Adults and children had signi®cantly different medical needs, as re¯ected in
their relative use of specialists for the management of selected extracutaneous manifestations. 15%
and 3.6% of all adult RDEB patients were seen by surgical oncologists and psychiatrists, compared
to 0% and 13% of RDEB children, respectively. In contrast, children with JEB were more likely to
be treated by gastroenterologists than were adults with JEB (18 vs. 8.3%). Overall, adults sought
more frequent evaluation by dermatologists (JEB, 92 vs. 77%; RDEB, 75 vs. 63%) than did
children. About 73% of all children with EB were treated by a pediatrician whereas less than half of
all adults with EB required treatment by an internist or family practitioner. Most medical care for
EB in the United States was provided as outpatients. 14% of adults and 29% of children with JEB,
and 32% of adults and 25% of children with RDEB, required hospitalization. The average number
of hospitalizations per year among those requiring inpatient care differed by age group and EB type
(JEB:1.3 in children, 1.4 in adults; RDEB:1.7 in children, 2.0 in adults). Relative satisfaction in
overall health care and speci®c physician attributes varied by EB type and age group. A recurrent
complaint, especially by parents of more severely affected children, was that EB clinical research
was proceeding too slowly.
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The Cost of Health Care for Inherited EB in the United States: Differences in Relative
Coverage for Inpatient and Outpatient Services, and Overall Estimates of Yearly
Expenses
H. Chuan, J. Fine, L. Johnson, A. Stein, C. Suchindran, and M. Weiner
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Approximately 400 randomly chosen enrollees in the NEBR, representative of all major EB types
and subtypes, were studied in an effort to better assess the relative cost of medical care for each of
these diseases within the United States. Patients (or their parents or guardians, if minors) were
questioned in detail about their medical insurance coverage and overall costs during the 12 months
preceding each interview. Considerable differences were noted across EB types as to the frequency
with which patients experienced out-of-pocket costs for different aspects of their health care.
Whereas over 80% of all EB children had all inpatient costs covered by some form of insurance or
health care program, only about 60%, 35%, and 10±42% of all EB children had all costs related to
outpatient clinic visits, private physician appointments, and prescription medications covered by
some third party payer. Surprisingly, 15±20% and 42±51% of all JEB and RDEB patients had to pay
out-of-pocket for over 76% of their costs for nutritional supplements and wound care supplies,
respectively, despite the frequency with which each was required by these patients on at least a
daily basis. Although considerable variations were noted within each major EB group, the annual
average costs for medical care which was directly related to EB was estimated in children to be
$430 for EBS, $846 for DDEB, $68,632 for JEB, and $11,747 for RDEB. This can be contrasted in
adults with estimated costs of $753 for EBS, $542 for DDEB, $2,168 for JEB, and $29,365 for
RDEB. These striking differences in overall costs of care for children versus adults with JEB and
RDEB re¯ect differences in the relative frequencies of costly and clinically signi®cant
extracutaneous sequelae in childhood and adult life within these two major EB types.
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Activities of Daily Living (ADL) and Disease-Associated Pain in Children with Inherited
Epidermolysis Bullosa (EB)
M. Morgan, J. Fine, L. Johnson, A. Stein, C. Suchindran, and M. Weiner
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Standardized questionnaires were used to assess the physical and emotional functionality of
approximately 400 randomly chosen enrollees in the NEBR who represented all major EB types
and subtypes of this disease which are seen within the United States. The level of independence of
six ADLs (toileting; feeding; bathing; dressing; grooming; ambulation) were assessed, using
conventional criteria. Whereas 90% of all EBS and DDEB children were totally independent for
each function, excluding ambulation, the frequency of totally independent patients with JEB and
RDEB ranged from only 42±73%. No DDEB children and only 2% of EBS patients were totally
dependent by ADL, in comparison to 8±27% of JEB 2±27% of RDEB children. Totally
independent physical ambulation was reported in only 31%, 31%, 67%, and 24% of EBS, JEB,
DDEB, and RDEB children. Daily level of EB-related pain was assessed in children by their
parents on a linear scale of 0 (no pain) to 10 (unbearable pain). Whereas 14±19% of all children
with EBS, JEB, and DDEB were graded 5, 32% of all RDEB children reportedly suffered this
much pain. Increased frequencies of pain 5 were most often noted in those with more clinically
extensive or severe EB subtypes. These included JEB-Herlitz (20% vs. 14% in JEB-non-Herlitz)
and RDEB-Hallopeau-Siemens (47% vs. 20% in all other RDEB subtypes). Conversely, only 5%
of all RDEB children reportedly were pain-free, compared to 12±14% of those with EBS, JEB, and
DDEB.
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Inherited Epidermolysis Bullosa (EB): Impact of an Affected Child on Parental
Interpersonal Relationships, Marital Status, and the Decision to have Additional
Children
K. Beasley, J. Fine, L. Johnson, A. Stein, C. Suchindran, and M. Weiner
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Standardized questionnaires were used to assess the impact of the presence of EB in one or more
children on the personal relationships shared between their parents. In general, the presence of a
severely affected child with EB had rather profound effects on many aspects of marriage. This
ranged from complaints of lack of interest in participating in activities as couples (JEB, 45%;
RDEB, 25%), lack of energy to invest in such pursuits (JEB, 82%; RDEB, 50%), limitations in
opportunities for sharing nonintimate physical activities (reported in nearly 78% of EBS parents),
and a signi®cantly negative impact on parental sex life (among JEB parents, reported in 55%; in
RDEB, in 39%). 10%, 64%, 25%, and 36% of parents of an affected child with EBS, JEB, DDEB,
and RDEB, respectively, characterized their relationships as couples as revolving almost exclusively
around the day-to-day care of their affected children. Only 46% and 19% of parents with a child
with EBS or DDEB denied any global alteration in their marriage as a result of having one or more
affected children. The severity of disease in an affected child clearly in¯uenced parenteral decisions
about having more children. 54% and 63% of parents of children with JEB and RDEB chose not to
have additional children, compared to only 24±26% of parents with children having EBS or
DDEB. This choice was most often pursued via tubal ligation; less often, alternative means of
surgical sterilization were chosen. Divorce was common among EB parents (range, 17% in EBS to
31% in JEB) and, with the exception of parents of an EBS child, was usually directly attributed by
one or more of the parents to the profound impact that this disease had exerted on their marriages.
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Inherited EB: Impact of an Affected Child on Parental Feelings of Guilt, Blame,
Anxiety, Self-Image, and Depression, Religious Beliefs and Ability to Cope, and the
Risk of Suicide in Affected Adults
H. Kim, J. Fine, L. Johnson, A. Stein, C. Suchindran, J. Amushed, and M. Weiner
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
We have assessed the impact of a child with inherited EB on a variety of parental emotions or
beliefs. Roughly 1/3±2/3 of all parents, regardless of the EB type present in their child or its
genetic mode of transmission, admitted to feeling that their spouses were somehow to blame for
this disease. 36%, 30%, 65%, and 38% of parents with a child with EBS, JEB, DDEB, and RDEB,
respectively, blamed themselves, even in the absence of previous evidence of this disease within
their families. A common complaint among parents was that ``nobody understood the personal
burden of this disease'' (range, 44% in EBS to 80% in JEB parents), adding to their sense of isolation
and despair. Religious beliefs in parents were reportedly changed, following the birth of an affected
child, in only 5% and 14% of EBS and DDEB parents, as compared to 28±29% of parents of
children with JEB and RDEB. In the majority of those who admitted to having experienced such a
change, religious beliefs became more important by the presence of their affected child, as was their
overall belief in God. Rare parents of children with JEB and RDEB, however, also concurrently
admitted to blaming God for their childrens' disease. Fatigue, anxiety, altered self-image, and
depression were common, especially among parents of more severely affected children.
Approximately half of all JEB and RDEB parents complained of fatigue, and 85% and 80% of
JEB and RDEB parents, respectively, compared the frequent ¯uctuations in their lives to those of
``someone on a roller coaster.'' On the other hand, learning to cope with and to manage their
childrens' disease was described by over half of all EB parents as having made them better persons.
Suicidal ideation (18±26%) and suicidal attempts (17±22%) were reported by a signi®cant minority
of adults affected with JEB and RDEB.
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Impact of an Affected Child with Epidermolysis Bullosa (EB) on the Functionality of the
Family Unit and the Ways in which Parents are Regarded by Others within their Own
Communities
P. Guest, J. Fine, L. Johnson, A. Stein, C. Suchindran, and M. Weiner
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
We have employed a detailed questionnaire on nearly 400 patients with inherited EB in an effort to
assess the possible impact of their disease on their immediate families, relatives, and friends. In
general, families having one or more children affected by JEB or RDEB were the most affected,
regardless of the parameter which was assessed, when contrasted with families of children with
DDEB and EBS. The ®nancial burden of JEB and RDEB negatively impacted in many ways on
affected families, to include the ability of the families to afford nonessential but still desirable
purchases, to take family vacations or otherwise travel outside of their own communities, to eat
outside of their homes, to afford to own their own houses (in 63% of JEB families; 24%, RDEB),
to afford private education for unaffected children, or allow parents to pay for their own additional
education. Over a quarter of all JEB families also reported having had to give up attending church
as a result of the severity of their childrens' disease. About 25%, 46%, 19%, and 40% of parents of
children with EBS, JEB, DDEB, and RDEB felt that that they were neglecting their other children
as a result of the many burdens imposed on them by having an affected child with EB. A variety of
antisocial behaviors were attributed to interactions with nonfamily members, including social
ostracization (in 30±50%), false accusations of child abuse (38±70%), not being made to feel
welcome by strangers (in 56±80% of non-EBS families), having their affected children excluded
from play with other children, and concerns raised by others about EB being potentially
contagious. Some parents also reported decreased interactions with previously close friends
although no obvious changes were reported among relationships with relatives who were outside
of the immediate family unit.
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Impact of Gene vs. Protein Replacement on Genomic Expression Patterns in Junctional
Epidermolysis Bullosa
J. Goodnough, P. Robbins, S. Sheu, and P. Khavari
VA Palo Alto and Department of Dermatology, Stanford University, Stanford, California
Identi®cation of the genes responsible for over 80 human genetic skin diseases provides a rational
basis for development of new targeted molecular therapeutics. However, the relative ef®cacy of
gene vs. protein-based therapies in achieving phenotypic correction is unclear. Similarly, the global
impact of each approach on genomic expression patterns is unknown. While most molecular
therapy studies have examined impacts on a limited number of parameters, different approaches
may impact many biological systems within cells and tissue. In our efforts to develop an effective
molecular therapy for junctional epidermolysis bullosa (JEB), we found that laminin 5 b3 gene
transfer corrects the JEB skin phenotype in vivo including tissue ultrastructure and the localization
of key proteins of the basement membrane zone. To model the relative effects of gene transfer vs.
protein therapy for JEB, we cultured primary keratinocytes from six JEB patients following three
different treatment regimens (1. nontreated, 2. gene therapy, 3. protein therapy) and compared
cellular morphology, growth kinetics and gene expression pro®les using cDNA microarrays
encompassing 2068 known human genes; the latter were performed in triplicate for each patient
and site matched normal control. While both protein and gene delivery restored JEB cell short-
term growth kinetics to that of normal controls, b3 gene transfer resulted in cellular morphology
and gene expression pro®les more closely resembling normal than did b3 protein transfer. As
anticipated, many of the genes whose expression was restored to the normal range following
treatment were those encoding adhesion molecules and components of the hemidesmosomes.
Although gene transfer normalized the expression of a higher percentage of genes than did b3
protein transfer, neither approach fully normalized expression of all of the genes examined. In
addition, both approaches altered the expression of some genes, but protein transfer disrupted
expression of a larger proportion of the genes examined. These observations indicate that gene and
protein transfer exert different and unanticipated biological effects in primary JEB keratinocytes.
These ®ndings are likely to have broad implications for the development of new molecular
therapies.
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A Prospective Nonrandomized Comparison of Ef®cacy and Safety of Intravenous
Immunoglobulin to Conventional Therapy in Ocular Cicatricial Pemphigoid
E. Letko, E. Miserocchi,* W. Christen,² C. Foster,* and A. Ahmed
Oral Medicine, Harvard School of Dental Medicine, Boston, Massachusetts; *Immunology and Uveitis
Service, Massachusetts Eye and Ear In®rmary, Boston, Massachusetts; ²Preventive Medicine, Brigham and
Women's Hospital, Boston, Massachusetts
Ocular cicatricial pemphigoid (OCP) is a systemic autoimmune disease presenting as chronic
cicatrizing conjunctivitis. Involvement of other mucous membranes or the skin can occur during
the course of the disease. We performed a prospective nonrandomized comparison of ef®cacy and
safety of intravenous immunoglobulin (IVIg) to conventional therapy in patients with OCP who
initially presented with cicatricial pemphigoid involving skin and/or mucous membranes other
than conjunctiva and whose disease progressed to involve the eye in spite of systemic
immunosuppressive therapy. Eight patients in group A were treated with intravenous
immunoglobulin after the diagnosis of OCP was established. The ef®cacy and safety of IVIg
therapy were compared to a clinically similar group of eight patients recently treated with
conventional immunosuppressive therapy (group B). The median time between initiation of
therapy and clinical remission in group A and group B was 4 months and 7.5 months, respectively
(p < 0.01). Recurrence of ocular in¯ammation was not observed in any patient in group A. At least
one recurrence (median 1) was observed in ®ve patients in group B (range 0±4, p < 0.05). No
disease progression was recorded in group A. On the contrary, four eyes of three patients
progressed to an advanced stage of OCP. Four patients in group A suffered from drug related side-
effects in the course of IVIg therapy. The total number of side-effects recorded in eight patients in
group B was 33 and was statistically signi®cantly higher when compared to group A (p < 0.001).
Intravenous immunoglobulin is more effective and safer in treatment of patients with OCP when
compared to conventional immunosuppressive therapy.
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Successful Outcome with IVIg Therapy in Treatment Resistant Pemphigus Foliaceus
N. Sami* and A. Ahmed
Department of Medicine, New England Baptist Hospital, Boston, Massachusetts; *Department of Oral
Medicine, Harvard School of Dental Medicine, Boston, Massachusetts
Pemphigus foliaceus is a chronic autoimmune blistering skin disease which is commonly treated
with oral corticosteroids and conventional immunosuppresive therapy. Pemphigus foliaceus in
some patients can be refractory to systemic treatments and the resultant side-effects of prolonged
immunosuppression can be potentially fatal Alternative therapies to control the disease by
immunomodulation are needed. The purpose of this study is to report treatment outcomes in 11
patients with severe pemphigus foliaceus, refractory to Prednisone and immunosuppressive
therapy. The development of serious and debilitating side-effects warranted treatment with
intravenous immunoglobulin (IVIg). In 11 patients, selection criteria included a biopsy and
immunopathologically proven pemphigus foliaceus, treatment resistance and/or side-effects to
conventional therapy, and a minimum of 12 months of follow-up after cessation of IVIg therapy.
IVIg was administered according to a de®ned protocol. Criteria for clinical response to IVIg
included control of disease, duration of IVIg maintenance therapy, total duration of IVIg, total
number of cycles, use of Prednisone and adjuvant immunosuppressive therapy, and the number of
recurrences and relapses. The pre- and post IVIg data was statistically analyzed using the SAS
UNIVARIATE and 2-sided Wilcoxon sign rank and sign tests. All the patients had an effective
clinical response and remained in clinical remission after discontinuation of IVIg therapy. No
serious side-effects from IVIg use were recorded. IVIg therapy is an appropriate, effective, and safe
biological agent in inducing and maintaining prolonged clinical remissions in pemphigus foliaceus
patients who fail to achieve this goal by conventional treatments. IVIg is effective as monotherapy
but is needed for a prolonged period to achieve long-term remission. Use of IVIg therapy can
prevent the development of serious and characteristic side-effects from Prednisone and adjuvant
immunosuppressive agents.
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Intravenous Immunoglobulin Therapy Results in Long-Term Remission in Bullous
Pemphigoid Patients Non-Responsive to Conventional Immunosuppressive Treatment
A. Ahmed
Department of Oral Medicine, Harvard School of Dental Medicine, Boston, Massachusetts;
*Department of Medicine, New England Baptist Hospital, Boston, Massachusetts
Several patients with bullous pemphigoid do not respond to conventional immunosuppressive
therapy consisting of oral Prednisone alone or in combination with another steroid sparing
immunosuppressive drug. In spite of such therapies some patients do not go into a prolonged
clinical remission and continue to have relapses and remissions. In 15 patients with recurrent
bullous pemphigoid who were resistant to conventional therapy and had developed numerous
side-effects to such therapy, treatment with intravenous immunoglobulin was administered. Details
of clinical course, dose of Prednisone, immunosuppressive agents, their duration, side-effects,
frequency of relapses and recurrence response to therapy, number of hospitalizations, total days
hospitalized and quality of life were noted pre and post intravenous immunoglobulin therapy. The
results were compared and statistically analyzed. Fifteen bullous pemphigoid patients that were
resistant to treatment, upon receiving IVIg went into a prolonged sustained clinical remission.
There was a statistically signi®cant difference in the clinical course of disease pre and post IVIg.
IVIg is a safe and effective agent in treating severe bullous pemphigoid patients resistant to
conventional therapy. IVIg may also be useful in patients who have developed or have the risk of
developing serious or potentially fatal side-effects to conventional immunosuppressive therapy.
After clinical control is achieved IVIg therapy should be gradually withdrawn over a period of time
and not abruptly discontinued.
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Treatment of Epidermolysis Bullosa Acquisita with the Humanized anti-Tac mAb
Daclizumab
C. Egan, M. Brown, J. White* and K. Yancey
Dermatology Branch, DCS, NCI; DLM, CCÃ; Of®ce of Cancer Complementary and Alternative Medicine;
*National Institutes of Health, Bethesda, Maryland
Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering disease
characterized by IgG antibasement membrane autoantibodies to collagen VII. Patients may
present with blisters and erosions precipitated by trauma, dystrophic EBA, or widespread
in¯ammatory lesions, in¯ammatory EBA. Since autoantibody formation in EBA patients is thought
to be T cell-dependent, the degree of T cell activation in 3 patients (all male, ages 33±44 year) was
assessed by quantitation of soluble Tac, a fragment of the a-subunit of the high af®nity IL-2
receptor (CD25). Soluble Tac levels in all patients were elevated (highest random values: 2,430,
920, 560 [normal range 112±502 IU per ml]). Based on such ®ndings, these patients were treated
with a humanized murine monoclonal anti-Tac antibody, Daclizumab (1 mg per kg body weight,
6±12 IV treatments at 2±4 week intervals). All patients had a signi®cant, rapid, and persistent
decrease in lymphocyte CD25 expression (e.g. 38% to 0.7% 2 weeks after ®rst treatment). Though
a slight decrease in lymphocyte expression of 7G7, an IL-2 receptor epitope not bound by
Daclizumab, was noted, stable levels of CD3 cells and in vitro saturation studies indicated that
Daclizumab effectively bound CD25 and did not promote clearance of such cells from peripheral
blood. There were no complications and no patient developed antibodies against Daclizumab.
While no apparent bene®t was seen in patients with dermolytic disease, the patient with
in¯ammatory EBA had a favorable response. This patient stopped prednisone and signi®cantly
reduced dapsone dosage while on Daclizumab. Furthermore, his disease ¯ared when treatment was
stopped, and resumption of Daclizumab again effected improvement within 2 weeks. Daclizumab
therapy is safe and well tolerated in EBA patients. It may be effective as a corticosteroid sparing
agent in patients with in¯ammatory EBA.
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Anti-CD20 Chimeric Monoclonal Antibody (Rituximab) for the Treatment of
Recalcitrant, Life-Threatening Pemphigus Vulgaris: Implications for its Use in Other
Autoimmune Antibody Mediated Diseases
T. Salopek, S. Logsetty,* and E. Tredget*
Division of Dermatology & Cutaneous Sciences, University of Alberta, Edmonton, AB, Canada;
*Department of Surgery & Fire®ghter's Burn Treatment Unit, University of Alberta, Edmonton, AB,
Canada
The development of chimeric antibodies which target constituent cellular antigens is expected to
radically alter our approach to neoplastic and immunological disorders. Rituximab (Rituxan), a
chimeric monoclonal antibody directed against CD20 of B cells has been used in patients with B-
cell Non-Hodgkin's lymphoma with good effects. Over the past year, there have been anecdotal
reports of the use of rituximab in autoimmune disorders, speci®cally, a case of autoimmune
thrombocytopenia and a small series (10 patients) with rheumatoid arthritis. In both settings,
rituximab had a dramatic effect on the targeted condition. In this report, we describe the use
rituximab in a patient with refractory pemphigus vulgaris (PV). The case concerns a 30-year-old
woman who failed to improve with conventional therapies for PV including: systemic steroids
(continuous prednisone and pulsed methylprednisolone), azathioprine, continuous and pulsed
cyclophosphamide, plasmapheresis, intravenous gamma globulin, and mycophenolate mofetil. Due
to recurrent bouts of life-threatening septicemia with multiple-drug resistant microbes, we opted
to treat her PV with weekly infusions of rituximab (total of 6). After the ®rst infusion, there was a
complete obliteration of her B cells, which has remained nondetectable 4 months post-treatment.
Similarly, her PV titers dropped dramatically after the ®rst two infusions. Despite elevated PV titers
(range 1:80±1:640), her skin has completely re-epithelialized. Knocking-out plasma cell precursors
(i.e. Pro-B cells to mature B cells) presumably temporarily, in patients with auto-antibody
mediated disorders such PV may be lifesaving in those individuals recalcitrant to conventional
therapies.
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Comparison Between IVIG and Conventional Immunosuppressive Therapy Regimens
in Patients with Severe Oral Pemphigoid: Effects on Disease Progression in Patients
Nonresponsive to Dapsone
J. Colon and A. Ahmed*
Oral Medicine, Harvard School of Dental Medicine, Boston, Massachusetts; *Department of Medicine, New
England Baptist Hospital, Boston, Massachusetts
Mucous membrane pemphigoid initially limited to oral cavity may so remain or progress to involve
other mucosae. In patients with severe progressive disease, treatment with dapsone is
recommended. We treated 20 patients in whom dapsone could not be used. Eight patients
received intravenous immunoglobulin therapy (IVIg) and 12 received oral prednisone with an
immunosuppressive agent as conventional therapy. After initiation of therapy, patients in both
groups were followed for a mean of 60 months. Clinical outcome was measured by duration of
treatment, side-effects, rate of recurrence, relapse and remission, progression of disease to involve
extraoral mucosal sites, and quality of life. Statistical analysis demonstrated that the two groups
were similar with respect to age, gender, duration of disease prior to treatment, dose and duration
of dapsone treatment, and total length of follow-up. The IVIg treatment group compared to the
conventional treatment group showed statistically signi®cant less duration of treatment, fewer
relapses, more remissions, fewer side-effects from treatment, less extra oral disease progression, and
a better subjective quality of life. IVIg is a safe and effective modality to treat mucous membrane
pemphigoid. It appears be a good option for patients who cannot be treated with dapsone and in
whom conventional therapy is contraindicated or results in the development of serious side-effects.
In patients with progressive mucous membrane pemphigoid, IVIg may arrest disease progression.
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Difference between Prodromal Bullous Pemphigoid and Fulminant Bullous
Pemphigoid
J. Deng, K. Buschman, R. Mann, and E. Abell
Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania; *VAPHCS, Pittsburgh, Pennsylvania
We have undertaken a retrospective study of bullous pemphigoid. We looked at a group of 53
patients, 22 treated at an academic medical center and 31 treated by community dermatologists.
We found that more patients were diagnosed with bullous pemphigoid in its prodromal stage when
the patients were treated in an academic setting compared to a community setting (78% vs. 39%).
We found that patients were more often treated with systemic steroids and immunosuppressive
agents when they were treated in an academic center compared to a community setting (91% vs.
52% treated with systemic steroids, 50% vs. 16% treated with immunosuppressive agents). We also
detected a trend toward younger age at diagnosis of prodromal bullous pemphigoid compared to
fulminant bullous pemphigoid (average age 72 vs. 78). Patients with prodromal bullous
pemphigoid could easily be controlled with lower dose of systemic steroids (40±60 mg prednisone
q.o.d. or high potent topical steroid. Prodromal bullous pemphigoid ran shorter clinical course
than that of fulminant bullous pemphigoid (1 years vs. 2+ years). In conclusion, bullous
pemphigoid can be diagnosed at an earlier stage as prodromal bullous pemphigoid, especially in an
academic setting. Prodromal bullous pemphigoid runs a milder and shorter clinical course.
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Novel Animal Model for Testing Anti-Acantholytic Treatments of Pemphigus
V. Nguyen, and S. Grando
Department of Dermatology, University of California, Davis, California
High doses of corticosteroids is the life-saving therapy of autoimmune pemphigus but the
mechanism of action is not completely understood. Methylprednisolone blocks pemphigus vulgaris
(PV) antibody-induced acantholysis in skin organ cultures, suggesting direct antiacantholytic effect
on keratinocytes (KC). However, dexamethasone does not block PVIgG-induced acantholysis in
1±2 d old Balb/c mice, suggesting a role for immunosuppression. We found that 3±5 d old Balb/c
mice may respond to antiacantholytic treatments with corticosteroids or cholinomimetics, but
untreated positive controls do not always produce PV lesions, because rapidly developing hair
follicles may reinforce their epidermal integrity. Therefore, we sought to develop a more reliable
animal model, and tested athymic nude mice. The neonates injected with 10 mg per g per day of
PVIgG at different ages developed clinical and histologic signs of PV. The 1±2 d old pups died
despite any antiacantholytic treatments, whereas the 5±7 d old pups responded to treatments and
survived subsequent injections of PVIgG given together with a test drug. Therefore, we selected 5±
7 d old athymic nude mice weighting ~2 g as a model for testing antiacantholytic drugs. The extent
of acantholysis was assayed by measuring the length of intraepidermal split, at least 4 basal cells long,
in at least 5 different microscopic ®elds (3100), and expressing results as percent of the total length
of epidermis in the ®eld, taken as 100%. All mice treated with methylprednisolone, 15 mg per g per
d, survived at least 3 injections of PVIgG. Microscopically, the extend of acantholysis decreased
from 77.5 6 2.3% in nontreated control to 22.5 6 4.3% (p < 0.05). Carbachol, 40 ng per g per day,
decreased the extent of acantholysis to 40.8 6 5.1% (p < 0.05). Neither drug prevented PVIgG
from binding to mouse KC, as determined by semiquantitative immuno¯uorescence, thus
illustrating direct antiacantholytic effects of both drugs on KC. Methylprednisolone could protect
KC from acantholysis by increasing their expression of the PV antigen pemphaxin. To test this
hypothesis, we compared relative amounts of pemphaxin in the epidermis of intact mice injected
with 15 mg per g per d of methylprednisolone and found an increase from 31.5 6 4 to 59.3 6 7.0
(p < 0.05). Thus, our novel animal model of PV allows accurate testing of the ef®cacy of
antiacantholytic drugs. The direct antiacantholytic action of corticosteroids on KC can be
mediated, at least in part, by overexpression of pemphaxin.
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Systemic Isotretinoin and Recessive Dystrophic Epidermolysis Bullosa (RDEB): Results
of a Phase 1 Clinical Trial
M. Weiner, J. Fine, A. Stein, C. Suchindran, and L. Johnson
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
RDEB patients are at high risk for the development of squamous cell carcinomas (SCCs); most will
die of metastatic SCC within ®ve years of their diagnosis. This argues strongly for the need for
some form of effective chemoprevention. Intriguing data in many other diseases suggest that
systemic isotretinoin may be effective as a chemopreventive agent against a variety of tumors. An
8-month, nonblinded, Phase 1 trial was undertaken on 20 patients with RDEB, aged 15 or older,
to determine whether patients with this disease would be able to tolerate this drug at a targeted
maintenance dosage of 0.5 mg per kg per day. Patients ranged in age from 15 to 67 years; 15 and 5
had generalized forms of non-Hallopeau-Siemens (RDEB-nHS) and Hallopeau-Siemens (RDEB-
HS) disease, respectively. Drug-induced hypertriglyceridemia occurred in one. Four of the
remaining 19 were unable to achieve maintenance dosage. Common complaints included
increased dryness of the skin (65%) or oral cavity (20%), skin fragility (45%), pruritus (25%), and
epistaxis (20%). Most of these, however, were relatively mild or infrequent. One patient developed
excessive granulation tissue which resolved at a lower dosage. No patients developed new tumors
while on therapy, although such an effect was not expected to occur within this limited time
period. RDEB subtype did not appear to in¯uence the relative frequency of subjects developing
increased dryness of the skin or mouth, or of epistaxis. Only 3 of 19 subjects now eligible for Phase
2 treatment wishes not to receive further treatment, attesting to the reasonable level of tolerance to
systemic isotretinoin at this dosage, as well as patient interest and motivation. Intriguingly, 55% of
all subjects (80%, RDEB-HS; 47.7%, RDEB-nHS) reported some clinical lessening in blister
formation while on systemic isotretinoin.
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Osteopenia and Osteoporosis in Recessive Dystrophic Epidermolysis Bullosa (RDEB):
Results of DEXA scans in 42 Consecutively Studied Patients within the United Kingdom
and United States
F. Keane,* J. Fine, M. Weiner, A. Stein, J. McGrath,* and R. Eady
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; *St. John's
Institute of Dermatology, London, United Kingdom
It is well established that malnutrition occurs in patients with the more generalized forms of
recessive dystrophic EB (RDEB), especially in those with the Hallopeau-Siemens (RDEB-HS)
subtype. In other debilitating conditions, chronic immobility may contribute to development of
osteopenia or osteoporosis. Data are lacking as to whether patients with RDEB are at risk of
developing decreased bone mass. We have therefore performed DEXA scans on 42 consecutive
patients (male, 23; female, 19) with RDEB, aged 15±66, who were evaluated at the two largest
referral sites for EB patients within the United Kingdom and United States (the latter af®liated with
the National EB Registry). 25, 11, 4, and 2 patients had HS, generalized mitis, inversa, and
localized forms of RDEB. 43% and 41% had evidence of osteoporosis or osteopenia, respectively.
Abnormal ®ndings were most commonly seen in RDEB-HS, with 60% and 32% having
osteoporosis or osteopenia. Surprisingly, only 27% of mitis patients had normal DEXA scans; 18%
met criteria for osteoporosis and and the remaining 55% had osteopenia. A similar distribution was
seen among inversa patients. Gender had no apparent effect on the distribution of patients having
osteoporosis, osteopenia, or normal scans. When strati®ed by age, abnormal DEXA scans were
most commonly seen in younger aged patients. Only 8% of those under 21 had normal scans and
75% showed evidence of osteoporosis. Taken collectively, these ®ndings suggest that osteopenia
and osteoporosis are common ®ndings among all of the major RDEB subtypes, even in those
subtypes not usually associated with clinically profound growth retardation.
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Graftskin Therapy in Epidermolysis Bullosa
D. Fivenson, L. Scherschun, M. Reep, and M. Choucair
Dermatology, Henry Ford Health System, Detroit, Michigan
Graftskin is a bi-layered human skin construct which is derived from foreskin keratinocytes and
®broblasts. It is approved for the treatment of venous leg and diabetic foot ulcers. As it contains
none of the keratin gene mutations of epidermolysis bullosa (EB), we have used graftskin to treat a
series of children with EB including: 2 Dowling-Meara-type EBS (#sites = 30), 1 Weber-
Cockayne EBS (#sites = 6); 1 Herlitz-type JEB (#sites = 2) and 2 RDEB (#sites = 39). All active
lesions were debrided prior to application of fenestrated graftskin. Wounds were dressed with
nonstick gauze, a hydrofoam dressing and a compression wrap. Graft take and persistence was
assessed clinically @ weeks 1 and 4 and by EM and analysis for donor DNA @ weeks 3, 4, 6, 12,
20. All sites treated in EBS and RDEB showed 90±100% healing by 1 week post grafting, with
many of the sites appearings as normal skin by 10±14 days. Two RDEB cases had mitten deformity
release procedures with ®nger web space graftskin reconstruction, resulting in 50±75% increase in
range of motion @ 6 weeks. Recurrences were common, but were limited to only the most highly
trauma prone areas (plantar feet, knees and elbows) and responded well to repeat grafting. The
children's parent's all reported diminished pain, less bleeding and improved ambulation after
graftskin treatment. EM showed normalization of tono®lament clumping at 6 weeks in 1 child
with DM-EBS. PCR analysis using primers for a donor-speci®c HLA-Db1 allele revealed
persistence of donor speci®c DNA @ 3 and 12 weeks in 2 cases, no donor DNA in 1 case @ 4 and
20 weeks and 2 cases that shared the same allele as the donor. DNA ®ngerprint analysis failed to
detect any donor speci®c sequences in 7/7 samples. The encouraging clinical results reported here
support that graftskin is doing more than simply functioning as a bandage or a source of growth
factors to stimulate autologous closure of the wounds in EB. Although most of the molecular
analyses failed to document long-term persistence of donor DNA, ultrastructural and clinical
features of treated sites do suggest a long-term, dynamic effect of graftskin in EB patients. Future
studies will require longterm follow-up of treated sites and more speci®c molecular probes to
determine what the precise mechanism of action may be. Even if long-term/permanent
engraftment is not realized in these children, the improved quality of life and the achievement of
development milestones makes this an exciting step forward in the care of the EB patient.
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The In Vitro and In Vivo Effects of Slow-Release Antiseptics
L. Zhou, W. Nahm, T. Yu®t, and V. Falanga
Dermatology and Skin Surgery, Roger Williams Medical Center, Boston University School of Medicine,
Providence, Rhode Island
Antiseptics have become more important therapeutic agents in view of increasing bacterial
resistance to antibiotics. Moreover, the slow-release mode of new antiseptics preparations is
allowing their clinical use with minimal or no toxicity. In these studies, we used a prototypic slow-
release antiseptic preparation, cadexomer iodine (CI), which carries iodine [0.9% (w/w)]
immobilized in bead molecules of dextrin and epichlorhydrin, and which is highly effective in the
management of exudative wounds. Our hypothesis has been that, within a certain concentration
range, CI is nontoxic to cells and tissues and can also trap microorganisms within its cadexomer
component. We ®rst exposed cultured neonatal foreskin ®broblasts to increasing concentrations of
CI [(0.45%-1.4% (w/v)] for 24 h. The use of up to 0.45% CI was not associated with any decrease
in cell viability, as determined by trypan blue exclusion. In an attempt to mimic more closely the in
vivo situation, cultured ®broblasts were exposed daily to a fresh preparation of CI (0.45%) for up to
120 h. We found no decrease in cell viability using this experimental protocol of more intense
exposure of ®broblasts to CI (p > 0.05). To determine the effects of wound ¯uid on CI beads,
swabs of CI, after being placed for 24 h in an exudative ulcer, were formalin ®xed and gram
stained. Microscopic analysis showed bacteria trapped within the beads. Histological evaluation of
biopsies taken from ulcers treated with CI showed no morphological evidence of cell toxicity. In
summary, ®broblast cell toxicity with CI is dose dependent in vitro. However, there are optimal CI
concentrations, which even with prolonged incubation are nontoxic to dermal ®broblasts. For the
®rst time, we also provide evidence that bacteria can be trapped in the cadexomer beads, probably
independently of the iodine component. These data with this prototypic agent add to the emerging
view that slow-release antiseptics can be safely used, and provide a framework for testing additional
preparations.
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Tissue-Engineered Derived Growth Factors as a Topical Treatment for Rejuvenation of
Photodamaged Skin
G. Naughton, E. Pinney, J. Mansbridge, and R. Fitzpatrick*
Executive, Advanced Tissue Sciences, La Jolla, California; *Dermatology, Dermatology Assoc. of San Diego
Co., Encinitas, California
Growth factor containing conditioned medium from the manufacture of three-dimensional tissue-
engineered dermal constructs using human dermal ®broblasts was tested in in vitro studies and in
safety and ef®cacy studies to assess their ability to promote skin cell growth and collagen
deposition. Clinical safety studies with daily application of concentrated medium on sun-damaged
forearm showed no irritancy or adverse reactions. Dermapathological evaluation and computerized
histomorphic analysis of biopsies of treated areas showed a 50±80% increase in Grenz zone collagen
in 2 of the 3 formulations designed to optimize growth factor penetration. Computerized
measurement of tissue density and texture showed a 42±53% increase in newly deposited ®ne
matrix ®bers. These results are consistent with in vitro results which showed a statistically signi®cant
increase in both ®broblast and keratinocyte proliferation, collagen deposition, and antioxidant
activity. These studies indicate that medium from tissue-engineered skin products may provide a
unique bene®t as a topical agent which can result in skin remodeling and regeneration.
VOL. 117, NO. 2 AUGUST 2001 ABSTRACTS 543
925
Wound Healing in Leg Ulcers Treated by Combined Skin Allograft and Autograft
E. Pianigiani, P. Taddeucci, S. Mancini,³ C. Miracco,² C. Alessandrini,* G. Grasso, and M.
Fimiani
Dermatology and Skin Bank, University of Siena, Siena, Italy; *Histology and General Embryology,
University of Siena, Siena, Italy; ²Pathological Anatomy and Histology, University of Siena, Siena, Italy;
³General Surgery, University of Siena, Siena, Italy
Combined transplant of skin allograft and autograft is a useful surgical method for chronic
nonhealing leg ulcers. The role that homologous dermis plays in guiding wound healing is unclear
under these conditions. The aim of the present study was to evaluate expression of certain
cytokines involved in the healing process and certain adhesion molecules expressed by
immunocompetent cells that may be involved in reject. Twelve patients with chronic nonhealing
leg ulcers were treated by cryopreserved de-epidermized dermal (DED) allograft followed by
autologous skin mesh grafts. The allografts were obtained from living donors undergoing plastic
surgery. They were de-epithelized enzymatically, incubated with 15% glycerol for 2 h at 4°C, g-
irradiated with 60 Gy and then frozen at ±80°C until use. Autologous mesh grafts were placed over
the wound bed, 7±10 days after grafting with DED. Biopsy samples of transplanted skin were
obtained 7, 14 and 28 days after grafting. Sections were examined by classical histology,
transmission electron microscopy and immunohistochemistry (CD3, CD4, CD8, CD68, IFN-g,
TNF-a, endothelin-1, EGF, MIB-1). DED did not seem to give rise to any reject reaction that
could prejudice taking of the autologous mesh. When it was possible to compare healing by both
methods in the same subject (allograft with DED + autograft vs. spontaneous healing), healing
guided by DED was found to produce a less sclerotic dermis, con®rming that DED truly guides
regeneration of physiological connective tissue.
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Apligrafq Counteracts the Growth Inhibitory Activity Present in Chronic Wound Fluid
H. Park, T. Phillips, C. Kroon, and D. Young
Dermatology, Boston University, Boston, Massachusetts
Chronic Wound Fluid (CWF) collected from venous ulcers was shown to inhibit growth of
dermal ®broblasts, contributing to the impaired healing. To determine whether Apligrafq could
counteract this growth inhibitory activity, thus promoting the healing process, effects of Apligrafq
on the growth of dermal ®broblasts in presence of CWF was examined. Dermal ®broblasts were
cultured from a biopsy taken at the edge of the venous ulcer. Paired cultured were plated onto
transwell at 3000 cells per well and sterile cotton ®lter papers with two 8 mm punch biopsies of
Apligrafq, epidermal side exposed to the air, were placed. Then CWF or Bovine Serum Albumin
(BSA) as control was added at the concentration of 500 mg per well. Cells were allowed to grow for
two weeks with two feedings per week containing fresh CWF or BSA. At the end of two weeks,
the total cell number in each transwell was determined using Coulter Particle Counter. CWF
inhibited the growth of ®broblasts as expected (250 000 vs. 160 000 cell per well). In presence of
Apligrafq, CWF-induced growth inhibition was counteracted and cells grew at a normal rate
(160 000 vs. 300 000 cells per well). When CWF collected from ®ve different venous ulcers was
tested, Apligrafq increased the growth of ®broblasts by 1.7±2.0 folds above that of the growth in
the absence of Apligrafq in all CWF tested. In cells treated with only BSA, Apligrafq also increased
the growth of the ®broblasts by 1.5±2.0 folds. Moreover, Apligrafq counteracted CWF with a
wide range of growth inhibitory activity (from 32 to 86% inhibitions). Therefore, these results
demonstrate that Apligrafq enhances basal growth of dermal ®broblasts cultured from chronic
venous ulcers. In addition, Apligrafq can further stimulate healing of chronic venous ulcers in part
by counteracting the growth inhibitory activity present in CWF.
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The Role of Dermal Skin Substitutes in the Management of ``Hard-To-Heal'' Unusual
Wounds
D. Williamson and R. Sibbald
Dermatology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
Dermal skin substitutes have been shown to be effective in the treatment of both full-thickness,
nonhealing diabetic neurotrophic foot ulcers and ``hard to heal'' venous leg ulcers. Case studies
have suggested that these skin substitutes may also have a role to play in managing wounds in
patients with recessive, dystrophic epidermolysis bullosa (RDEB). Dermal skin substitutes were
therefore applied to four patients with this condition. Areas of persistent ulceration, at multiple
body sites, were treated with skin substitutes on successive occasions. Over an eight-week period,
between 50 and 100% graft take was noted in all patients. Ulcers involving the pretibial area of the
lower leg with exposed bone in the base of the ulcer can result from osteomyelitis or trauma. These
ulcers often represent a therapeutic challenge as they fail to heal by secondary intention and there is
no vascular supply within the base to allow skin grafting. Two patients with such ulcers were
treated. Burr holes were drilled into the bone base and a dermal skin substitute was applied, on
successive occasions, over the ulcer and secured to the surrounding skin. Islands of granulation
tissue subsequently appeared around the burr hole openings. These merged to become con¯uent
with the wound margins, resulting in a 30±50% reduction in wound size. Dermal skin substitutes
with living ®broblasts appear to stimulate wound healing in patients with RDEB and exposed bone
in the ulcer base. In addition to control of bacterial burden, overlap technique and adequate
anchoring of the skin substitute appear to be important factors in facilitating healing.
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Keratinocyte Growth Factor-2 (KGF-2) Reverses Delayed Healing in Patients with
Venous Ulcers and High Bacterial Burden at Presentation
V. Falanga, D. Odenheimer,* and P. Bagchi*
Dermatology, Boston University School of Medicine, Boston, Massachusetts; *Human Genome Sciences,
Rockville, Maryland
The effects of bacterial burden and healing rates on wound closure were evaluated in a 15 center,
randomized, double-blind, 94 patients study of the safety and ef®cacy of topically applied KGF-2
in patients with venous ulcers (VU). Patients were eligible for enrollment in this 12-week study if
they had a VU of 3±30 cm2 in size and 3±36 months in duration. Bacterial burden was evaluated by
tissue biopsy. Patients with a bacterial colony count 106 per gram of tissue were excluded but could
be enrolled if after initial wound management had a subsequent colony count of < 106. The rate of
wound healing was prospectively calculated based on the modi®ed Gilman equation. We found
that complete wound closure occurred in 29 (40%) of 72 patients with an initial colony count < 106
compared to 2 (9%) of 22 patients with a colony count 106 (p < 0.01). This effect was independent
of wound size and duration. For the latter 22 patients, at least 75% healing was achieved by 62% (8/
13) and 11% (1/9) of KGF-2 and placebo treated patients, respectively (p = 0.03). Thus,
presentation with a high bacterial count was associated with a failure to heal even when measures
were taken to reduce counts. However, KGF-2 appeared to remedy this situation. The rate of
healing in the ®rst 4 weeks of treatment was predictive of complete wound closure. An increased
rate of healing was observed in the KGF-2 treated group. In conclusion, bacterial burden at
presentation and the rate of healing during the ®rst 4 weeks of treatment were predictors of
complete wound closure. The data indicate that KGF-2 may reverse the association between
increased bacterial burden at presentation and delayed wound healing.
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Mean Healing Rates at 4 Weeks can Predict Complete Wound Closure of Diabetic Foot
Ulcers
M. Sabolinski,* V. Falanga, K. Giovino,* and T. Toole*
Department of Dermatology and Skin Surgery, Boston University School of Medicine, Roger Williams
Medical Center, Providence, Rhode Island; *Medical and Regulatory Affairs, Organogenesis Inc, Canton,
Massachusetts
In a prospective, multicenter trial, 96 control patients with diabetic foot ulcers were treated with
standard therapy consisting of aggressive debridement, moist wound dressings, and of¯oading with
pressure relieving footwear, wheelchairs and/or crutches for 12 weeks. The objective of the
healing rate analysis was to determine if the mean healing rate at 4 weeks was predictive of
complete wound closure. Wound tracings were obtained at each visit, and computerized
planimetry was used to evaluate ulcer area. Healing rates (HR) in cm per week were caluculated
using an established formula (DA/Dp, A = Area, p = perimeter). At study completion, we
determined the mean HR at 4 weeks for all healers (n = 36) and nonhealers (n = 60). Wounds that
completely healed during the study had increased mean HRs of 0.11 cm per week at 4 weeks (95%
CI between 0.09 cm per week and 0.13 cm per week). Wounds that did not heal showed decreased
mean HRs of 0.05 cm per week (95% CI between 0.04 cm per week and 0.07 cm per week). The
mean HRs of healers compared to nonhealers were statistically signi®cant at 4 weeks (p < 0.0001).
A sensitivity and speci®cally analysis were performed using a target HR0.075 cm per week to
predict complete wound closure. 28 of 36 patients were correctly identi®ed as nonhealers with a
HR < 0.075 cm per week. We conclude that a target HR0.075 cm per week is 78% sensitive and
80% speci®c in predicting complete wound closure in diabetic foot ulcer patients.
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Quantitative Assessment of Psoriasis Patients' Preference for Foam Vehicle
T. Salam, B. Mellen,* S. Feldman, S. Rapp,² and A. Fleischer
Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; *Public Health
Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina; ²Psychiatry &
Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Patients' acceptance of the vehicles used in topical therapy contributes to adherance to the
treatment plan and subsequent outcomes. Betamethasone valerate in foam vehicle (Luxiq,
Connetics Corp) has greater ef®cacy for scalp psoriasis than other betamethasone valerate
preparations. The foam preparation is non-greasy, easily applied and residue free; thus, it is more
appealing to patients than cream or ointment preparations. We sought to quantify patients'
preference for this vehicle. Focus group sessions were held with patients with psoriasis to determine
patients' perceptions of the advantages and disadvantages of different topical psoriasis therapies.
This information was used to derive a ``treatment adversity measure'' to assess different topical
therapies. 20 patients with psoriasis sampled different topical psoriasis medications and completed
the ``treatment adversity measure'' for each. The foam preparation was much preferred over cream,
ointment, gel and emollient preparations. This foam product provides an opportunity to achieve
improved compliance with topical corticosteroid treatment.
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HLA-Cw*0602 but not Promoter Polymorphism of TNF-a is Associated with Development of
Psoriasis in Japanese Patients
M. Nakamura, H. Tateno, K. Nagai, K. Yamamoto, and M. Muto
Dermatology and Biomolecular Sensing, Yamaguchi University School of Medicine, Ube, Japan
The population survey with human leukocyte antigen (HLA) has provided evidence that
susceptibility to psoriasis is linked to HLA with racial differences. Tumor necrosis factor (TNF)-a
gene is also mapped within the HLA region and its product has been reported as one of the most
important cytokines in the pathogenesis of psoriasis. In the present study the association of HLA
genotypes and promoter polymorphism of the TNF-a with susceptibility for development of
psoriasis vulgaris (PsV) was investigated. A hundred Japanese patients (76 males and 24 females)
suffering from PsV were studied (the median age was 56 y, ranged from 15 to 90). Among them 32
patients were before age 40 (type I) and 68 were 40 or over age 40 (type II). Cw*0602 was
signi®cantly increased in the type I patients as compared with type II patients (25.0% vs. 7.4%
p = 0.0144). On the other hand, there were no signi®cant differences in the promoter
polymorphism at ±238 and ±308 of TNF-a gene. These results suggest that Cw*0602 also is
the main association of psoriasis in Japanese patients as peviously reported in Caucasians. However,
TNF-a may vary across racial backgrounds.
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Using an Administrative Database to Assess the Risk of Malignancy Associated with
Psoriasis
D. Margolis, W. Bilker,* S. Hennessy,* C. Vittorio, J. Santanna,* and B. Strom
Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; *Biostatistics and
Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
The goal of this study was to measure the incidence of cancer in patients with psoriasis, strati®ed by
the severity of their disease as determined by the use of systemic pharmaceuticals. This was a cohort
study that utilized a database of administrative claims records from Medicaid programs in three US
states. All individuals in the claims database were included in the study if they quali®ed for one of
®ve groups: severe psoriasis, as de®ned by systemic medication use; less severe psoriasis; severe
eczema; history of organ transplant; and hypertension. For each individual it was determined
whether they had a diagnosis of cancer more than 6 months after they quali®ed for group
classi®cation. Individuals with severe psoriasis were more likely than those with hypertension to
develop a malignancy (risk ratio: 1.78; 95% CI: 1.32. 2.40). The risk of malignancy in the severe
psoriasis group approached that seen in organ transplant patients (risk ratio 2.12; 95% CI: 1.80,
2.50). Most of these cancers were due to nonmelanoma skin cancers and lymphoproliferative
malignancies. Those with less severe psoriasis were only slightly more likely to develop a new
malignancy than those with hypertension (1.13; CI: 1.03, 1.25). In conclusion, patients with
psoriasis were at an increased risk of developing a malignancy as compared to patients with
hypertension. This increased risk was greatest for those with severe disease (i.e. psoriatics using
systemic agents) and was minimal, if at all, for those with less severe disease, compared to those in
the hypertension group. Many of these malignancies were lymphoproliferative cancers and
nonmelanoma skin cancers.
933
In¯iximab Clears Psoriasis in 80% of Patients With Moderate to Severe Disease
U. Chaudhari, P. Romano, L. Mulcahy,* L. Dooley,* D. Baker,* and A. Gottlieb
Clinical Research Center, University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical
School, New Brunswick, New Jersey; *Centocor, Inc., Malvern, Pennsylvania
TNFa recruits lymphocytes, stimulates intracellular adhesion molecule expression, stimulates
neutrophil and monocyte chemotaxis, and induces other in¯ammatory mediators, such as Il-1, Il-6,
and Il-8 in psoriatic plaques. Extracts of psoriatic lesional skin have signi®cantly greater
concentrations of TNFa compared to noninvolved skin. In¯iximab is a chimeric monoclonal IgG
antibody that binds to both soluble and transmembrane TNFa thereby inhibiting its activity. In
this investigator-initiated, single site, randomized, double-blind, placebo-controlled clinical trial,
33 patients with moderate to severe plaque psoriasis were randomized to receive in¯iximab
infusions at 5.0 mg per kg, 10.0 mg per kg or placebo in a 1:1:1 fashion. Patients were not allowed
the use of any other concomitant therapy for psoriasis. Administration of either intravenous
in¯iximab or placebo occurred at weeks 0, 2 and 6. Patients were assessed for response at week 10,
which was de®ned as a ``good'', ``excellent'' or ``clear'' on the Physician's Global Assessment. A
total of three patients withdrew during the course of the study, one from each group. The
proportion of responders were 9/11 (81.8%) and 10/11 (90.9%) in the in¯iximab 5.0 mg per kg
and 10.0 mg per kg groups, respectively, vs. only 2/11 (18.2%) patients in the placebo group
(p < 0.05, Fisher's Exact Test for each in¯iximab vs. placebo comparison). Nine out of 11 (81.8%)
and 8/11 (72.7%) patients had 75% improvement in PASI in 5.0 mg per kg and 10.0 mg per kg
dosing groups, respectively, compared to only 2/11 (18.2%) in the placebo group (p < 0.05,
Fisher's Exact Test for each in¯iximab vs. placebo comparison). The median percent improvement
in PASI was 93% and 95% in the in¯iximab 5.0 mg per kg group and 10.0 mg per kg group,
respectively, vs. 11% for the placebo group. The median time to response was 4.0 weeks for both
in¯iximab groups. There were no serious adverse events and the drug was well tolerated. In
conclusion, in¯iximab is the only biologic agent to date to clear psoriasis in a high proportion of
patients in a manner comparable to cyclosporine.
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Circulating CD4+and CD8+ Memory-Effector (CD45RO+) T Cells: Pharmacodynamic
Markers During Alefacept Therapy
G. Krueger, D. Bennett,* J. Haney,* D. Shrager,* and A. Vaishnaw*
University of Utah, Salt Lake City, Utah; *Biogen, Inc., Cambridge, Massachusetts
Alefacept (human LFA-3/IgG1 fusion protein, LFA3TIP, currently being developed under the
trade name AMEVIVE(tm)) binds CD2 and speci®cally and reversibly reduces memory-effector T
cells (CD4+CD45RO+, CD8+CD45RO+). We tested if CD45RO+ subset reduction correlated
with clinical improvement in 229 chronic plaque psoriasis patients (pts) who were randomized to
placebo or alefacept (0.025, 0.075 or 0.15 mg per kg IV) weekly for 12 week. Circulating T-cell
subset levels and changes in PASI were monitored weekly during therapy and 4 times postdosing
over 12 week. Effects on CD45RO+ subsets were quanti®ed by ``effect area under curve''
(EAUC). CD45RO + EAUC and percentage change in PASI for each patient were correlated. An
important correlation was found for CD8+CD45RO+ (r = ±0.3361, p = 0.001) and
CD4+CD45RO+ cells (r = ±0.3154, p = 0.001). Pts in the 0.075-mg per kg group were put in
3 groups based on T-cell changes in the ®rst 4 week of dosing and response (= 75% PASI reduction
12 week after last dose) was compared. Pts with the greatest reductions in
CD8+CD45RO+ (= 62% reduction) had a 60% response, compared to 27% and 7% in the other
groups. Pts with the greatest reductions in CD4+CD45RO+ (= 45% reduction) had a 53%
response, compared to 21% and 20% in the other groups. 62 pts were retreated (within 1 years)
with alefacept 7.5 mg IV weekly for 12 week. Results showed similar reversible effects on
CD45RO+ subsets and signi®cant correlations between EAUC and PASI reduction for
CD4+CD45RO+ (r = ±0.4629, p = 0.001) and CD8+CD45RO+ (r = ±0.4576, p = 0.001).
These data provide novel insights for circulating CD45RO+ T cells as a predictor of response
in psoriasis and suggest that peripheral T cells contain the pathogenic mediators of disease. This is
the ®rst report of a relationship between a speci®c T-cell subset reduction and clinical outcome in
an autoimmune disease. Alefacept-mediated reduction of CD45RO+ cells appears promising for
chronic plaque psoriasis.
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Gene Pro®ling of Blood Cells from Psoriatic Patients after Oral Treatment with SDZ
ASM 981
J. Kehren, A. Cordier, M. Polymeropoulos, C. Lavedan, M. Ebelin, G. Greig,* K. Wolff,* and S.
Chibout*
Novartis Pharma AG, Basel, Switzerland; *Department of Dermatology, University of Vienna, Vienna,
Austria
SDZ ASM 981 is a selective inhibitor of in¯ammatory cytokine release, speci®cally developed for
the treatment of in¯ammatory skin diseases. Topical SDZ ASM 981 is ef®cacious in atopic
dermatitis and allergic contact dermatitis without the side-effects of topical corticosteroids. In the
initial four week study, oral SDZ ASM 981 was shown to be effective and safe in patients with
moderate to severe plaque psoriasis. In the context of this study, blood samples were collected from
9 patients before and after 13 or 14 days of treatment (7 patients treated with 30 mg b.i.d. SDZ
ASM 981 and 2 placebo-treated patients). Samples were subjected to gene expression analysis using
gene chips allowing the survey of 7129 genes. A common genomic pro®le of SDZ ASM 981
(about 100 genes) was identi®ed. At the mRNA expression level, the compound was shown to
strongly down-regulate the expression of genes belonging to the macrolactam target pathway, e.g.
macrophilin-12, calmodulin, cellular activation and proliferation (histone 2, histone 3.3, cyclin
D2), in¯ammatory mediators (leukotriene A4 hydrolase, prostaglandin endoperoxide synthase),
chemotaxis and cellular migration (LFA-1, P-Selectin ligand, L-Selectin, RANTES) as well as of
HLA class II (Ii invariant chain, CD74). No changes in gene expression were observed which
might be linked with toxicity, i.e. genes associated with apoptosis, stress, and enzymatic induction.
In conclusion, the genomic analysis of blood from psoriasis patients treated with oral SDZ ASM
981 indicates a broad anti-in¯ammatory activity without evidence of toxicity. The mRNA
expression changes are thus consistent with the observed clinical ef®cacy and safety. To the best of
our knowledege, the gene expression analysis reported here is the ®rst of this kind in
dermatological diseases.
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Tazarotene 0.1% Gel in the Treatment of Fingernail Psoriasis: A Double-Blind,
Randomized, Vehicle-Controlled Study
R. Scher, M. Stiller, and Y. Zhu
Columbia University Presbyterian Medical Center, New York, New York
To compare the ef®cacy and tolerability of once-daily tazarotene 0.1% gel and once-daily vehicle
gel, both occluded and nonoccluded, in the treatment of ®ngernail psoriasis. (Tazarotene is not
approved for the treatment of ®ngernail psoriasis.) Patients eligible for recruitment were adults with
psoriasis affecting at least 2 ®ngernails that was characterized by at least 3 of the following: pitting,
onycholysis, subungual hyperkeratosis, leukonychia, nail plate crumbling and/or nail plate loss,
splinter hemorrhages, and nail bed discoloration. Patients were randomized to receive tazarotene
gel or vehicle gel, to be applied to each target ®ngernail and the surrounding nail folds every
evening for up to 24 week. One target ®ngernail was occluded with polyethylene ®lm/sheeting
during the treatment period. No other medications were allowed on the ®ngernails. Data are
available from 28 patients to date (18 in tazarotene group, 10 in vehicle group). For nonoccluded
nails, the tazarotene regimen was consistently more effective than vehicle in reducing onycholysis
(p = 0.05 at Wk 12). For occluded nails, the tazarotene regimen was signi®cantly more effective
than vehicle in reducing pitting (p = 0.05 at Wk 24). There were no other signi®cant between-
group differences in onycholysis, pitting, subungual hyperkeratosis, leukonychia, nail plate
crumbling/loss, splinter hemorrhage, or nail bed discoloration in nonoccluded or occluded nails.
Three patients (all tazarotene group) reported treatment-related adverse events (peeling of
proximal nail fold skin, irritation of skin on ®nger, and erythema of proximal nail fold). All such
adverse events were mild. Applications of tazarotene 0.1% gel to psoriatic ®ngernails and the
surrounding nail folds can signi®cantly reduce onycholysis (in nonoccluded nails) and pitting (in
occluded nails). This information in part will be also submitted to the AAD.
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Randomized Double-Blind Placebo-Controlled Trial Using Interleukin-10 For Psoriasis
A. Kimball, T. Kawamura, M. Turner, and A. Blauvelt
Derm Br, NCI, Bethesda, Maryland
Psoriasis lesions are characterized by high levels of pro-in¯ammatory and type 1 cytokines (e.g.
TNF-a, IFN-g). Because of this, several investigators have reported on the open-label use of
recombinant human interleukin 10 (rhIL-10), a type 2 cytokine, in psoriasis patients. Here, we
performed a 12- week randomized double-blind placebo-controlled trial using rhIL-10 in patients
with moderate-to-severe psoriasis (PASI scores 10). 28 patients who were off all other psoriasis
medications were enrolled; 26 were subsequently considered statistically evaluable. 2/3 of patients
received 20 mg per kg rhIL-10 and 1/3 received placebo injected SC 3X/ week. The primary
endpoint was the PASI score at week 12. There were no signi®cant differences in the change in
PASI scores from baseline to week 12 between the rhIL-10 group and control patients (mean
percentage change in PASI = 17% and 13%, respectively; p = 0.69). However, a strong trend
toward improvement was noted in patients receiving rhIL-10 vs. placebo at 6 week (32% vs. 7%,
respectively; unadjusted p = 0.057) and at 8 week (36% vs. 13%, respectively; unadjusted
p = 0.027). Pancreatitis occurred in 1 rhIL-10-treated patient, but was well tolerated by the other
patients. Declines in hemoglobin at 2 week (p = 0.0078), platelet counts at 1 week (p = 0.00034),
and cholesterol at every time point were observed in the rhIL-10 group. Intracellular cytokine
staining of PBMC from the rhIL-10 treated patients revealed progressive declines in the IFN-g/IL-
4 ratio and TNF-a production in CD4+ T cells, as well as decreases in TNF-a production in
monocytes, over the 12-week period. In summary, we found that rhIL-10 was well tolerated by
most patients, induced distinct hematologic and immunologic changes, and demonstrated
signi®cant antipsoriatic effects for 6±8 week following onset of treatment. However, we conclude
that rhIL-10 is not useful as a treatment option for psoriasis patients because clinical responses were
not maintained, despite clear shifts in the type 1/type 2 cytokine pro®le in PBMC.
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Alefacept Treatment for Psoriasis Reduces the Number of In®ltrating IFNg+-Producing
T cells in Lesional Skin
S. Kobayashi, H. Sugiyama, R. Gyulai, T. McCormick, N. Korman, S. Stevens, K. Cooper, A.
Vaishnaw, and D. Shrager
Department of Derm., University Hosp. Research Institute and Case Western Reserve University, Cleveland,
Ohio; *Biogen, Inc., Cambridge, Massachusetts
Psoriasis is a chronic in¯ammatory skin disease mediated, in part, through IFNg production by
activated lesional T cells (Th1 skewed). Alefacept (human LFA-3/IgG1 fusion protein, LFA3TIP,
currently being developed under trade name AMEVIVE(tm)) is a novel recombinant protein that
leads to a reversible reduction in CD3+CD45RO+ T cells. To study effects on skin T cells, an
open-label phase 3 study was conducted in 6 patients with psoriasis who received alefacept 7.5 mg
IV once weekly for 12 consecutive weeks. The percentages of CD3+ T cells and IFNg-producing
CD3+ populations in total epidermal or dermal cells were analyzed by ¯ow cytometry, and
CD3+ or IFNg+CD3+ cell densities as cell number/mm2 were calculated. In the 5/6 patients
demonstrating clinical improvement at week 13, the density of epidermal T cells producing IFNg
(IFNg+CD3+) was reduced to 0.26 6 0.3% of baseline. The mean density of IFNg+CD3+ cells
for all 6 patients at baseline was 182 6 91 per mm2 vs. 77 6 45 per mm2 after 12 weeks of alefacept
treatment (p = 0.05). For all 6 patients, PASI improvement correlated with percentage change in
IFNg+CD3+ epidermal cells with r = 0.80 (p = 0.06). Interestingly, in the initial phase of
treatment, several patients demonstrated transient increases in IFNg+CD3+ lesional T cells at week
3, in association with a transient increase in epidermal thickness; both the IFNg+CD3+ T cells and
epidermal thickness then decreased in subsequent weeks. Our results suggest that alefacept can
signi®cantly reduce the number of in®ltrating Th1-type IFNg+CD3+ T cells, in association with
clinical improvement. Because IFNg is believed to be a key factor in psoriasis pathogenesis, the
reduction of Th1 cells in the skin may represent a critical step in the clinical improvement of
psoriasis.
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IL-10 Therapy in Psoriasis: Effects on the Skin Immune System
K. Asadullah, M. Friedrich, W. Doecke,* S. Hanneken, C. Rohrbach, H. Audring, H. Volk, and
W. Sterry
Dermatology and Allergy, Charite, Humboldt University, Berlin, Germany; *Immunology, Charite,
Humboldt University, Berlin, Germany
With its anti-in¯ammatory and immunosuppressive properties interleukin (IL)-10 plays an
outstanding role in several immune reactions including regulatory mechanisms in the skin.
Recently, we performed a phase II trial in 10 psoriatic patients, receiving subcutaneously
recombinant human IL-10 over a 7-week period. The clinical response (PASI decrease over 50%)
suggested that IL-10 might represent a novel antipsoriatic drug. In order to better understand the
mode of action and to elucidate the effects of systemic IL-10 treatment on the skin immune system,
skin punch biopsies were analysed, obtained from the patients before (day ± 6), at the end (day 50),
and 3 weeks after IL-10 therapy (day 71) during this study. Histological examination showed a
decrease of several parameters re¯ecting the psoriatic disease activity as acanthosis and extension of
the horny layer. Immunohistological examination demonstrated decreasing numbers of in®ltrating
epidermal and dermal T-cells, dermal CD1a+ cells, and a diminished proliferation of epidermal
cells. Using a novel, quantitative RT-PCR approach a signi®cant shift within the cytokine pattern
was found. So IL-10 therapy lead to an increase of cutaneous IL-4 and decrease of IL-8 and IL-10
mRNA expression. No signi®cant changes within of IL-2, IL-6, TNF-a, and IFN-g expression
were found. So a shift from a type1 towards a type 2 cytokine pattern. The changes within the local
cytokine pattern seems to be disease related, since an inverse course was found in the single IL-10
nonresponding patient. Our ®ndings demonstrate the considerable effects of systemic IL-10
application on the skin immune systems. Those might contribute to the antipsoriatic activity of IL-
10.
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IL-10 Therapy in Psoriasis: Systemic Imunological Effects
W. Doecke,* M. Friedrich, G. Belbe,* M. Ebeling, H. Volk,* W. Sterry, and K. Asadullah
Dermatology and Allergy, Charite, Humboldt University, Berlin, Germany; *Immunology, Charite,
Humboldt University, Berlin, Germany
A clinical phase II trial with long-term (49 days) subcutaneous administration of recombinant
human IL-10 revealed clinical ef®ciency in 9 of 10 psoriatic patients. Despite temporary very high
systemic IL-10 levels (500 pg per ml) only moderate signs of immunodepression and no infectious
complications were observed. So, IL-10 treatment caused transient falls in monocytic HLA-DR
expression and proin¯ammatory cytokine secretion capacities (TNF-a, IL-1b, IL-12) as well as in
IL-12 plasma concentrations. Interestingly, monocytic expression of CD64 and transferrin receptor
as well as the plasma levels of IL-6, C-reactive protein, soluble IL-2R and the blood sedimentation
rate increased in parallel indicating monocytic activation/differentiation and an acute phase
response. For lymphocytes, decreases of T-cell HLA-DR expression and NK-cell numbers and
increased plasma IgE levels were found. In contrast to these transient changes during IL-10 therapy,
other alterations persisted or even further strengthened in the post-theraeutic 7-weeks observation
period. We observed strong increases of T-cell IL-4 and NK-cell IFN-g production capacities as
well as rising numbers of CD5+ B-cells indicating lasting re-regulation of the immune system.
Moreover, persistently decreased expression of monocytic accessory molecules in parallel with
increased IgA and decreased TGF-b1 plasma levels indicated an enhanced TGF-b utilisation as one
mechanism of lasting immunomodulation. From these results we hypothesize that IL-10 may have
the capability to lastingly improve the immunopathophysiological situation in psoriasis
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Comparison of the National Psoriasis Foundation Psoriasis Score with Psoriasis Area
and Severity Index
P Mathew, U. Chaudhari, Y. Gaffar, L. Dooley,* Y. Kuo, L. Mulcahy, D. Baker, and A. Gottlieb
Clinical Research Center, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey;
*Centocor, Inc, Centocor, Inc, Pennsylvania
The National Psoriasis Foundation (NPF) Medical Advisory Board has developed a new NPF
Psoriasis Score (NPF-PS) to measure clinically signi®cant improvement as a function of psoriasis
treatment. This dynamic, ®ve-component method, which incorporates a quality of life
measurement, has been proposed in response to the limitations of the Psoriasis Area and
Severity Index (PASI) including its reliance on imprecise estimates of the involved Body Surface
Area (BSA). The equally weighted primary endpoints of the NPF-PS, which contribute a score
range of 0±30, include an assessment of induration of two target lesions, BSA, Physician's and
Patient's Global Assessments, and itching. We compared the performance of the NPF- PS with the
PASI in an investigator-initiated, single site, randomized, double-blind, placebo-controlled clinical
trial of in¯iximab (an anti-TNFa monoclonal antibody) in patients with moderate to severe plaque
psoriasis. Thirty-three patients were randomized to receive in¯iximab infusions at 5.0 mg per kg,
10.0 mg per kg or placebo in a 1:1:1 fashion. For purposes of this comparison, patients were
considered responders based on the NPF-PS and based on the PASI if there was a = 75%
improvement in the score. Patients were pooled across the three treatment groups for this
comparison. The Spearman rank correlation was used to assess the linear association between the
scores. The Kappa statistic was used to determine the agreement among the categorical outcome of
responder status using the two scores. The three patients that withdrew during the course of the
study (one from each group) were considered as nonresponders. The raw scores at each time point
(biweekly from week 0±10) and the percentage improvement in scores during treatment compared
to baseline (Week 2±10) showed a moderate linear correlation. Incorporating all time points
(n = 187), the Spearman correlations between NPF-PS and PASI were 0.87 (raw scores) and 0.93
(% improvement). At week 10, the Kappa statistic of 0.94 (n = 33) showed an ``almost perfect''
agreement between NPF and PASI in differentiating responders. In this therapeutic trial, the NPF-
PS showed a signi®cant association with the PASI in measuring clinically signi®cant outcomes. To
date, this is the ®rst report of a double-blind, placebo controlled study that demonstrates an
association between the NPF-PS and PASI.
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Comorbidity Incidence of Acne and Depressive Disorders in Isotretinoin Users Versus
Non-users: A Retrospective Analysis of the National Ambulatory Medical Care Survey
Database
S. Feldman, J. Rohrback, A. Fleischer Jr, and D. Krowchuk
Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Isotretinoin-induced depression in acne patients has been anecdotally reported, but in a recent
population-based study this association was not supported. We determined the incidence of of®ce
visits for outpatients diagnosed with concurrent acne and depression in order to assess the
proportion attributable to isotretinoin exposure. Using a nationally representative database, an
estimated 85 000 visits occurred at which acne and depression were diagnosed together between
1995 and 1998. None of these events were observed in patients treated with isotretinoin.
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Cost Analysis of Isotretinoin for Treatment of Severe Acne
C. Ellis, J. Crystal-Peters,* M. Smith,* J. Hong,² and M. Neary²
Dermatology, University of Michigan Medical School, Ann Arbor, Michigan; *MEDSTAT Group, Inc.,
Washington, District of Colombia; ²Roche Laboratories, Inc., Nutley, New Jersey
Objective: A retrospective analysis of administrative claims data was performed to evaluate the
impact of a single course of isotretinoin therapy on the direct cost of medical treatment for severe
acne. Data and Methods: Using the MEDSTAT Marketscan database, we identi®ed 475 subjects
aged 12-35 who received a single course of isotretinoin lasting 90 days or longer from 1995
through 1998. Acne-related expenditures were calculated during isotretinoin treatment and for
periods of 12 months before and after isotretinoin use. Direct costs, including cost of isotretinoin,
systemic and topical antibiotics, laboratory tests, and doctor of®ce visits, were examined. The
analyses included univariate statistics and multivariate analyses to evaluate how healthcare
expenditures were affected by individual subject characteristics such as gender, age, and health plan.
Results: On average, subjects received isotretinoin for 141 days at a cost of $1231. Mean total
acne-related expenses declined from $471 (median, $311) per year prior to isotretinoin therapy to
$135 (median, $48) per year after treatment (p < 0.01). More than 25% of subjects had no acne-
related expenditures for at least 12 months following isotretinoin therapy. Conclusion: Isotretinoin
therapy substantially reduces direct costs for acne-related medical care. Direct costs associated with
over-the-counter preparations and unreimbursed expenses (e.g., for cosmetic procedures) were not
included. Furthermore, indirect costs of therapy for severe acne, including travel and time away
from school/work for doctor's appointments, and value attributed to changes in quality of life were
not included. Inclusion of such costs and value would likely substantially increase the calculated
cost-bene®t of isotretinoin in the treatment of severe acne.
944
Use of Accutane and Treatment for Depression: A Prescription Sequence Symmetry
Analysis
M. Neary, W. Klaskala, K. Hersom,* H. Levaux,* and J. McLan
Roche Laboratories, Inc., Nutley, New Jersey; *The Lewin Group, San Francisco, California
Objective: Data from a large sample of patients with incident use of both Accutane and
antidepressants were reviewed to calculate, within study period, the ratio of asymmetry and the
incidence rate ratio of antidepressant prescriptions in Accutane-treated patients to determine if
there may be a causal relationship between Accutane use and depression. Secondary objective was
to evaluate validity of Accutane analysis using Minocycline, an agent not suspected to cause
depression. Methods: Prescription sequence symmetry analysis (PSSA) was successfully used by
Hallas (Epidemiology 7:478-484, 1996) to demonstrate possible causal relationship between certain
beta blockers and antidepressant use. Applying PSSA, analysis of dispensing patterns of Accutane
and antidepressants was performed using Synergy Healthcare, a large U.S. claims database.
Prescribing order of Accutane and antidepressants was determined to identify any possible
association between Accutane and depression. Ratio of asymmetry was computed as the ratio of
number of patients prescribed antidepressants second over number of patients prescribed
antidepressants ®rst. Antidepressants were classi®ed by class (amines, SSRIs, ``other'') or in
aggregate. Data were reviewed from July 1998 through March 2000, and waiting period analysis to
determine incidence use restricted study period to June 1999 through March 2000. Results: Of 90
million patients represented in Synergy pharmacy ®le, 5,753,565 patients ®lled prescriptions for
Accutane and/or an antidepressant. Of those, 17,348 patients ®lled prescriptions for both Accutane
and antidepressants yielding 2,821 incident users of both drugs during study period. Resulting
ratios of asymmetry were 0.99 (95% CI = 0.93-1.06) for selective serotonin reuptake inhibitors
(SSRIs), 0.90 for amines (95% CI = 0.78-1.04), 0.95 (95% CI = 0.85-1.05) for ``other''
antidepressants, and 0.97 (95% CI = 0.92-1.02) for all antidepressants combined. Results suggest
little to no effect on sequence of Accutane and antidepressant prescribing order when analyzed by
antidepressant class or in aggregate. Conclusion: Results of these analyses show no signi®cant
asymmetry in prescription order of Accutane and antidepressants. This provides evidence against
casual association between use of Accutane and treatment for depression. In addition, results
obtained from Minocycline analysis con®rmed reliability of Synergy database and validity of PSSA
methodology.
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Treatment of In¯ammatory Acne with an Oral 5-Lipoxygenase Inhibitor
C. Zouboulis, S. Nestoris, Y. Adler, M. Picardo,² E. Camera,² M. Orth,* and C. Orfanos*
Department of Dermatology, University Medical Center Benjamin Franklin, The Free University of Berlin,
Berlin, Germany; *Institute of Clinical Chemistry, University of Berlin, Berlin, Germany; ²Laboratory of
Cutaneous Physiopathology, San Gallicano Dermatological Institute, Rome, Italy
Peroxisome proliferator-activated receptors (PPARs) have recently been shown to be involved in
the differentiation of the sebaceous gland cells. Regulation of PPARa has been associated with a
pro-/anti-in¯ammatory action and lipid catabolism. Leukotriene B4 (LTB4), a 5-lipoxygenase
metabolite of arachidonic acid, is a ligand for PPARa. Therefore, an ethic committee-approved,
industry-independent, clinical proof of principle (1C) study was conducted to treat in¯ammatory
acne with an oral selective 5-lipoxygenase inhibitor. Ten consecutive patients with acne
papulopustulosa (m:f 6:4, aged 19 6 5 years) were treated with (+/±)-1-(1-benzo[b]thien-2-
ylethyl)-1-hydroxyurea 4 3 600 mg per day p.o. for 3 months after providing written consent.
Clinical evaluation by counting of lesions and determination of overall severity index after Allen
and Smith, assessment of casual skin surface lipids by Sebumeter(r) and of liver enzymes in serum
were performed at baseline, weeks 2, 4, 8, 12 of treatment and a 2-week post-treatment period.
LTB4 in blood by radio-immunoassay and sebum lipid fractions by gas chromatography were
determined at baseline and on week 12. Patients were photographed before and at the end of
treatment. The acne severity index continuously decreased in a time-dependent manner being
41 6 28% of the initial score at week 12 (p < 0.05). This was due to a decrease of the number of
in¯ammatory lesions to 29 6 24% (p < 0.01), while comedones did not respond to treatment.
Neither subjective nor objective adverse events were registered. In addition, total sebum lipids
signi®cantly decreased (35 6 51%, p < 0.05) and the pro-in¯ammatory free fatty acids (22 6 18%)
and lipoperoxides (26 6 30%) were markedly diminished in patients' sebum under treatment. The
magnitude of clinical improvement strongly correlated with the reduction of total sebum lipids
(p = 0.0009, r2 = 0.81) and free fatty acids (p = 0.0003, r2 = 0.82). In contrast, LTB4 levels in blood
and the casual skin surface lipids were not affected. All parameters studied remained practically
unchanged during the 2-week post-treatment observation. In conclusion, we could provide ®rst
indirect evidence that acne is a genuine in¯ammatory disorder. In¯ammatory acne lesions
signi®cantly responded to an oral 5-lipoxygenase inhibitor. Moreover, systemic inhibition of
arachidonic acid metabolism decreased total sebum lipids and pro-in¯ammatory lipid fractions in
sebum, which are considered to be responsible for the development of in¯ammatory acne lesions.
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The Ef®cacy of a Low-Dose Oral Contraceptive for the Treatment of Moderate Acne
and its Effects on Biochemical Markers of Androgenicity: Two Randomized, Placebo-
Controlled Trials
K. Washenik, H. Katz,* and F. Stanczyk²
Department of Dermatology, New York University School of Medicine, New York, New York; *Minnesota
Clinical Study Center, Minneapolis, Minnesota; ²Department of Obstetrics and Gynecology, University of
Southern California School of Medicine, Los Angeles, California
The purpose of these studies was to evaluate the ef®cacy of a low-dose oral contraceptive (OC)
containing ethinyl estradiol 20 mg/levonorgestrel 100 mg (EE/LNG) for the treatment of moderate
acne and its impact on biochemical markers of androgenicity. Data from two randomized, double-
blind, placebo-controlled, multicenter trials were pooled and analyzed. Healthy females
(n = 721; > age 14) with regular menstrual cycles and moderate facial acne were randomized to
receive EE/LNG or placebo for 6 cycles of 28 days. Primary ef®cacy endpoints included
in¯ammatory, nonin¯ammatory, and total lesion counts; data analyzed for these endpoints included
the last observation carried forward for all patients. Ovarian, adrenal and peripheral androgens, and
sex hormone-binding globulin (SHBG) were also measured and analyzed in a subset of patients
(n = 30). At the end of the study, EE/LNG signi®cantly reduced the number of total lesions from
baseline compared to placebo (p < 0.01). There was also a signi®cantly lower number of
in¯ammatory and nonin¯ammatory lesions in EE/LNG patients compared to placebo patients
(p < 0.05). After 6 cycles of treatment, signi®cant decreases in ovarian (androstenedione, free
testosterone, bioavailable testosterone) and peripheral (3a-androstanediol glucuronide, androster-
one glucuronide) androgen levels, and a signi®cant increase in SHBG were observed with EE/
LNG compared to placebo (p < 0.05). Compared to baseline, EE/LNG signi®cantly reduced free
testosterone, bioavailable testosterone, and 3a-androstanediol glucuronide, and signi®cantly
increased SHBG at cycle 6 (p < 0.05). Signi®cant positive correlations were found between
changes in total lesions and changes in androstenedione, free testosterone, and dehydroepian-
drosterone sulfate levels (p < 0.05), and a trend toward a signi®cant (p = 0.0595) inverse correlation
was found between changes in total lesions and changes in SHBG levels. In conclusion, this low-
dose OC, Alesse(r), containing 20 mg EE/100 mg LNG, is effective and safe for the treatment of
moderate acne and improves biochemical markers of androgenicity.
947
Topical Azelaic Acid in the Treatment of Rosacea
J. Bamford, C. Gessert,* and C. Renier*
Section of Dermatology, St. Mary's/Duluth Clinic Health System, Duluth, Minnesota; *Division of
Education and Research, St. Mary's/Duluth Clinic Health System, Duluth, Minnesota
Topical 20% azelaic acid cream was compared with placebo in a nine-week, randomized,
controlled trial at a large multispecialty clinic in the upper Midwest. Subjects with rosacea were
recruited over a one-year period, excluding those who were under 25 years of age, pregnant, or
lactating, or had recently used topical or oral medications that affect rosacea. A total of 60 subjects
met study criteria and provided informed consent. Baseline assessment of subjects' rosacea included
papules/pustules, erythema (5 sites) and telangiectasia (5 sites). Subjects were randomized to
treatment and control groups, and were instructed to apply cream ± azelaic acid or placebo ± twice
daily for the duration of the nine-week trail. Fifty-three subjects completed the trial. Post-
treatment assessments were conducted on day 63. For each variable, baseline and post-treatment
assessments were compared to determine if the subject was improved, unchanged, or worse after
treatment. Azelaic acid treatment was associated with improvement in papules/pustules (p < 0.05).
No other signi®cant difference between azelaic acid and control regimens was noted. These
®ndings con®rm the reported ef®cacy of azelaic acid in the treatment of the papulopustular form of
rosacea. Additional work is needed to clarify the role that azelaic acid may have in the treatment of
the full spectrum of clinical presentations of rosacea.
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Application of Dermatopharmacokinetic Approach in the Assessment of Clinical
Bioequivalent And Bio-inequivalent Tretinoin Gel Products
L. Pershing, J. Nelson, J. Corlett, D. Hare,* and S. Shrivastava*
Dermatology, University of Utah, Salt Lake City, Utah; *Of®ce Pharmaceut. Sci., FDA, Rockville,
Maryland
Dermatopharmacokinetics (DPK) has been proposed as a method for bioequivalence (BE)
assessment of locally acting topical drug products. Multiple adhesive discs are used to harvest
stratum corneum (SC) from treated skin sites at various time points after product application and
removal. Three 0.025% tretinoin gels: Retin-A(r) gel (Ortho), Tretinoin gel (Spear) and Avita(r)
gel (Bertek) were compared for drug uptake into and elimination from forearm SC in 49 healthy
subjects, using a 5-mL dose/1.13 sq cm surface area skin site. One skin site was used for each time
point and each gel evaluated. The products were applied simultaneously, side-by-side, in each
subject. SC from each skin site was harvested by a validated skin stripping method. Tretinoin and
isotretinoin concentrations were determined in the SC samples by a validated HPLC method.
Cmax of tretinoin and isotretinoin with the Ortho gel was 115 and 55 ng/sq cm. Tmax was 0.7
and 0.8 h, respectively. Elimination half-life was 5.6 and 9.4 h, respectively. AUC0-t was 430 and
303 ng- h/sq cm, respectively. The DPK BE results with these gels concur with the previous
clinical ®ndings. Thus, differences between Spear and Ortho gels, that are clinically bioequivalent
and qualitatively/quantitatively the same in composition, were smaller than between Bertek and
Ortho/Spear gels, which are clinically bio-inequivalent and differ in composition. These data
demonstrate that clinical and DPK approaches produce the same BE assessment of three 0.025%
tretinoin gels and validates DPK as an appropriate method for BE assessment of topical drug
products.
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Food Effect on a New Formulation of Accutane
K. Khoo, J. McLane, C. Garnett,* H. Pentikis,* D. Young,* and C. Trapnell
Medical Affairs, Roche Laboratories, Nutley, New Jersey; *2 Globomax LLC, Hanover, New Jersey
Purpose. Isotretinoin, 13-cis-retinoic acid, is approved for the treatment of severe recalcitrant,
nodular acne. The currently marketed formulation (Accutane,) must be administered with food for
optimal extent of absorption. A new formulation of isotretinoin was developed to minimize the
food effect and increase bioavailability. Methods. A 4-way crossover PK study was conducted in 87
(1F/86M) healthy adult subjects to assess the effect of food on a single oral 30 mg dose of the new
formulation compared with 80 mg of marketed Accutane under fed and fasted conditions. Plasma
concentrations were assessed for isotretinoin and its 3 major active metabolites. Results. The
primary PK parameters (mean6SD) of isotretinoin are: New Fed: AUC0-o 5469 6 1291 ng*h per
mL, Cmax 448 6 164 ng per mL; New Fasted: AUC0-o 4183 6 1140 ng*h per mL, Cmax 336 6
122 ng per mL; Marketed Fed: AUC0-o 10004 6 2198 ng*h per mL, Cmax 862 6 344 ng per mL;
Marketed Fasted: AUC0-o 3703 6 1704ng*h per mL, Cmax 301 6 191 ng per mL. These data
show that for the new formulation, the mean AUC0-o increased by ~30% under fed conditions; for
marketed isotretinoin, mean AUC0-o increased by ~200% under fed conditions. Similar results
were seen with the 3 major metabolites. Conclusions. The study shows that the new formulation
can be administered with or without food.
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Dose Proportionality of New Formulation of Accutane
K. Khoo, J. McLane, C. Garnett,* H. Pentikis,* D. Young,* and C. Trapnell
Medical Affairs, Roche Laboratories, Nutley, New Jersey; *GloboMax LLC, Hanover, New Jersey
Purpose. Isotretinoin, 13-cis-retinoic acid, is approved (Accutane,) for the treatment of severe
recalcitrant, nodular acne. A new formulation was developed to minimize the food effect on
isotretinoin and increase the bioavailability. Methods. A single oral dose, 3-way crossover PK study
was conducted in 42 healthy male subjects to establish the dose proportionality of 2 3 7.5 mg, 2 3
15 mg, and 2 3 22.5 mg capsules of the new formulation. Pharmacokinetics were assessed for
isotretinoin and its 3 major active metabolites. Results. The mean ratios for dose-normalized
AUC0-o (ng* h per mL) and Cmax (ng per mL) are as follows: Isotretinoin AUC0-o Ratio for 15:30
mg: 111%; for 45:30 mg: 90%. Isotretinoin Cmax Ratio for 15:30 mg: 105%; for 45:30 mg: 96%. 4-
oxo-isotretinoin AUC0-o Ratio for 15:30 mg: 101%; for 45:30 mg: 89%. 4-oxo-isotretinoin Cmax
Ratio for 15:30 mg: 86%; for 45:30 mg: 92%. Tretinoin AUC0-o Ratio for 15:30 mg: 92%; for
45:30 mg: 84%. Tretinoin Cmax Ratio for 15:30 mg: 85%; for 45:30 mg: 105%. 4-oxo-tretinoin
AUC0-o Ratio for 15:30 mg: 90%; for 45:30 mg: 97%. 4-oxo-tretinoin Cmax Ratio for 15:30 mg:
106%; for 45:30 mg: 92%. Conclusion. The data show that the exposure to isotretinoin and its 3
major active metabolites is dose proportional within the range of 15 mg to 45 mg.
951
Development of New 5-a-Reductase Inhibitors
A. Piccirilli, J. Legrand, and P. Msika
R & D, Laboratoires Pharmascience, Epernon, France
5-a reductase, the enzymes system that metabolizes testosterone into dihydrotestosterone (DHT),
occurs in two isoforms, the type A which represents the ``cutaneous type'' and the type 2 which is
located mainly in the epididymis, seminale vesicles, prostate,¼Androgen-dependent skin
disorders, such as seborrhoea, acne, female hirsutism and/or androgenetic alopecia are among
the most common diseases encountered by the dermatologist. Thus the development of new
compounds that effectively inhibit the type 1 isoenzyme of 5-a reductase are of major importance
for dermatological purpose. The aim of this work is to present new compounds which are able to
inhibit signi®cantly 5-a reductase type 1. The ef®ciency of these molecules was tested on human
skin ®broblasts in culture. Cells were cultured with radiolabelled testosterone and the evaluation of
DHT formation by thin-layer chromatography has been applied to evaluate 5-a reductase activity.
Fatty esters and natural extracts have been tested. Concerning fatty compounds, a maximal
inhibitory effect is observed in the presence of mono unsaturated C18 long chain butyl ester and/
or ricinoleic group. These results emphasize the potentiel bene®t of butyl avocadate and methyl
ricinoleate as 5-a reductase inhibitors and their application for the development of cosmetic and
pharmaceutical products dedicated for the treatment of dermatological disorders such as acne,
hirsutism and alopecia.
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R115866: A Selective Retinoic Acid Metabolism Inhibitor Acts Topically as a Retinoidal
Agent in Cutaneous Model Systems
G. Gendimenico, P. Stoppie,* J. Van Wauwe,* V. Mezick, J. Liebel, W. Mack, J. Mallon, W. Li,
and S. Shapiro
Johnson & Johnson Consumer Products Worldwide, Skillman, New Jersey; *Janssen Research Foundation,
Beerse, Belgium
R115866 is a highly potent and selective inhibitor of P450-mediated all-trans-retinoic acid (RA)
metabolism. This compound has been shown to exhibit retinoidal effects when given orally. The
purpose of our studies was to pro®le R115866 for topical retinoid activity in a variety of cutaneous
models. In rhino mouse skin, a model of follicular keratinization, R115866 was two times less
potent than RA at reducing utriculus size, but both compounds were equiactive at 0.03%.
R115866 at 0.003, 0.01 and 0.03% was also effective at causing connective tissue repair in
photodamaged hairless mouse skin. In a mouse model of glucocorticoid-induced skin atrophy,
R115866 at 0.03%, like RA, completely prevented skin thinning. R115866 also induced
hyperplasia of the epidermis in swine (0.1% dose) and xenografted human skin (0.03% dose). In the
ear of the Abyssinian 3 Shorthair guinea pig, R115866 reduced the amount of epidermal melanin
in a dose-related fashion (0.01±0.1%). In the rabbit dermal irritation model, R115866 caused
minimal irritation (erythema) at 0.1%, compared to RA at the same dose, which was irritating.
These ®ndings suggest the use of R115866 as a new topical dermatotherapeutic agent for treating
retinoid-responsive skin disorders including acne, photodamage, psoriasis and hyperpigmentation.
953
In Vivo Evaluation of an Antiaging Cosmetic Product Containing both Avocadofurane
and Soy Iso¯avones Using 31P Magnetic Resonance Spectroscopy of the Skin
N. Piccardi, B. Chadoutaud,* and P. Msika
R & D, Laboratoires Pharmascience, Epernon, France; *Consulting, BC Consulting, Toulouse, France
The cutaneous aging process includes intrinsic physiological factors and extrinsic environnemental
factors mainly related to solar irradiation. After menopause, hormonal deprivation of sexual steroids
due to the loss of ovarian activity plays an important role in intrinsic aging. Clinically, menopausal
women present signs of dry, thin and pale skin which are related to the. We have developped a
cosmetic product, containing both avocadofurane (1%) and soy iso¯avone, which is speci®cally
dedicated to the treatment of hormonal skin aging. 31P nuclear magnetic resonance spectroscopy is
a non invasive tool to quantify energy metabolism of human skin via the measurement of the main
phosphorylated metabolites: inorganic phosphate (Pi), phosphocreatine (PCr) and adenosine
triphosphate (ATP). The aim of this work was to evaluate the changes in the energy metabolism of
the skin, after application of antiaging product (Helyx+, Noviderm). Subjects applied the product
twice daily on one wrist (the other was taken as control). Spectra of the skin of both wrist were
acquired at T0, T + 4, T + 7 h to assess short-term effects, and at T + 14 days (evaluation of a
remanent effect). Treatment with Helyx + results in a signi®cant short (PCr/Pi + 9.1% at T + 3 h)
and long-term (ATP/Pi + 16.9% at T + 14 days) improvement in the energetic status of the skin.
This study allow us to conclude that Helyx + is an energizing cosmetic product speci®cally
designed for the treatment of hormonal skin aging. Indeed the association of both avocadofurane,
which is able to induce TGF-b1 and collagen synthesis, and soy iso¯avones may contribute to the
restoration of the energetic status of aged skin and by the way to the improvement of the visible
signs of hormonal cutaneous aging.
954
Clinical Assessment of Topical Tissue-Engineered Growth Factors for Reversal of
Photodamaged Skin
R. Fitzpatrick* and G. Naughton
Executive, Advanced Tissue Sciences, La Jolla, California; *Associate Clinical Professor, Department of
Medicine/Dermatology, University of Californiaat San Diego, San Diego, California
A clinical evaluation was conducted with 12 moderately wrinkled patients who were screened to
have type (4 thru 6) wrinkles as de®ned by the Fitzpatrick scale. Patients were treated topically with
formulations containing naturally secreted skin growth factors including VEGF, KGF and TGFb.
Preliminary data analysis of a previous pilot study showed a 10±30% increase in epidermal
thickening and a 20±60% increase in Grenz zone collagen after 30 days of daily application. In the
current evaluation, dose ranging studies were performed with a clinically relevant target dose of
TGFb (16 ng per ml) and sequentially reduced dosing. 60-day biopsies are pending and will be
assessed. Patients received biopsies of the cheek on the ®rst of®ce visit and the last of®ce visit,
which was at the end of the 60-day evaluation. Subjects also received surface pro®lometry testing
of wrinkles on the initial of®ce visit and the last of®ce visit. Patients treated the entire face twice
daily for 60 days and returned for evaluation at four-week intervals. 60 day biopsies are pending and
will be assessed for increases in Grenz zone collagen and epidermal thickening Clinical responses
were also analyzed utilizing clinical ratings of the Fitzpatrick scale as well as assessment of optical
pro®lometry. While there were no controls in this evaluation, the assessment from baseline
demonstrated that the topical tissue-engineered growth factor used twice daily results in both
remodeling and rejuvenation of skin.
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Molecular Transporters Facilitate Topical Protein Transduction into the Skin
J. Rothbard,* P. Robbins, S. Sheu, S. Oliver, J. Goodnough, P. Wender, and P. Khavari
VA Palo Alto and Department of Dermatology, Stanford University, Stanford, California; *CellGate,
Sunnyvale, California
The skin provides a formidable barrier to delivery of molecular therapeutics. Recently, new
molecular transporters in the form of protein transduction sequences (PTS) derived from proteins
such as HIV1 TAT and Drosophila antennapedia have been found to rapidly traverse cell and
visceral tissue barriers, including the blood±brain barrier. Carrying cargo up to 40 nm in size, these
transporters appear to rely on arginine residues that are also present in evolutionarily conserved
sperm protamines that facilitate delivery of macromolecules such as the male haploid genome. To
determine if these PTS could transport cargo across the cutaneous permeability barrier, we have
recently characterized successful transdermal delivery of cyclosporin A conjugated to arginine
heptamers. To further investigate the use of PTS for transdermal delivery and to de®ne optimal
transporters, we designed a series of oligoarginine PTS ranging in size from R7 to R10 and
conjugated them either to a peptide with biological function or a biotin label. Additionally, similar
constructs with a glycine-spaced heptarginine as well as transporter sequences from TAT and
antennapedia were constructed in parallel. A disul®de linkage to PTS was designed that releases
functional cargo upon entry into the reducing environment within the cell. We compared the
toxicity and ability of this array of transporter sequences to carry their cargo into keratinocytes in
culture as well as across the skin barrier in vivo. We found that PTS alone have varying levels of
toxicity when applied to cultured human keratinocytes. At concentrations of 100 mM to 0.1 mM
the decamer of arginine was found to display keratinocyte toxicity. Over the same range of
concentrations, a heptamer of arginine was less toxic and the TAT PTS was nontoxic. The level of
toxicity was roughly correlated to the effectiveness of the transporter. We demonstrated ef®cient
transportation of FITC labeled PTS into keratinocytes in vitro and with biotinylated PTS
conjugated peptides to intact mouse skin in vivo. Therefore, it appears that arginine-based PTS are
generally effective transporters into keratinocytes in culture and across the cutaneous barrier in vivo.
This new molecular transport technology thus represents a promising new platform for topical
delivery of therapeutics to skin.
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The Skin as a Bioreactor: A Transgenic Mouse Model with Regulated Cutaneous
Delivery into the Central Circulation
T. Cao, W. He,* X. Wang,* and D. Roop²
Paci®c Biomedical Research Center, University of Hawaii-Manoa, Honolulu, Hawaii; *Department of
Dermatology, Baylor College of Medicine, Houston, Texas; ²Department of Molecular and Cellular Biology,
Baylor College of Medicine, Houston, Texas
Epidermal keratinocytes secrete a large number of polypeptides, and some of these have been
shown to achieve systemic distribution via the vascular system within the dermis. This raises the
possibility that the epidermis may be used as a bioreactor to produce proteins for systemic release to
treat disease. The initial reports documenting the feasibility of this approach utilized vectors that
directed constitutive expression of therapeutic genes. Expression of a therapeutic gene usually must
achieve a threshold level in order to have therapeutic effects, however, constitutive expression of a
transgene at high levels may be deleterious to the cells and organism. To circumvent these
problems, inducible vector systems have been developed which allow regulated expression of
transgenes. To test the feasibility of using these inducible vectors in vivo in the skin, we have
developed a transgenic mouse model in which expression of the transgene can be regulated
temporally by topical induction. In this system, a transcription activator driven by an epithelial-
speci®c promoter remains inactive until topical application of an inducer. Upon induction, the
activator activates transcription of the therapeutic gene, human growth hormone (hGH), in basal
keratinocytes. High levels of hGH were detected in the circulation within hours after a single
application of the inducer. Maximum hGH levels (~1000-fold higher than controls) were observed
a few days later, with the serum levels gradually returning to base line. Repeated induction resulted
in up to 45% weight gain in adult transgenic mice, compared with 7% in control mice. We also
demonstrated that the serum levels of hGH were dependent on the amount of inducer applied. To
simulate how this inducible system might eventually be used in the clinic, skin biopsies from these
transgenic mice were grafted onto nude mice. Following induction of the grafted area,
physiological levels of hGH were detected in the serum. These results clearly demonstrate the
feasibility of regulating the delivery of therapeutic proteins into the circulation via genetically
modi®ed keratinocytes.
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Sustainable Systemic Erythropoietin Delivery via a Single Injection of Lentivirus into
Human Skin
S. Baek, S. Sheu, Q. Lin, P. Robbins, and P. Khavari
VA Palo Alto and Department of Dermatology, Stanford University, Stanford, California
The skin offers an attractive tissue site for systemic gene therapy because of its accessibility and
ability to deliver proteins to the bloodstream. Among systemic disorders potentially amenable to
cutaneous gene transfer are those characterized by inadequate blood levels of speci®c polypeptides,
such as is seen in erythropoietin (EPO)-responsive anemia. In an effort to achieve systemic EPO
delivery via cutaneous gene transfer, we generated a VSV-G pseudotyped third generation HIV-1-
based lentiviral vector encoding human EPO for delivery to full thickness human skin xenografts
on SCID mice. Intradermal injection of 1, 5 and 10 mg p24 equivalent [n = 5 mice/group]
produced dose-dependent levels of human EPO of 5, 11 and 35 mIU/ml [control = 0] and
hematocrit of 49, 54 and 65 [control = 40], respectively. EPO expression and increased hematocrit
are stable out to at least 10 months after a single injection. To determine if the infectious virus was
only localized to skin rather than disseminated to visceral tissues, skin biopsy of the injection sites of
mice injected with 1 and 10 mg of lentivector was performed at 4 weeks. Within days after removal
of the injected skin tissue site, blood EPO fell to undetectable levels, con®rming that the skin was
the only site of infection and EPO production. Double immunostaining of human skin to identify
the skin cell types targeted revealed that lentivectors effectively transduce keratinocytes, ®broblasts,
macrophages and endothelial cells of skin within the area closely localized around the site of needle
injection. 3343 + 1438 cells of all types within skin were transduced per mcg p24 equivalent of the
EPO lentivector, indicating that a as few as 30 000 EPO-expressing cells within skin may suf®ce to
boost hematocrit over 60%. Thus, lentiviral vectors are capable of sustained delivery of a
therapeutic polypeptide to the bloodstream after a single injection with localized infection of
multiple cell types within skin and provide a promising approach for future cutaneous gene
transfer.
958
Physiological Effect of ``Green Odor'' on the skin
E. Kinoshita, Y. Takahata, T. Ishida, A. Hatanaka* and M. Muto
Dermatology and Biomolecular Sensing, Yamaguchi University School of Medicine, Ube, Japan; *Plant Life
Science, University of East Asia, Shimonoseki, Japan
``Green Odor'' is a natural fragrance we feel fresh and green in and around the forest. To clarify the
relationship between ``Green Odor'' and skin conditions, we used leaf-alcohol (3Z-hexenol) and
leaf-aldehyde (2E-hexenal) as ``Green Odor''. We studied 5 patients with atopic dermatitis (one
male and 24 female, 21±31 year) and 87 normal healthy controls (63 males and 24 females, 22
to43 year). In a room with temperature kept at 23°C and 60% humidity, the subjects sat
comfortably for 30 min, smelling leaf-alcohol and leaf-aldehyde both diluted to 1% with solvent
(triethyl citrate). Before and after their smelling, we measured the following three points: (1) skin
temperature of both hands with thermography (2) water content of the stratum corneum in both
hands with Skicon-200, and (3) blood pressure, pulse rate, and body temperature. Estimations of all
experiments were indicated as ratio of the value of after-smelling/the value of before-smelling.
Two of the 5 patients with atopic dermatitis showed decrease of the skin temperature and increase
of the water content of the stratum corneum, while no obviously detectable change was observed
in the 87 normal healthy controls. We had patch tested ``Green Odor'' on 93 normal healthy
controls and one patient with atopic dermatitis and had con®rmed none of them had shown
positive reaction. In conclusion, it seems that ``Green Odor'' may contribute to the improvement
of the physiologically aberrant skin conditions of patients with atopic dermatitis.
959
Doxycycline-Inducible Retroviral Expression of Green Fluorescent Protein in
Immortalized Human Keratinocytes
P. Gill, G. Krueger,* and D. Kohan
Medicine, University of Utah, Salt Lake City, Utah; *Dermatology, University of Utah, Salt Lake City,
Utah
Ease of culture, potential for transplantation and reported success of expression of transgenes are
features that make keratinocytes attractive for localized or systemic delivery therapeutic genes.
Insertion of a regulatable switch for transgene expression into keratinocytes would greatly enhance
their clinical utility for gene therapy. We describe a method wherein immortalized human
keratinocytes (IMKc) that have been shown to form a functional epidermis in vivo can be
transduced with high ef®ciency with the retroviral vectors of the RetroTet-Art system which
confers stable doxycycline (Dox) inducible green ¯uorescent protein (GFP) expression. This
system houses a transactivator and a transrepressor of the transgene which are activated with the
tetracyclines. After one round of transduction, approximately 50% of IMKc expressed GFP; after
puromycin selection 90±100% of cells expressed GFP. With this retroviral vector system no
baseline expression of GFP was observed in the genetically modi®ed IMKc. Dox treatment of these
transduced cells induced GFP expression in a dose- and time-dependent manner. Peak GFP
expression occurred after 72 h of Dox treatment and dropped to baseline when Dox was removed.
Our observations demonstrate an ef®cient method for achieving stable Dox-regulatable transgene
expression in human keratinocytes. These transduced keratinocytes maintain their ability to form a
functional epidermis in vitro.
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The Secret of Measuring Sweat pH: With the Incorporation of Important Controls,
there are no Gender Differences in Axillary Sweat pH Values
J. Burry, H. Coulson, I. Esser, V. Marti, S. Melling, A. Mills, A. Rawlings, and G. Roberts
Unilever Research Port Sunlight, Bebington, United Kingdom; *Elida Faberge, Leeds, United Kingdom;
²Unilever Research India, Bangalore, India
As the pH of eccrine sweat is a critical factor for the gelation of antiperspirant actives, the accurate
measurement of axillary sweat pH is of vital importance for the antiperspirant industry. Although
one study has reported that females have an axillary sweat pH of 7.0 and males a sweat pH of 5.6,
three other studies have demonstrated that no gender differences exist in axillary skin surface pH.
In order to clarify this situation, we have executed a series of studies aimed at measuring the pH of
thermally induced axillary sweat with the incorporation of critical controls; the most important of
these being the equilibration of sweat samples with physiological levels of CO2. In the present
study, two age-balanced groups of male and female subjects (18±60 years) were recruited with the
requirement that they had refrained from using antiperspirant products in the axilla for a period of
at least 5 weeks. Three days prior to the study, subjects shaved their test axilla. On the study day,
sweating was induced at a temperature of 43 6 1°C and 65 6 5% relative humidity. Following a
warm-up period, eccrine sweat droplets were collected from the axillary vault and placed in glass
vials. In order to mimic physiological conditions and thus gain a true representation of sweat pH,
pH was measured following equilibration of samples with 5%CO2/95%O2; the rationale for this
being that sweat pH is primarily controlled by a HCO3
±/CO2 buffer system and uncontrolled
losses of CO2 to the atmosphere leads to arti®cially high pH readings. Using this methodology, we
demonstrated that the pH of axillary sweat was 6.54 6 0.32 (mean 6 standard deviation, n = 18)
for the male group and 6.50 6 0.31 (n = 15) for the female group. These readings were not
signi®cantly different (p = 0.74; unpaired t test).
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Assessing the Irritation Potential of Antiperspirants
V. Marti, G. Brennan, P. Clarke, R. Lee, A. Rawlings, and P. Walsh
Unilever Research, Bebington, United Kingdom
Adverse reactions from cosmetics are rare relative to their widespread and regular usage. However,
both irritant and allergic contact dermatitis from cosmetics is well established, and underarm
products have been implicated in causing a signi®cant proportion of these reactions. In order to
measure the irritation potential of marketed underarm products, and to enable the development of
less irritating antiperspirants, we have developed a range of sensitive and reproducible measures of
the irritation potential of this class of cosmetic. The single application forearm patch test is an
appropriate rapid screen for irritation potential that is shown to discriminate between marketed
antiperspirants. Including a model treatment for underarm shaving has further enhanced the
relevance of the forearm patch test methodology. This modi®cation is shown to increase the
observed irritation potential of underarm systems ±, e.g. in a 50 panellist test the frequency of
occurrence of visible in¯ammation changes from 21 out of 50 (unshaved patch) to 35 out of 50
(shaved patch) for the no treatment control site. Product rankings, however, are not affected.
Finally, an exaggerated-use axillary protocol (comprising a direct paired-comparison of two
products over a four-week period) has been developed to assess irritation potential under more
consumer relevant conditions. This less rapid, more resource intensive protocol, is used to validate
the results from the forearm patch test screens. These clinical protocols have been used to assess the
irritation potential of a range of marketed antiperspirants, and have highlighted an exceptionally
mild antiperspirant stick. The comparison of this stick with a standard marketed stick in a 31-
panellist exaggerated-use axillary test showed it to be consistently and signi®cantly milder with
respect to expert assessed irritation. The ultramild stick was assessed as milder in 26 panellists,
harsher in 3 panellists and not different in 2 panellists during the ®nal test week (p < 0.001).
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Sub-Surface Skin Imaging and Evaluation by Optical Coherence Tomography (OCT)
A. Knuttel, S. Bonev, A. Hoepfner, and C. Kugler
ISIS Optronics Gmbh, Mannheim, Germany
Optical Coherence Tomography (OCT) is an emerging powerful imaging technique for probing
turbid tissue like skin below surface in a noninvasive manner. It works similar to high-frequency
ultrasound imaging except of the employment of near-infrared light rather than acoustical waves.
The bene®ts compared to ultrasound imaging are considerably higher spatial resolution and the
optional evaluation of tissue via optical parameters. Potential applications for OCT are in
cosmetic/pharmaceutical research and clinical diagnosis as well. Particularly in cosmetics, repeated
and rapid skin testing is required during product development to ensure ef®cacy and to monitor
general skin reactions. In clinical routine, various types of skin diseases may be diagnosed more
rapidly and cost-ef®cient as compared to biopsies and subsequent histologies. We assembled an
OCT device to perform imaging in 2 (2D) and 3 (3D) dimensions at a resolution of about 5 mm
(cell size). Penetration depths of up to 1 mm can be achieved, depending on the type of tissue. An
additional feature of the device is to evaluate local moisture content of tissue. Skin 2D and 3D data
sets from volunteers have been acquired in a research study. Morphological features in stratum
corneum, epidermis and upper dermis can be delineated. Dynamic processes of externally applied
perturbations have been monitored over a duration of 1 h. In a preliminary medical study NCN
(Naevus Cell Naevus) and adjacent healthy skin are compared with histology. Relative local
moisture levels were retrieved by additional data processing. Comparing to histology, our OCT
images are in many cases of suf®cient quality to serve as prediagnostic tool at penetration depths
between 0.5 and 1 mm. Relative local moisture content can only be retrieved by OCT under
noninvasive conditions.
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Epidermal and Dermal Dimensions of Human Skin can be Determined In Vivo by Optical
Coherence Tomography
I. Sadiq, D. Kligman, T. Stoudemayer, and A. Kligman
S.K.I.N. Inc., Conshohocken, Pennsylvania
Optical Coherence Tomography (OCT) is a new technique to record skin structures at various
depths. This ®lls the gap between the high resolution (~ 1 micron) Confocal microscopy and lower
resolution techniques like ultrasonography and Magnetic Resonance Imaging (resolutions 50±300
microns). OCT images skin as vertical sections with resolutions reaching 3 microns in lateral
direction and 5 microns in depth. OCT is based on an optical interferometry principle where a
broad band light beam of short coherence length is split into sample and reference beams; the
re¯ected light is coupled to produce an interference signal. Dermal and epidermal structures are
clearly outlined. Stratum corneum (SC) is visualized as a bright band and its thickness can be
estimated. The geometry of isolated legions such as comedones and seborrheic keratosis can be
visualized. OCT is useful to follow changes induced by experimental chemicals including irritants.
OCT studies are at a very early stage but offer great promise as a means of studying human skin in
health and disease.
964
Immunoelectron Microscopic Analysis of Lysosomal Deposits in a-N-acetylgalactosa-
minidase (a-NAGA) De®ciency with Angiokeratoma Corporis Diffusum (ACD)
A. Kanda, T. Kanzaki, S. Tsuyama, F. Murata, K. Kodama,* and Y. Hirabayashi
Dermatology and Anatomy, Kagoshima University Faculty of Medicine, Kagoshima, Japan; *Dermatology,
Hokkaido University, Sapporo, Wako, Japan
a-NAGA de®ciency with ACD (Kanzaki disease) is one of the lysosomal storage diseases. Since the
substrate of a-NGAG is GalNAca1-O-Ser/Thr, this substance is theoretically accumulated in
lysosomes, but galactose and/or neuraminic acid conjugated substances, typically NeuAca2±
3Galb(NeuAca2±6) 1±3GalNacaÂ1-O-Ser/Thr, are actually excreted in patient urine. In this study,
we analyzed the lysosomal deposits in two Japanese patients by immunoelectron microscopy with
mouse monoclonal antibodies to Tn, sialosyl Tn and T antigens to know whether GalNAca1-O-
Ser/Thr, which is a Tn antigen, or other materials are deposited in patients lysosomes. We stained
ultrathin sections of specimens routinely ®xed with osmium tetroxide and embedded in epoxy
resin after a bleaching procedure and obtained excellent results from morphorogical and
immunohistochemical point of view by this simple method. The results of immunoelectron
stainings were that only Tn antigen was positive and we found that GalNAca1-O-Ser/Thr was
accumulated in enlarged lysosomes of vascular endothelial cells, eccrine sweat gland cells and
®broblasts of patient's skin. These results clari®ed that conjugation of galactose and neuraminic acid
to this substance does not occur in any cells of the skin. These sugar conjugation appears to be
carried out in other cells or organs and this suggests that this disease is caused by a de®ciency of a
single lysosomal enzyme.
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Innervation Changes of the Vulval Vestibule in Patients with Vulvodynia
P. Tympanidis, G. Terenghi,* and P. Dowd
Department of Dermartology, University College of London, London, United Kingdom; *Department of
Surgery, Blond McIndoe Laboratories, UCL, London, United Kingdom
Vulvodynia is a condition characterised by the sudden onset of a painful burning sensation, lowered
pain thresholds (hyperalgesia), mechanical allodynia, and occasionally pruritus, of the vaginal
vestibule. Pain precipitated in the absence of nociceptor stimulus might be triggered by the release
of mediators that set off inappropriate impulses in nonmyelinated pain ®bres, thus sensitising the
dorsal horn neurones. The objective of this study is to demonstrate the pattern of the innervation
of the vulval vestibule, and distinguish any variance from this normal pattern, in vulvodynia
patients, which might provide objective evidence for a sensory neurone abnormality. Biopsies were
obtained from the affected area of patients (n = 10), and from a matched site of asymptomatic
controls (n = 8), and processed for immunocytochemistry. The mean age of patients and controls
was 32 years, and patients, satis®ed Friederich's criteria for vulvodynia. 15 mm frozen sections were
immunostained with antisera to the neuropeptide calcitonin gene related (CGRP), and the general
neuronal marker PGP9,5, using the peroxydase avidin-biotin complex protocol (ABC). Sections
were studied by computerised image analysis (Image Pro-Plus). The results re¯ect the mean of
visual estimates of the density of immunoreactive innervation in the epidermis, and papillary
dermis, where the pattern of the innervation presented quantitative variability between patients and
controls. The quantitative grading was performed indipendently by two observers who were
unaware of the study group to which each of the specimens belonged. The overall pattern of the
distribution of the immunoreactive axons was similar in patients and controls qualitatively.
However, vulvodynia patients specimens, had signi®cant statistical increase in the number of
PGP9,5 immunoreactive ®bers in the papillary dermis (up to 62%) and in the epidermis (up to
30%), compared with the controls. Furthermore, considerable number of the PGP9,5
immunoreactive nerve ®bres enters or run along and through the epidermis of affected subjects.
Interestingly, no signi®cant change was found in the distribution and discrete quantitative analysis
of the CGRP immunoreactive axons between patients and controls. This increase in the sensory
innervation of the papillary dermis and epidermis of the affected areas may be of diagnostic and
aetiologic signi®cance in vulvodynia.
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Familial Cylindromatosis: A Mutation in the CYLD Gene Undelies Multiple Tumors of
Skin Appendages and Allows Prognostic Diagnosis for Genetic Health Services
J. Frank, P. Poblete, T. Eggermann,* T. Beermann, E. Grussendorf-Conen, K. Zerres,* and H.
Merk
Dermatology, University Clinic of the RWTH Aachen, Aachen, Germany; *Human Genetics, University
Clinic of the RWTH Aachen, Aachen, Germany
Familial cylindromatosis (turban tumor syndrome; Brooke±Spiegler-syndrome) (OMIM numbers
123850; 313100) is a rare skin disorder, inherited in an autosomal dominant fashion and usually
presenting in the second or third decade of life. With female preponderance, dermal tumors
predominantly arise in hairy areas of the body with approximately 90% on the head and neck,
rarely on the face or trunk. Transformation to malignancy seems to be rare. Recently, the
susceptibility gene CYLD which reveals the genetic attributes of a tumor-suppressor gene
(recessive oncogene) has been localized to chromosome 16q and mutations have been identi®ed in
affected families. Here, we studied the molecular basis of familial cylindromatosis in a
multigeneration family of German origin. Using PCR, microsatellite analysis, heteroduplex
analysis, and automated sequencing, we identi®ed a frameshift mutation in the CYLD gene in
several individuals. Mutation analysis most importantly allowed exclusion of the tumor
predisposition in a 6-year-old boy. Interestingly, in several family members with identical
genotype we observed distinct phenotypic expression. While some individuals revealed discrete
small skin colored tumors localized in the nasolabial region, one family member showed expansion
of multiple big tumors on the trunk and in a turban like fashion on the head. The reasons for
different clinical expression patterns of the same genetic defect in this disease remain elusive.
Identi®cation of the CYLD gene and modern genetic techniques enable us to rapidly con®rm
putative diagnoses on the genetic level, to give a prognosis for family members at risk for
developing multiple tumors, and to provide affected families with genetic counselling.
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HLA-Haplotypes in Patients with Porphyria Cutanea Tarda and their Relatives
N. Kuznetsova, A. Yu, and I. Afanasyeva
Department of Dermatology, Medical University of Irkutsk, Irkutsk, Russian Federation
HLA-haplotypes distribution has been studies in 50 patients with porphyria cutanea tarda (PCT)
(42 men and 8 women) and their relatives (30). The clear manifestation of the disease was not
observed in 44 patients, but these patients did have dyschromia, atrophic scar, and hypertrichosis of
the facial skin. The vulnerability cutis of the facve and hands was noted in all the patients. The
haplotypes A1B8, A1B18, A3B7, A2B5 were revealed during investigation. But the haplotype
A1B18 was occurred the most frequently (p < 0.05). The haplotypes A1B8 and A3B7 are markers
of the skin damage. The haplotype A1B18 was found in patients with liver disease. The
examination of the patients' relatives showed the high rates of antigen. A2, B12, B13, Dr1 and
Dr5. The haplotypes A2B12 and A2B13 were associated with hypertrichosis and hyperpigmenta-
tion symptoms. The increased rate of antigen B18 occurring with combination of antigen A1
con®rms about linkage equilibrium between these antigens. It may be used in popular genetic to
prognoses the risk of disease development.
968
Update: A Population-Based Genetic Epidemiologic Survey of Alopecia Areata
J. Baumgarten, K. Ronningen,* S. Iyengar,² and A. Sinha
Dermatology, Weill Medical College of Cornell University, New York, New York; *SAEP, National
Institute of Public Health, Oslo, Norway; ²Epidemiology and Biostatistics, Case Western Reserve
University, Cleveland, Ohio
We are examining a broad AA phenotype by collecting families and genotyping candidate genes.
Candidates were largely self-referred through information made available from the National
Alopecia Areata Foundation and a project website. In addition, subjects were identi®ed from the
Dermatology clinics at the New York Presbyterian Hospital/Weill Medical College of Cornell
University. Of 316 AA patients, 292 (92.4%) consented to participate. The racial composition of all
consenting participants (N = 292) is 11% African-American, 3% Asian-American, 72% Caucasian,
13% Hispanic, and 1% Other. The racial composition of probands with a family history (N = 124)
is 6% African-American, 82% Caucasian, 10% Hispanic, and 2% Other. Age-at-onset of the
probands ranged from 9 months to 70-year-old and sibship size ranged from 0 to 9. Of the 124
probands with a family history of AA, 56% (N = 69) have a ®rst-degree relative with AA, 19%
(N = 23) have a second-degree relative with AA, and 27% (N = 34) have a third-degree relative
with AA. DNA from blood samples of probands with (N = 25) and without (N = 33) a family
history of AA was typed for polymorphisms at the HLA-D locus. Of the 58 patients, 21% were
DR4 positive. Fourteen of the 58 (24%) probands who were HLA typed carried the DQA1*0501-
DQB*0301 haplotype. These interim data suggest that AA aggregates in families. We plan to
perform candidate gene analysis and genome scanning of AA in multiplex families from this cohort
to facilitate the identi®cation of disease susceptibility genes.
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Excessive Facial Hair is Common in Both General and Physician Of®ce Populations
T. Salam, A. Derrow, B. Mellen,* S. Lahiry, S. Rapp,² D. Hawes, S. Grummer, S. Feldman, A.
Fleischer, and A. McMichael
Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; *Public Health
Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina; ²Psychiatry &
Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina; ³Family
& Community Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Unwanted facial hair is a common problem for women. However, the prevalence of excessive
facial hair in patients seen in physicians' of®ces, a population with good potential for treatment, is
unknown. The aim of this study was to measure the prevalence of excessive facial hair in women
seen in physicians' of®ces. A convenience sample of 200 women was surveyed for excessive facial
hair in physician of®ces: 100 in a dermatology of®ce and 100 in a family physician practice.
Another 100 were surveyed outside of medical of®ces for comparison (84 in a shopping mall plus
16 at a health fair). Subject demographics, hair removal techniques, menstrual history, other
medical problems, and quality of life were assessed. A modi®ed Ferriman-Gallwey (F-G) scale was
used as an objective self-assessment of facial hair. Overall, 26% of subjects reported excessive facial
hair: 16% in the dermatology of®ce, 29% in the family physician of®ce, and 32% in the nonmedical
setting (p = 0.02, c2 test of association). Excessive facial hair was more common in non-Whites
(32%) than in Whites (23%), but the difference was not statistically signi®cant. Excessive facial hair
was positively associated (two-sided p < 0.05) with obesity, extremes of menstrual ¯ow, number of
hair removal methods, and the F-G score, which con®rm the construct validity of the measure. In
conclusion, excessive facial hair is common in both the general population and the populations
seen in dermatologic and family physician of®ces. Physicians and the public should be made aware
of currently available treatment options.
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Lupus Erythematosus Autoantibodies among Patients without Collagenosis Symptoms
R. Spiewak and N. Stojek
Occupational Biohazards, Instytut Medycyny Wsi, Lublin, Poland
The study was carried out on sera of 130 consecutive patients who sought medical advice during a
prophylactic action (65 females and 65 males, aged 9±82 years). None of the patients was suspected
of having autoimmune disease. The serum samples were tested using EIA (Varelisa ReCombi
ANA, Pharmacia & Upjohn) for the presence of autoantibodies speci®c to the following antigens:
dsDNA, RNP, and Sm. Presence of these antibodies is considered typical for SLE. One or more
antinuclear autoantibodies were detected in 18 of all 130 patients; 13 of 65 females were ANA-
positive (13/65F, 20.0%) in comparison to 5 of 65 males (5/65 M, 7.7%). The dsDNA-speci®c
autoantibodies were found in 8/65F and 4/65 M (total 12/130), RNP ± in 4/65F and 2/65 M
(total 6/130), Sm ± in 2/65F and 0/65 M (total 2/130). In general, ANAs were more frequently
detected in females (p = 0.05), however, differences for each particular antibody did not prove
statistically signi®cant. Altogether, antinuclear autoantibodies were found in 13.8% of subjects with
no symptoms of autoimmune disease (con®dence interval at p = 0.05: 7.9±19.8%). These ®gures
should be kept in mind when interpreting results of tests for ANAs. To our knowledge, this is the
®rst serological survey on antinuclear autoantibodies among Poles free from autoimmune disease.
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The Prevalence and Clinical Signi®cance of Anti-U1 RNA Antibodies in Patients with
Systemic Sclerosis
Y. Asano, H. Ihn, K. Yamane, M. Kubo, N. Yazawe, M. Fujimoto, and K. Tamaki
Dermatology, Univ of Tokyo, Tokyo, Japan
We studied the prevalence and clinical signi®cance of anti-U1 RNA antibodies (anti-U1 RNA) in
patients with systemic sclerosis (SSc). The presence of anti-U1 RNA was determined using
immunoprecipitation in SSc patients with anti-U1 RNP antibodies (anti-U1 RNP) (n = 36),
antitopoisomerase I antibodies (n = 20), anticentromere antibodies (n = 20), MCTD (n = 23), SLE
patients with anti-U1 RNP (n = 26), and normal controls (n = 20). Moreover, antigen speci®cities
for anti-U1 RNP were examined in patients with SSc by immunoblotting. Anti-U1 RNA was
detected in 22 of 36 SSc patients (61%) with anti-U1 RNP, 14 of 23 patients (61%) with MCTD,
and 8 of 26 SLE patients (31%) with anti-U1 RNP. Anti-U1 RNA was not detected in other
groups. As for SSc patients, the frequencies of PF and reduced %DLco were signi®cantly greater in
patients with anti-U1 RNA than in those without (80% vs. 25%, p < 0.005; 86% vs. 45%, p < 0.05,
respectively). Moreover, patients with anti-U1 RNA had signi®cantly lower %DLco and %VC
values than those without (47.1 6 17.3 vs. 73.1 6 20.3, p < 0.05; 80.9 6 21.2 vs. 96.0 6 18.5, p
< 0.05, respectively). Regarding the antigen speci®cities of anti-U1 RNP in SSc patients, the
frequency of anti70- kDa was signi®cantly lower in patients with anti-U1 RNA than in those
without (45% vs. 86%, p < 0.05). These results suggest that anti-U1 RNA could be useful for the
classi®cation of SSc patients with anti-U1 RNP and serve as a serological marker for pulmonary
®brosis in those patients.
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Discoid Lupus Erythematosus (DLE)-Like Lesion Induced by Uracil Tegafur (UFT)
T. Ohtani, T. Yoshimasu, A. Hiroi, K. Uede, and F. Furukawa
Dermatology, Wakayama Medical University, Wakayama, Japan
A mixture of uracil and tegafur (UFT) is a common antineoplastc agent in Japan. Fluorouracil
agents include tegafur, ¯uorouracil and UFT. The keratotic vesicular pigmented type accounts for
45% of cases with ¯uorouracil agent-induced skin lesions and discoid lupus erythematosus (DLE)
type for about 10%. First, we report a 64-year-old Japanese woman with DLE-like lesions which
were induced by UFT. After surgery to treat lung cancer, UFT (300 mg per day) was administered
and she developed round erythema at her right cheek. A skin biopsy specimen revealed atrophy of
the epidermis, a slight liquefaction, and patchy lymphocytic in®ltration. Antinuclear antibody was
weakly positive. After discontinuation of UFT, the erythema completely regressed within 2
months. Second, we collected 17 patients of DLE-like lesions induced by ¯uorouracil agents from
case reports in Japan and summarized the common features. Among the 3 different ¯uorouracil
agents, UFT showed the highest frequency of DLE-like eruptions (18%). When compared with 31
cases of idiopathic DLE which we experienced, the positive ANA ratio was relatively higher in
¯uorouracil agent-induced DLE-like eruption than in DLE. Despite the high ratio of ANA in the
former cases, all of the ANA disappeared within 1 years after discontinuation of medicine. The
positive LBT ratio was much higher in DLE than in ¯uorouracil agent-induced DLE-like
eruption. Fluorouracil agent-induced DLE-like eruptions regressed within 2 months after
discontinuation of medicine, whereas idiopathic DLE tends to persist for a long time. Fluorouracil
agent-induced DLE-like eruption is an excellent model for better understanding the
pathomechanisms of development of discoid lesions in LE, and further study may provide new
insights into autoimmune interface dermatitis.
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Skin Findings in Proteus Syndrome
D. Nguyen, J. Turner,* L. Biesecker,* and T. Darling
Department of Dermatology, Uniformed Services University, Bethesda, Maryland; *National Human
Genome Research Institute, National Institutes of Health, Bethesda, Maryland
Proteus syndrome is a sporadic, mosaic disorder with progressive asymmetric overgrowth of
multiple tissues during childhood. These patients may have connective tissue nevi, linear epidermal
nevi, vascular malformations, dysregulated adipose tissue, abnormal facial features, disproportionate
overgrowth such as digital gigantism or hemihyperplasia, and tumors before age 20. We evaluated
23 consecutive patients with Proteus syndrome that meet published diagnostic criteria (Biesecker
et al 1999). A total body skin examination was performed on 14 males and 9 females ages 10 months
to 40 years (median age 12 years). The skin ®ndings included connective tissue nevi in 20 patients
(on the soles of the feet in 18), linear epidermal nevi in 15, cutaneous vascular malformations in 20
(3 capillary, 4 venous, 1 lymphatic, 10 capillary/venous, 1 capillary/lymphatic, and 1 capillary/
venous/lymphatic malformation), lipomas in 20, and lipoatrophy in 9. Dermal hypoplasia was
present in 2 of the 23 patients. The extent of these skin ®ndings varied from small 3-mm macules
and papules to massive lesions distributed over the trunk and extremities. More extensive skin
®ndings appeared to correlate with more severe overgrowth of bones and internal organs. Features
of Proteus syndrome not previously reported include connective tissue nevi on the palms in 3 and
accessory nasal alae in 2 patients. Although it is a mosaic disorder that is variable in extent and areas
of involvement, Proteus syndrome exhibits a de®ned spectrum of cutaneous manifestations.
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Prevalence of HIV-Associated Opportunistic Skin Diseases under Highly Active
Antiretroviral Therapy
M. RoÈcken, S. Sammet, E. Thoma-Greber, A. Crispin,* A. Sakrauski, J. Prinz, M. Meurer, O.
Braun-Falco, and G. Plewig
Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany; *Institute for IBE,
Ludwig-Maximilians-University, Munich, Germany
Highly active antiretroviral therapy (HAART) strongly reduced incidence and severity of
numerous opportunistic diseases in patients with AIDS and signi®cantly improved life expectance.
The broad documentation of these ®ndings did not allow to determine the relation between
clinical improvement and restoration of immune functions. The strong reduction in opportunistic
diseases may be due either to the reconstitution of the immune system or to the direct
antimicrobial effects of substance such as proteinase inhibitors. To assess the clinical signi®cance of
the immune reconstitution in HAART-treated patients, we compared prevalence and severity of
HIV-associated opportunistic skin diseases in 910 HIV infected patients in two cohorts that were
normalized to comparable numbers of CD4+ T cells. Cohort I had not received HAART, cohort
II was treated with HAART. Mantel-Haenszel test revealed that HAART treated patients with
CD4+ T cells < 200 per ml, signi®cantly lower prevalence of oral candidiasis (0.56{0.33±0.71})
and Kaposi sarcoma (KS; 0.41{0.20±0.85}) than the control population. Surprisingly, the opposite
was true for other uncomplicated zoster (2.01{1.34±3.01}) and viral warts (2.23{1.51±3.30}),
which were signi®cantly more prevalent in the HAART treated cohort II. Thus, HAART was a
risk factor for the occurrence of viral warts and zoster, but directly protected against candidosis and
KS. Importantly, protease inhibitors can directly abrogate the pathogenicity of various candida
strains. Together the data suggest, that the percentage of CD4+ T cells in the peripheral blood of
HAART treated patients overestimates the real immune reconstitution and that at least some
bene®ts induced by HAART are related to the direct antimicrobial or anti-in¯ammatory effects of
protease inhibitors.
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